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INTRODUCTION  1 
1 Introduction 
 
In the early 1980s, magnetic resonance imaging (MRI) caught the attention of clinicians by its 
ability to visualise abnormalities in the posterior fossa of the brain and in the upper cervical 
spine. Visualisation of lesions in these regions by computer tomography (CT), the only 
alternative imaging technique for such applications, had failed before due to the bony 
structures of these areas. While in the beginning MRI was mostly used only for such special 
problems, over the last two decades it has evolved into one of the most powerful tools in 
diagnostic clinical medicine and biomedical research. Today, MRI is not only on a par with 
CT - in many diagnostic areas, such as the detection and characterisation of brain tumors, 
MRI has outstripped CT.1-3  
The strong expansion of medical MRI, however, was only possible due to the concomitant 
development of a new class of pharmacological products, named contrast agents (CAs). These 
compounds are designed in order to enhance the contrast between normal and diseased tissue 
or to indicate organ function or blood flow after administration of the CA to the patient. 
Nowadays, more than 30 % of all MRI investigations use a contrast medium, a number still 
set to increase.1 
The CAs which are to date in clinical use, like Dotarem™ or Magnevist™, are mainly low 
molecular weight extracellular perfusion agents which distribute non-specifically throughout 
plasma and interstitial spaces and are rapidly excreted via the kidneys or, in the case of more 
lipophilic hepatobiliary CAs, via the liver.4 
Current research is focused on a new generation of CAs. These novel CAs are designed in 
order to allow a more efficient and more specific imaging. So called targeted CAs are able to 
specifically locate certain types of cells and biomolecules within the body.5 Responsive or 
“smart” CAs afford the detection of changes in the physiological environment of the CA, such 
as variations in the pH, concentrations of inorganic ions, the partial pressure of oxygen or 
enzyme activity. This enables the visualisation of the cellular function and the follow-up of 
the molecular process in living organisms without perturbing them.4 
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2 General Basics 
2.1 Magnetic Resonance Imaging 
Magnetic resonance imaging (MRI) is an imaging technique used primarily in medical 
settings to produce high quality images of the inside of the human body. MRI is based on the 
principles of nuclear magnetic resonance (NMR) spectroscopy. The human body consists of 
water to more than 55%. For this reason MRI primarily images the 1H NMR signal from the 
hydrogen nuclei of the water molecules. 
In order to generate images from an NMR measurement, it is necessary to encode spatial 
information into the NMR signal. This is accomplished by the use of time-dependent, linear 
magnetic field gradients G along the three directions in space. The magnetic field B(x, t) in x-
direction at a time t is thereby given by the following relationship: 
	
,  =  + 	
 (2.1) 
where B0 describes the external magnetic field, x is the spatial coordinate along the x-axis, 
measured from the magnet centre, and Gx(t) is the gradient strength. The equation is valid 
analogously for the y- and z-directions. Altogether this results in a Larmor frequency ω which 
depends on the spatial position r and the time t: 
	,  = −	, ,  = 
 (2.2) 
where γ is the gyromagnetic ratio. 
With the gained position-dependency of the resonance frequency it is possible to excite only 
spins of water protons in certain parts of the body. The use of all three field gradients and 
combinations of them thereby allows the assignment of the signal intensity to a definite 
volume element (voxel). Furthermore, via the application of different pulse sequences it is 
possible to create a dependency of the signal intensity on the longitudinal relaxation time T1, 
the transverse relaxation time T2 or the spin density ρ of the water protons. Those factors are 
in turn influenced by the chemical environment and thus by the type of tissue in which the 
water molecules are located. The NMR signal intensity of each voxel is then transformed into 
the brightness of a gray-level scale. A matrix of these voxels makes up the final MR image.1 
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2.2 Contrast Agents in Magnetic Resonance Imaging
Spin-lattice relaxation times 
significantly shortened in the presence of 
application of CAs for MRI. All CAs which are used in MRI 
possess unpaired electrons which influence 
CAs which mainly shorten the transverse relaxation times are called “
typically iron oxide (Fe3O4
ions and are said to have superparamagnetic properties if the magnetic ions are mutually 
aligned. By using certain pulse sequences the shortening of the 
significantly reduced transverse magnetisation already before the
is recorded. This results in a weaker signal and therefore in darker 
On the contrary, a brightening of the affected area can be achieved 
(Figure 1). Since any CA which reduces 
inaccurate. However, as T1
much larger than the rel
population of the hydrogen 
a given delay time after the first pulse sequence
magnetisation before each repetition of the pulse sequence, the signal intensity and thus the 
image brightness increases.
positive contrast enhancement is often 
agents are based on paramagnetic metal ions.
Figure 1. MR images of a brain tumor. a) without a CA, b) with a 
In order to have a strong influence on the longitudinal relaxation time 
water protons the paramagnetic metal ions do not only have to 
unpaired electrons resulting in a large magnetic moment, the
a) 
 
 
T1 and spin-spin relaxation times T2 of NMR active nuclei can be 
unpaired electron spins. This effect is utilised 
are metal based agents which 
T1 and/or T2 of the surrounding water protons.
) nanoparticles which are made up of several thousand m
T2-relaxation 
 free induction decay (FID) 
regions in the MR image.
via 
T1 must also reduce T2, this term might seem 
 ≫ T2 for most tissues, the relative effect of a 
ative effect on T2. With shorter T1-relaxation times, 
nuclei surrounding the CA relaxes back to the equilibrium state 
. As this results in a higher longitudinal 
 For most applications T1-agents are favoured over 
more easily detectable as a negative one.
1, 6
  
          
T1-agent
possess a high number of 
y also need long electron 
b) 
3 
in the 
 
T2-agents”. Those are 
agnetic 
time leads to a 
 
the use of “T1-agents” 
T1-agent on T1 is 
a larger 
in 
T2-agents, as a 
 Typical T1-
 
 
T1 of the surrounding 
spin 
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relaxation times T1e. For example, dysprosium(III) and holmium(III) have the largest 
magnetic moments of all elements, but due to the asymmetry of their electronic states they 
show very rapid electron spin relaxation and thus water protons are hardly influenced by the 
effects of these ions.6 On the contrary, in the transition metal ions manganese(II) and iron(III) 
as well as the lanthanide ion gadolinium(III), having half-filled d or f shells, the pathways for 
electronic relaxation are relatively inefficient. Hence their electron spin relaxation is more 
closely in tune with the proton’s frequency.6, 7 Gadolinium(III) is most commonly used in 
CAs, as with seven unpaired electrons it has in general the strongest effect on the longitudinal 
proton spin relaxation. Additionally favorable is the short residual time τm of the water 
molecules on the gadolinium aqua complex (τm = 0.94 ns), which allows thousands of water 
molecules to transiently coordinate to a single ion on the MRI time scale.8 
The major drawback of gadolinium(III) based CAs is the high toxicity of free Gd3+ ions. With 
an ionic radius (107.8 pm) close to that of Ca2+ (114 pm), but a higher charge, gadolinium(III) 
is an inorganic blocker of many types of voltage-gated calcium(II) channels and several other 
calcium(II) regulated processes within the body.9 To diminish the toxicity to clinically 
acceptable levels, gadolinium(III) needs to be complexed by multidentate ligands. Since the 
relaxation time shortening effect of the paramagnetic metal ion on the water protons vanishes 
rapidly with increasing metal-proton distance, it is desirable to have at least one remaining 
coordination site on the gadolinium(III) ion for water to coordinate. Examples are 
[Gd(DOTA)H2O]- (Dotarem™ (1), Guerbet, France, DOTA = 1,4,7,10-tetraazacyclo-
dodecane-1,4,7,10-tetracetic acid) or [Gd(DTPA)H2O]2- (Magnevist™ (2), Bayer-Schering 
Pharma, Germany, DTPA = diethylenetriaminepentaacetic acid) (Figure 2). 
 
Figure 2. Structures of the commercially available CAs Dotarem™ (1) und Magnevist™ (2). 
2.3 Mechanistic Aspects of Gadolinium(III)-based Contrast Agents 
The general theory of the influence of paramagnetic substances on the nuclear relaxation of 
the surrounding solvent was developed by the groups of Solomon, Bloembergen and others.10-
12
 Accordingly, the observed longitudinal or transverse relaxation rate 1/T1,2obs of the water 
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GENERAL BASICS  5 
protons consists of a diamagnetic term 1/T1,2d, describing the relaxation rate of the protons in 
the absence of a paramagnetic solute and an additional paramagnetic term 1/T1,2p due to the 
presence of the paramagnetic compound: 
1, !"# = 1, $ + 1, % (2.3) 
The paramagnetic contribution is thereby directly proportional to the concentration [Gd] of 
the paramagnetic species: 
1, !"# = 1, $ + &, [Gd] (2.4) 
The concentration [Gd] is usually given in mmol/L, however for non-dilute systems, the 
linear relationship is valid only if [Gd] is expressed in mmol/kg of solvent. The 
proportionality constant r1,2 is called relaxivity [mM-1s-1]. For a gadolinium complex in water, 
the relaxivity is a direct measure for the efficiency of the complex to act as a contrast agent.1 
The paramagnetic relaxation of the water protons originates from the dipole-dipole 
interactions between the large and fluctuating local magnetic field caused by the unpaired 
electron spins and the nuclear spins of the water protons. Since the magnetic field around the 
paramagnetic centre falls off rapidly with distance, random translational diffusion of solvent 
molecules and the complex as well as specific chemical interactions that bring the solvent 
molecules close to the metal ion (e.g., within 5 Å) are important in transmitting the 
paramagnetic effect. Each type of chemical interaction can yield different relaxation 
efficiencies as governed by the distance and time scale of the interaction. The sum of these 
contributions and that due to translational diffusion gives the total relaxivity of the 
paramagnetic species.7 
 
Figure 3. Different types of interactions of water molecules with a gadolinium(III) based CA. 
The relevant contributions for water proton relaxivity can be classified in three distinct types 
of interactions (Figure 3). The effect on bulk water molecules which diffuse in the 
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surroundings of the paramagnetic complex is defined as outer-sphere (OS) relaxation. For 
gadolinium(III) complexes, the specific interaction is mainly the binding of water molecule(s) 
in the first coordination sphere of the metal ion. These inner-sphere (IS) water molecules 
exchange with the bulk solvent which propagates the paramagnetic influence into the bulk. 
This mechanism is depicted as the inner-sphere contribution to the overall relaxivity. In 
certain agents, solvent molecules that are not directly bound to the first coordination sphere 
can also remain in the proximity of the paramagnetic centre for a relatively long time, e.g. due 
to hydrogen bridges to carboxylate or phosphate groups of the ligand. The relaxivity 
contribution originating from these interactions is called second-sphere (SS) relaxivity, and to 
this contribution the same theory as for the inner-sphere term applies. However, as the 
involved parameters are hardly available, its effect is usually taken into account in the outer-
sphere term.1, 7 The total paramagnetic relaxation rate enhancement due to the paramagnetic 
agent is therefore generally given by equation 2.5, or expressed in relaxivities in equation 2.6: 
+ 1, %, = + 1, %,
-. + + 1, %,
/.
 
(2.5) 
&, = &, -. + &, /. (2.6) 
For the currently used low molecular weight gadolinium(III) based CAs, like 
[Gd(DOTA)H2O]- (1) and [Gd(DTPA)H2O]- (2) (Figure 2), the outer and inner-sphere 
relaxation mechanisms contribute approximately to the same extent to the observed relaxivity 
at magnetic field strength used in MRI.1 However, it is the inner sphere term that can be 
considerably manipulated by chemists, whereas the outer-sphere contribution can hardly be 
modified. Since gadolinium(III) based CAs are T1-agents, the following sections focus on the 
factors that determine the longitudinal inner-sphere and outer-sphere relaxation mechanisms. 
2.3.1 Inner-Sphere Relaxivity 
The longitudinal relaxation contribution from the inner-sphere mechanism results from a 
chemical change of the coordinated water molecules with the bulk, and thus represents a two-
site exchange problem. The bulk site is much more populated than the site of coordinated 
water, and the observed signal corresponds to that of the free water. The longitudinal inner-
sphere relaxation rate is therefore given by equation 2.7: 
0 11 = 0 233 + 431 = [Gd]555.5 0 13 + 431 (2.7) 
where, Pm is the mole fraction of bound water nuclei, T1m is the proton relaxation rate in the 
bound water, τm is the lifetime of a water molecule in the inner sphere of the complex (equal 
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to the reciprocal water exchange rate, 1/kex), q is the number of bound water molecules per 
gadolinium ion (hydration number) and [Gd] is the molal concentration of gadolinium ions. A 
schematic representation of a gadolinium(III) chelate with the most important parameters of 
inner-sphere relaxivity is depicted in Figure 4. 
The longitudinal relaxation time T1m of the bound water protons is governed by a dipole-
dipole (DD) (“through space”) and a scalar (SC) (“through bonds”) mechanisms. The dipolar 
interaction is modulated by the reorientation of the nuclear spin-electron spin vector, by 
changes in the orientation of the electron spin (electron spin relaxation T1,2e) and the water 
(proton) exchange rate kex. The scalar interaction does not depend on the reorientation of the 
molecule, but is modulated by electron spin relaxation and water exchange. 
 
Figure 4. Schematic representation of a gadolinium(III) chelate having one inner-sphere 
water molecule. τR is the rotational correlation time of the complex, kex is the water (proton) 
exchange rate, T1m is the longitudinal relaxation time of the bound water protons and T1,2e are 
the longitudinal and transverse relaxation times, respectively, of the gadolinium(III) electron 
spin. 
The longitudinal relaxation rate 1/T1m of the bound water protons and its depending 
parameters are expressed by the modified Solomon-Bloembergen equations:13 
13 = 188 + 1.9 (2.8) 
188 = 215 +-
 ; <= &>$?@ , A	A + 1 B<4DE
 +7 4G 1 + H. 4G  + 3 4G1 + H- 4G , (2.9) 
1.9 = 2A	A + 13 0Jℏ1
 + 4K 1 + H. 4K  , (2.10) 
 kex Gd3+ 
T1,2e 
 H2O 
 τR 
  T1m 
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where γI is the nuclear gyromagnetic ratio, g is the electron g-factor, µB is the Bohr magneton, 
rGdH is the electron spin-proton distance, S is the total electron spin of the metal ion, ωI and ωS 
are the nuclear and electron Larmor precession frequencies, respectively (ω = γΒ), and A/ ℏ is 
the electron-nuclear hyperfine or scalar coupling constant. The dipolar and the scalar 
relaxation mechanisms are modulated by the correlation times τc1,2 and τe2 as the following: 
14G, = 14L + 1, K + 143 (2.11) 
14K = 1 K + 143 (2.12) 
where τR is the rotational correlation time or, more precisely, the reorientational correlation 
time of the metal-proton vector, and T1,2e are the longitudinal and transverse electron spin 
relaxation times, respectively, of the gadolinium(III) ion. 
The field dependence of T1,2e can be described by the theory developed by Bloembergen and 
Morgan.10 In this theory the paramagnetic electron spin relaxation is interpreted in terms of a 
zero-field-splitting (ZFS) interaction: 
0 1K1
MN. = 2O + 11 + H. 4P + 41 + 4H. 4P , (2.13) 
0 1 K1
MN. = O + 51 + H. 4P + 21 + 4H. 4P + 3, (2.14) 
O = 150 R 4P[4A	A + 1 − 3] (2.15) 
where ∆2 is the mean-square zero-field-splitting energy and τν is the correlation time of the 
modulation of the zero-field-splitting interaction.
 
The inclusion of these equations into the modified Solomon-Bloembergen equations 
constitutes a complete theory for relating the observed paramagnetic relaxation rate 
enhancement to the microscopic properties, which is generally referred to as the Solomon-
Bloembergen-Morgan theory. However, the theory is based on several assumptions.1 First of 
all, they are valid only within the Redfield limit. This assumption, referred to as the so-called 
strong-narrowing condition, demands that the motions in the lattice must occur on a much 
faster time scale than the motions in the spin system, i.e. τR ≪ T1,2e. Additionally, two main 
assumptions are involved, namely that the electron spin relaxation is uncorrelated with the 
molecular reorientation, and that the electron spin system is dominated by the electron 
Zeeman interaction and other interactions result only in electron spin relaxation. 
The above equations point out that proton relaxivity is influenced by numerous parameters. In 
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any case the inner-sphere contribution to the relaxation rate depends linearly on the hydration 
number q. Just in one case, namely when the water (proton) exchange is very slow (T1m ≪ 
τm), the exchange rate will be the only further determining factor (equation 2.7). Therefore a 
fast water exchange is appreciated. However, if τm becomes too small, no efficient interaction 
can take place. From equation 2.9 it is obvious, that a slightly longer Gd-H distance rGdH 
results in a significant decrease in r1 due to the sixth-power dependence. The influence of the 
other parameters is less evident to predict, as the influence of these parameters strongly 
depends on the magnetic field.  
For the rotational correlation time τR, the water exchange rate kex and the longitudinal electron 
spin relaxation T1e, the maximum relaxivity would be achieved when the correlation time τc1 
equals the inverse proton Larmor frequency (1/τc1 = 1/τR + kex + 1/T1e = ωI). It can be shown, 
that the reachable maximum decreases with increasing field strength. On the other hand, the 
use of higher magnetic fields allows a better resolution and sensitivity. T2e is not important for 
optimisation purposes, as the “7-term” in equation 2.9 becomes negligible at field strength 
above 0.5 T (B of scanners today in clinical use: 1-3 T).6 
Contrast agents that are currently in clinical use are far-off this optimum. The main reason is 
that their rotational correlation time (~ 10-10s) is too short and their water (proton) exchange 
rate (~ 106s-1) is too slow (~ 108s-1 would be optimal).1 
2.3.2 Outer-Sphere Relaxivity 
As mentioned above, all contributions to the relaxivity from water molecules outside of the 
inner coordination sphere are usually summarised in the outer-sphere term (2.5), without 
distinguishing between second- and outer-sphere water molecules. The relaxivity of the outer-
sphere arises from a dipolar intermolecular interaction between the nuclear spin I of the water 
protons and the total electron spin S of the gadolinium(III) ion, whose fluctuations are 
governed by the random translational diffusion of the water molecules near the 
gadolinium(III) complex. In the theory of outer-sphere relaxation, both the water molecules 
and the paramagnetic complex are treated as hard spheres. Thus, the outer-sphere relaxation 
rate can be described by equations 2.16 and 2.17:1, 6 
0 11
/. = 32D405 - . ℏ A	A + 1 TU[Gd]VW-. [7X	H. + 3X	H-] (2.16) 
X	H = YZ [ 1 + 41 +  + 49  + 19 ]^     with  = _`H48 +
48K (2.17) 
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where NA is the Avogadro number, d is the closest distance of approach of a water molecule 
and gadolinium(III), DIS is the sum of the diffusion coefficients DI and DS of water and the 
gadolinium(III) complex, respectively and τD is the diffusional correlation time (τD = d2/DIS). 
A direct determination of the outer-sphere relaxivity is only possible for complexes with no 
water molecule in the inner-sphere (q = 0). The only possibility to approximate the inner-
sphere relaxivity of a complex with q > 0 is the subtraction of the relaxivity of a chemically 
similar complex with q = 0 from the obtained overall relaxivity of the complex.6 The different 
types of gadolinium(III) complexes used in MRI are highlighted in the following section. 
2.4 Types of Gadolinium(III) Chelates for Magnetic Resonance Imaging 
2.4.1 Gd-DTPA and Derivatives 
Diethylenetriaminepentaacetic acid (DTPA) is a linear octadentate ligand, which is easily 
derivatised. Their gadolinium(III) complexes provide a widely used group of CAs (Figure 5). 
 
Figure 5. Commercial Gd-DTPA-based CAs. 
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Gd-DTPA (2) was marketed as Magnevist™ by Schering in 1988 and thereby was the first 
intravenous CA for MRI to become available for clinical use. The complex is two-times 
negatively charged and bears one inner-sphere water molecule. Due to its charge 2 is 
hyperosmolar with respect to body fluids. However, as the injected amounts are low (dosage 
about 0.1 mmol kg-1), the increase in blood osmolality after intraveneous injection does not 
cause significant disturbance of the organism’s osmotic balance.2 Nevertheless neutral 
derivatives with lower osmolalities, like Gd-DTPA-BMA (Omniscan™) (3) and Gd-DTPA-
BMEA (OptiMARK™) (4) were developed. The ligands of both complexes are amides of 
DTPA and are obtained by treating the dianhydride of DTPA with the corresponding amine.2 
All three complexes are freely soluble in water (usually to about 0.5-1.0 M). With relaxivities 
in water between 3.5 and 4.2 mM-1s-1 at 37°C and 0.47 T (Table 1), their efficiency as a 
contrast agent is comparably low. 2-4 are rapidly distributed in the extravascular space and 
excreted in unchanged form (no metabolism) exclusively via the kidneys by glomerular 
filtration (elimination half-lives are in the range of 1.5 hours in healthy volunteers, and almost 
all of the injected dose is recovered within 24 hours).14 Since these CAs do not diffuse 
through plasma membranes and are therefore unable to cross the intact blood–brain barrier 
(BBB), they are very efficient tools for detecting any pathological abnormality of the BBB, 
e.g. in tumors of the central nervous system.9 
Table 1. Clinically used DTPA-type gadolinium(III) complexes and their ionicity, relaxivity 
r1, thermodynamic stability constant KGdL and conditional stability constant K*GdL at pH 7.4. 
Complex Trademark Ionicity r1 [mM-1s-1] log KGdL log K*GdL 
Gd-DTPA Magnevist™ Di-ionic 3.9a 22.1 d 17.7 d 
Gd-DTPA-BMA Omniscan™ Neutral 3.5a 16.9 d 14.9 d 
Gd-DTPA-BMEA OptiMARK™ Neutral 4.2a 16.6 d 15.0 d 
Gd-BOPTA MultiHance™ Di-ionic 4.2a (6.7) c 22.6 d 16.9 d 
Gd-EOB-DTPA Primovist™ Di-ionic 5.3a (7.3) c 23.5 d N/A 
MS-325 Vasovist™ Tri-ionic 5.8b (19)c 23.2 e N/A 
aRef. 9, water, 37°C, 20 MHz; bRef. 15, water, 37°C, 20 MHz; cRef. 15, blood, 37°C, 1.5 T; dRef. 6; 
eRef. 16. 
 
In order to allow liver imaging the two CAs Gd-BOPTA (MultiHance™) (5) and Gd-EOB-
DTPA (Primovist™) (6) were developed. Both are Gd-DTPA derivatives which have a 
lipophilic aromatic moiety in their structure. Thereby they can be taken up by hepatocytes and 
undergo partial hepatobiliary excretion (2 %-4 % and 50 % for 5 and 6, respectively).14, 17 The 
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aromatic ring in 5 and 6 leads to some weak plasma protein binding, although the protein-
bound fraction is only about 10 %.17 The protein binding leads to an increase in relaxivity of 
these compounds in blood compared to that in water (Table 1). However, the binding does not 
appear to impact plasma clearance. By contrast, MS-325 (7), being marketed as Vasovist™, 
binds reversibly to human serum albumin (HSA) via a lipophilic biphenylcyclohexyl group, 
which increases the elimination half-life in subjects with normal renal function to 18.5 h.17 
The concentration of albumin in plasma is high enough (600-700 µM) to reversibly bind most 
of the CA after injection, leading to a significant increase in relaxivity (Table 1).  
All these CAs are usually well tolerated, show few side effects and were considered as 
generally safe.18 However, since a correlation between gadolinium(III) and the development 
of a new severe disease named nephrogenic systemic fibrosis (NSF) was reported in early 
2006,19 the in vivo stability of the CAs regained attention. Up to now, NFS appeared 
exclusively in patients with severe impaired kidney function. In these patients the renal 
excretion half-life of the CAs is significantly increased (e.g. for Omniscan™ from ~90 min in 
healthy persons to ~ 2000 min in diseased persons).20 Due to their eight-dentate ligands the 
thermodynamic stability KGdL (defined by equation 2.18) of 2-7 is quite high (Table 1).  
a>$b = [Vc][V][c] (2.18) 
To describe the in vivo stability, the conditional stability constant K*GdL is more appropriate 
than KGdL (Table 1). K*GdL is measured at pH 7.4 and takes into account all protonation 
constants of the ligand. The conditional stability constant is defined as: 
a>$b∗ = a>$b	1 + a1[e+] + a1a2[e+]2 + ⋯ + a1a2ag[e+]g (2.19) 
where K1, K2,…, Kn are the stepwise protonation constants of the ligand. Since also their 
K*GdL values are fairly large, 2-7 are generally considered as highly stable. However, blood 
and other body fluids are very complex milieus containing a large number of potential ligands 
and metal ions which can displace the gadolinium(III) from its complex. Hence, their kinetic 
inertia especially towards this so-called “transmetallation” must also be considered.  
Numerous studies were carried out in order to investigate transmetallation under various 
conditions.9, 14, 21-23 It could be shown that all linear, open-chained CAs release 
gadolinium(III) via transmetallation under physiological conditions whereby the neutral CAs 
3 and 4 exhibited a significantly lower kinetic inertness then their ionic derivatives. Therefore 
it is no surprise that most of the reported cases of NSF could be attributed to these two CAs.20 
However, there are also reported cases of NSF triggered by Magnevist™ (2) in patients with 
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severe renal dysfunction, showing that 2 is also not inert enough to prevent the release of too 
high amounts of gadolinium(III) if the CA remains in the body for a prolonged period of time. 
The comparatively low kinetic inertia of these open-chained chelates has been modeled by 
rapid unwrapping of these molecules due to their conformational mobility.24 The replacement 
of the two ionic carboxylate (COO-) donor moieties by non-ionic amide groups in the case of 
3 and 4 leads to a weaker binding of these moieties to gadolinium(III). This may introduce 
more flexibility and conformational mobility, which explains the significant loss in kinetic 
inertness of these systems. On the other hand, the introduction of an aromatic moiety in the 
case of 5-7 slightly improves kinetic inertia. This can be explained by the steric effect of the 
bulky substituents that hinders unwrapping of the ligand around gadolinium(III).25 
2.4.2 Gd-DOTA-type Contrast Agents 
Macrocyclic MRI CAs show a significantly higher kinetic inertia, which is attributed to their 
tight packing and their high conformational rigidity.26, 27 All commercially available 
macrocyclic CAs are based on a 1,4,7,10-tetraazacyclododecane ring (cyclen), which forms 
an ideal cavity for the complexation of gadolinium(III) (Figure 6). 
 
Figure 6. Gd-DOTA and derivatives. 
Gd-DOTA (1) was the first macrocyclic MRI CA. It was marketed under the trademark 
Dotarem™ in 1989 by the Guerbet Company. Due to its higher kinetic and thermodynamic 
stability (Table 2) Gd-DOTA (1) is considered as the safer alternative towards Gd-DTPA (2). 
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Up to now, there is no reported case of NSF in the peer reviewed literature which can be 
related exclusively to the administration of 1. Another advantage of 1 over 2 lies in its lower 
relative viscosity. This allows a faster injection for a given applied pressure, which minimises 
patient discomfort as a burning sensation due to hyperosmolality is felt otherwise.18 However, 
also for the macrocyclic CAs neutral derivatives of Gd-DOTA, namely Gd-HP-DO3A 
(Prohance™) (8) and Gd-BT-DO3A (Gadovist™) (9) were developed to further reduce 
osmolality. 
Table 2. Clinically used DOTA-type gadolinium(III) complexes and their ionicity, relaxivity 
r1, thermodynamic stability constant KGdL and conditional stability constant K*GdL at pH 7.4 
Complex Trademark Ionicity r1 [mM-1s-1] log KGdL log K*GdL 
Gd-DOTA Dotarem™ Ionic 3.4a 25.8 c 18.8 c 
Gd-HP-DO3A Prohance™ Neutral 3.1a 23.8 c 17.1 c 
Gd-BT-DO3A Gadovist™ Neutral 3.7a 21.8 c N/A 
Gd-DO3A - Neutral 4.8b 21.0 c 15.0 c 
aRef. 9, water, 37°C, 20 MHz; bRef. 28, water, 40°C, 20 MHz; cRef. 6 
 
Compound 8 shows a two orders of magnitude lower thermodynamic stability than 1 (Table 
2). This is not unexpected since the hard Lewis acid gadolinium(III) binds more tightly to 
negatively charged atoms rather than neutral ones. The introduction of additional hydroxyl 
groups in the case of 9 decreases KGdL even further. However, due to their excellent kinetic 
stability the lower thermodynamic stability has no impact on its use in patients. All three 
marketed macrocyclic CAs are extracellular fluid agents, which target no specific anatomical 
site or physiological function.29 Their increased stability does not lead to a lack in other 
properties. They show similar pharmacokinetics as their unspecific open-chained counter 
parts and, with relaxivities between 3.1 and 3.7 mM-1s-1 at 37°C and 20 MHz, display also 
comparable efficiencies (Table 2). As mentioned in chapter 2.3.1 the reasons why these 
relaxivities are far-off the theoretically possible values are their too short rotational 
correlation times and too slow water exchange rates. A further reason is their low hydration 
number q. All commercial CAs consist of octadentate ligands and thereby possess only one 
free coordination site for the interaction with water. A system with a heptadentate ligand is 
Gd-DO3A (10). The hydration number of 10 was determined to be about two30 However, a 
small fraction of monohydrated species was also observed.31 Due to this coordination 
equilibrium the water exchange rate kex of Gd-DO3A (10) is as twice as high as that of Gd-
DOTA (1). Hence, with 4.8 mM-1s-1 the relaxivity of 10 is about 40 % higher than that of 1 
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(Table 2). Unfortunately a clinical use of 10 is prevented by its comparably low conditional 
stability constant (Table 2) and by the possibility of reversible oxy-anion binding under 
physiological conditions which can lead to the complete loss of inner sphere water.32, 33 
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3 Calcium(II)-sensitive MRI Contrast Agents 
3.1 Introduction 
In the field of neuroscience the so-called functional magnetic resonance imaging (fMRI) 
offers a possibility to locate brain activity via MRI. Today, fMRI in the brain is based on the 
increase in cerebral blood flow to the local vasculature, which is involved in the increase in 
oxygen level and glucose consumption that follows neural activity in the brain. The release of 
dioxygen from hemoglobin causes its iron to become paramagnetic by changing from a low 
spin state to a high spin state.34 The so generated “internal CA” accelerates the relaxation rate 
of the surrounding water protons which in turn leads to a detectable blood-oxygen-level-
dependent (BOLD) magnetic resonance signal.35, 36 fMRI is currently the most widely used 
method for brain mapping and studying the neural basis of human cognition.37-39 Indeed, more 
detailed investigations showed in first approximation a linear relationship between the BOLD 
signal and the neural response elicited by a short stimulus duration. However, the 
hemodynamic response seems to be better correlated with the local field potentials (input 
signals of a neural population), implying that activation in an area is often likely to reflect the 
incoming input and the local processing in a given area rather than the spiking activity. Even 
though it can be expected that local field potentials will usually correlate with 
neurotransmitter release, fMRI experiments based on the BOLD signal may reveal activation 
in areas in which no single-unit activity is found in physiological experiments.35 Additionally, 
the indirect hemodynamic BOLD signal is associated with a time lag which broadens the 
response. All this can make BOLD fMRI insufficient for an accurate study of neural activity. 
A way to detect neuronal activity in a more direct manner could be the use of CAs which are 
able to respond to changes in the physiological environment directly linked to the release of 
neurotransmitters. 
Calcium(II) ions are a promising target for such CAs as they play a central role for the release 
of neurotransmitters into the synaptic cleft (Figure 7). When an action potential reaches the 
axon terminal, the electrical depolarisation of the synaptic membrane causes calcium channels 
to open. Calcium(II) ions flow through the presynapitic membrane which increases the 
calcium(II) concentration in the interior. This in turn causes vesicles to fuse with the 
membrane of the presynaptic cell, thereby opening the vesicles and releasing their 
neurotransmitter content into the synaptic cleft.40, 41 
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Figure 7. Schematic presentation of the synaptic signal transmission in a chemical synapse. 
Measurements in the cerebellar cortex of the cat revealed a decrease in the calcium(II) 
concentration of the extracellular microenvironment of the active neuron from 1.2 mmol/L to 
0.8 mmol/L.42 This concentration change then needs to be detected by the responsive or 
“smart” CA. 
3.1.1 Responsive or “Smart” Contrast Agents 
In recent years an increasing number of CAs were described in the literature, which are able 
to convert changes in physico-chemical parameters that characterise their physiological 
environment into a change in relaxivity r1 and hence in a contrast change. Typical parameters 
are enzyme activity, pH and metal ion concentrations. 
3.1.1.1 Agents sensitive to enzyme activity 
The first enzyme sensitive contrast agent was developed in response to the need to correlate 
biological events with gene expression during an imaging experiment. The Meade group 
thereto developed a CA (Gd-DO3A-β-gal (11)) whose relaxivity r1 responds to β-
galactosidase mRNA expression.43, 44 Gd-DO3A-β-gal (11) is a derivative of Gd-DOTA (1) 
which bears a galactopyranose residue (Scheme 1). This residue is a substrate of the β-
galactosidase enzyme and blocks the open coordination side of the gadolinium(III) ion. As no 
water molecule can therefore enter the inner coordination sphere, the relaxivity of 11 is 
diminished. Upon the production of the targeted enzyme the sugar moiety is cleaved 
irreversibly from the complex, allowing water to interact with the paramagnetic centre. The 
increase in inner sphere water then results in a 50 % higher r1 of 12 as compared to 11,44 
which allowed the successful use of 11 in the in vivo detection of β-galactosidase mRNA 
expression in living Xenopuslaevis embryos by MRI.43 
1. Action potential reaches the 
axon terminal 
2. Ca-channels open and 
influx of Ca2+ ions 
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Scheme 1. 
Himmelreich et al. recently developed a contrast agent for imaging of dendritic cells.45 The 
contrast agent, called Gd-DTPA-FA is a Gd-DTPA (2) derivative which contains two long 
fatty acid chains (COOC17H35) connected to the ligand surface via an ester bond. These chains 
make the CA insoluble in water, resulting in inactive particles showing no relaxivity r1. The 
particles are internalised into the dendritic cells by phagocytosis were they are solubilised by 
intracellular lipase activity through cleavage of the insolubilising moieties. Hence, the 
increase in intracellular relaxivity r1 is a function of the enzyme activity. MR images of the so 
labelled cells implanted into the rat brain showed the suitability of this CA for functional 
cellular in vivo MRI. 
A CA that is sensitive to the presence of the human carboxy peptidase B, thrombin-activatable 
fibrinolysis inhibitor (TAFI), was prepared by Nivorozhkin et al..46 The CA is a derivative of 
Gd-DTPA (2) exposing an aromatic group that has a high affinity for human serum albumin 
(HSA), like the biphenylcyclohexyl moiety of MS-325 (7) (see chapter 2.4.1). In contrast to 7 
the aromatic function of this CA is masked by a trilysine group, preventing a HSA binding. 
TAFI, which has been implicated in thrombotic disease, cleaves the trilysine masking group, 
allowing the CA to bind to albumin. The resulting longer rotational correlation time τR then 
leads to an increase in r1. 
A further example of enzyme sensitive CAs was reported by Bogdanov et al..47 Their CA is a 
Gd-DOTA (1) derivative which bears a benzene-1,2-diol moiety. In the presence of a 
peroxidase and an excess of hydrogen peroxide the monomeric CA oligomerises, yielding a 
three-fold increase in relaxivity r1 (0.47 T and 40°C) due to the accompanied increase in τR. 
This allows a detection of peroxidase concentration in vitro and has been used to detect E-
selectin expression on human endothelial cells in culture. 
 
N N
N NGd
3+
CO2-
CO2- O
O
OH
OH
OH
-O2C
OH
N N
N NGd
3+
CO2-
CO2- HO
-O2C
O
H H
β-Gal
11 12
CALCIUM(II)-SENSITIVE MRI CONTRAST AGENTS 19 
3.1.1.2 pH-dependent contrast agents 
pH-dependent CAs are of great interest especially in the detection of cancer, as the pH on the 
surface of tumors is about 0.4 units lower than in healthy tissue.48 
One CA which shows a pH dependency due to changes in its second-sphere was reported by 
the Sherry group.49 The CA, Gd-DOTA-4AmP, is a Gd-DOTA (1) derivative where the four 
carboxylic acid functions are replaced by amidomethylphosphonate groups. In this system the 
pH has no direct influence on the water exchange rate, however, the 
protonation/deprotonation of the phosphonates creates/destroys a hydrogen bonding network 
which provides a catalytic pathway for the exchange of protons from the bound water with 
protons of bulk water. The CA was applied in vivo for extracellular pH mapping by assessing 
the local concentration of the CA through the use of a pH-insensitive analogue, assuming the 
same biodistribution for the two systems.50 
In other examples the pH-dependency of the relaxivity r1 reflects changes in the hydration 
number q. Mamedov et al. developed a series of pH-sensitive CAs based on Gd-DO3A (10), 
where the forth cyclen nitrogen is alkylated with an ethyl or propylphosphonate moiety.51 At 
low pH the phosphonate group is mostly protonated and therefore not coordinated to the 
gadolinium(III) ion (13 in Scheme 2). This leaves two coordination sites free for water to 
coordinate. When the pH is increased the phosphonates become deprotonated which allows a 
coordination of the phosphonate moiety to the paramagnetic centre (14 in Scheme 2). The 
decrease in q results in a reduction of the relaxivity r1 to about 50-60 % of the starting value 
when increasing the pH from 4 to 7. 
 
Scheme 2. 
A similar approach was used by Lowe at al.52 Instead of an alkylphosphonate moiety, an 
alkylsulfonamide function was introduced, whose nitrogen is protonated at low pH thus 
preventing a coordination. As at higher pH the coordination of the deprotonated sulfonamide 
nitrogen hinders the interaction of any water molecule with the gadolinium(III) the effect on 
r1 is higher in this case. 
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Aime et al. prepared a macromolecular CA with 30 macrocyclic gadolinium(III) chelates and 
114 ornithine residues, which turned out to have a pH dependent relaxivity.53 The 
gadolinium(III) complexes are conjugated to the amino acid chain via squaric esters. The pH-
dependency arises from an interaction of the, at higher pH, deprotonated amide side chains 
with the squaric esters. This interaction increases the rigidity of the polymer, causing an 
increase in the rotational correlation time τR and therefore an increase in relaxivity r1. 
3.1.1.3 Metal ion sensitive contrast agents 
The first MRI CA which showed a change in its relaxivity r1 in the presence of a metal ion 
was reported by Aime et al. in 1993.54 However, it was not developed in order to respond in 
vivo to changes in the surrounding metal ion concentration, but to obtain a high relaxivity CA. 
The CA is a Gd-DTPA (2) derivative functionalised with salicylate moieties. Upon addition 
of iron(III), the Gd-DTPA–salicylate complexes bind to the iron(III) ions via the salicylate 
functional groups, thereby increasing τR and r1. 
A similar, but much more efficient approach to increase the relaxivity r1 was recently reported 
by Livramento et al..55 They developed a heterotritopic ligand named [bpy(DTTA)2]8- which 
has two diethylenediamine-tetraacetate units for gadolinium(III) binding and a 2,2’-bipyridine 
function for selective iron(II) coordination. In aqueous solution and in the presence of these 
metals, the ligand is capable of self-assembly to form a rigid supramolecular metallostar 
structure with six efficiently relaxing gadolinium(III) centres confined to a small molecular 
space. The metallostar has a remarkable high relaxivity r1 particularly at very high magnetic 
fields (r1 = 15.8 mM-1s-1 at 200 MHz and 37°C in H2O) and has already shown its potential in 
vivo.56 
Hanaoka et al. developed a CA which is capable to respond to changes in the surrounding 
zinc(II) ion concentration.57 This Gd-DTPA-bisamide complex (15) (Scheme 3) was designed 
on the basis that N,N,N’,N’-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN) readily 
complexes with Zn2+ ions but hardly complexes Ca2+ and Mg2+ ions. In the absence of 
zinc(II), water is bound to the gadolinium(III) ion. Upon the addition of Zn2+ ions, the 
pyridine moieties coordinate to zinc(II) thus restricting the access of water to the 
gadolinium(III) ion (Scheme 3). This decrease in q results in a decrease in r1. However, when 
the Zn2+-CA molar ratio exceeds 1:1 the relaxivity increases again as 15 is capable to form the 
2:1 complex 17 (Scheme 3). In terms of application this is problematic as one cannot 
distinguish for example the r1 values of solutions containing 0.3 and 1.5 equivalents of 
zinc(II). This problem could be circumvented by replacing one of the pyridine moieties on 
each of the amide functions of 15 by a carboxylate group.58 This CA showed a similar zinc(II) 
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sensitivity without the limitation of an increasing relaxivity above a 1:1 ratio. 
 
Scheme 3. 
The first calcium(II) sensitive MRI CA, called Gd-DOPTA (18) (Scheme 4) was invented by 
Li et al..59 It consists of two Gd-DO3A chelates attached to a 1,2-bis(o-aminophenoxy)ethane-
N,N,N′,N′-tetraacetic acid (BAPTA) moiety for selective calcium(II) coordination. As the 
zinc(II) sensitive CAs of Hanaoka et al., 18 is designed in order to change the hydration state 
of gadolinium(III) in the presence of the metal ion. However, the mechanism works in an 
opposite manner (Scheme 4). It is assumed that in the absence of calcium(II) the aromatic 
iminoacetates shield the gadolinium(III) ion from water resulting in a low longitudinal 
relaxivity (3.26 mM-1s-1 at 500 MHz and 25°C). With increasing calcium(II) concentration the 
BAPTA groups begin to coordinate the Ca2+ ions. This reorganisation of the complex exposes 
the gadolinium ion to bulk water, thereby increasing the relaxivity (plateau at 5.76 mM-1s-1 at 
500 MHz and 25°C after the addition of about one equivalent of calcium(II)). The assumption 
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rests on an observed change in the hydration number q from 0.5 for 18 to 1.0 for 19.60 
 
Scheme 4. 
Since then several approaches to further optimise the selectivity and efficiency of calcium(II) 
sensitive CAs were undertaken in particular by the Logothetis group.61-64 So far the strongest 
increase in relaxivity (98 % at 400 MHz and 27°C) upon the addition of calcium(II) was 
observed for Gd-DOPTRA (20) (Figure 8).63 
 
Figure 8. Gd-DOPTRA 
However, still not one of them proved its suitability to detect neuronal activity in the brain. 
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3.1.2 Aim of this Project 
An alternative to the systems with aminocarboxylate moieties for calcium(II)-sensing was 
developed by I. Mamedov65 in our research group. He synthesised a series of potential 
gadolium(III)-based calcium(II)-sensitive CAs bearing an alkylaminobis(methylene-
phosphonate) group as the calcium(II) sensor (Figure 9). Four different ligands with propyl 
(L1), butyl (L2), pentyl (L3) or hexyl (L4) linkers between the aminobis-
(methylenephosphonates) and DO3A were prepared in order to allow an optimisation of the 
calcium(II)-sensitivity. 
 
Figure 9. Structures of the aminobis(methylenephosphonates)-based potential calcium(II) 
sensitive CAs; L1, n= 1; L2, n= 2; L3, n= 3; L4, n= 4; Ln3+ = Gd3+, Y3+, Eu3+ 
The aminobis(methylenephosphonate) unit was chosen since the introduction of negatively 
charged phosphonate groups into common Gd3+-based CAs increases their relaxivity r1 due to 
an acceleration of the water exchange rate kex and their ability to form a second sphere water 
network around the Gd3+ complexes. Both factors are important to improve the MR signal, 
especially in high magnetic fields.16, 66, 67 The use of bis(phosphonates) attached to the DO3A 
core or to superparamagnetic iron oxide (SPIO) particles was already proposed for potential 
bone targeted CAs.68, 69 Most important, aminopolyphosphonic acids are well-known chelators 
for transition metal ions,70, 71 but also exhibit high complexation efficiency towards 
biologically important metal ions such as Ca2+, Mg2+ and Zn2+.72 
In a preliminary investigation Mamedov observed a calcium(II)-dependent relaxivity change 
for two systems. However, r1 decreased with increasing calcium(II) concentration which is 
inconsistent with the mechanism (Scheme 4) proposed for the other calcium(II)-sensitive 
CAs. 
The aim of this project was a more detailed investigation of the calcium(II)-sensitivity of 
these potiential MRI CAs in order to understand the mechanistic aspects leading to the 
decrease in r1. This should allow conclusions about the suitability of the novel type of 
calcium(II) sensor for biomedical applications. 
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3.2 Results and Discussion 
3.2.1 Relaxivity vs. Calcium(II) Concentration 
Initially, the paramagnetic response of the gadolinium(III) complexes GdL1-GdL4 to changes 
in the concentration of surrounding calcium(II) ions was studied by means of relaxometric 
titrations at complex concentrations of 2.5 mM (9.4 T, 25 oC). It could be shown that, already 
in the absence of calcium(II), the length of the pendant arm has an influence on the relaxivity 
of the complexes. r1 values of 6.92, 7.43, 6.70 and 5.76 mM-1s-1 were determined for GdL1, 
GdL2, GdL3, and GdL4, respectively. 
 
Figure 10. Relaxometric Ca2+ titration curves of GdL1 (■), GdL2 (○), GdL3 (∆) and 
GdL4 (▼) at [GdLn] = 2.5 mM, 9.4 T, 25 °C, pH 7.3 (HEPES buffer) 
Even more considerable were the differences between the complexes GdL1-GdL4 in their r1 
response to the addition of Ca2+ ions (Figure 10), namely, the sensitivity of the complexes 
towards calcium(II) increases with the extension of the aliphatic side chain. No changes in r1 
of GdL1 were found over the whole span of calcium(II) concentration. In the case of GdL2, a 
moderate decrease of r1 was observed on addition of calcium(II), whereas the r1 of the GdL3 
and GdL4 solutions showed a strong dependence on the calcium concentration resulting in the 
decrease to 66% and 61% of the initial r1 values, respectively. Upon addition of equimolar 
amounts of EDTA (ethylenediaminetetraacetic acid) after the titration of GdL3 and GdL4 
with calcium(II), the relaxivity of both complexes returned to the values in calcium(II)-free 
solutions, indicating that r1 changes are reversible and exclusively induced by calcium(II). 
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3.2.2 Relaxivity vs. Complex Concentration 
As already mentioned in chapter 3.1.2 the relaxivity decrease observed for GdL2-GdL4 upon 
the addition of calcium(II) ions is not explicable with the mechanism assumed for the 
previously reported calcium(II)-sensitive CAs (Scheme 4, chapter 3.1.1.3). Since GdL2-GdL4 
all bear only one amino(bismethylenephosphonate) function, a monomeric “blocking”-
mechanism as described for the zinc(II)-sensitive systems in chapter 3.1.1.3 (Scheme 3) is 
also very unlikely. However, phosphonates, diphosphonates and aminobis-
(methylenephosphonates) are able to form aggregates in solution, either hydrogen bonded 
(units with two or more molecules) or metal-assisted,72, 73 which might have an influence on 
the relaxivity. As the ratio between aggregated and non aggregated complexes should be 
concentration dependent, r1 was studied as a function of the GdL1-GdL4 concentration itself, 
in absence and presence of Ca2+ ions (Figure 11a and Figure 11b, respectively). 
 
Figure 11. Concentration-dependence of r1 for GdL1 (■), GdL2 (○), GdL3 (∆) and GdL4 (▼) 
in (a) the absence of Ca2+ and (b) the presence of three equiv. of calcium(II) at 9.4 T, 25 °C, 
pH 7.3 (HEPES buffer). 
In Ca2+-free solutions, only GdL1 has concentration independent relaxivities, while for GdL2-
GdL4, the r1 values have been found to be concentration dependent. The relaxivity of GdL2, 
GdL3 and GdL4 dropped by 14, 38 and 17 %, respectively, when the concentration was 
increased from 2.5 to 20 mM. However, when the same experiment was performed in the 
presence of three equivalents of calcium(II), the change in r1 for GdL3 and GdL4 was low, 
while r1 decreased by 19 and 20% for GdL1 and GdL2, respectively. This shows that also 
GdL1 has a calcium(II)-dependent r1, however only at higher complex concentrations than 
used in the initial r1 measurements ([GdL1] = 2.5 mM in Figure 10). If the same experiment 
would have been performed at a complex CA concentration of about 18.5 mM the addition of 
three equivalents would have resulted in a decrease in r1 of 18 % (cf. Figure 11). The 
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observed concentration dependences of the relaxivity give strong evidence for the presence of 
aggregates with and/or without the involvement of calcium(II), depending on the system. 
3.2.3 PGSE Diffusion 1H NMR Spectroscopy 
Pulsed gradient spin echo (PGSE) diffusion 1H NMR measurements were performed in order 
to confirm that the changes in relaxivity are the result of an aggregation / disaggregation 
process. Over the last years, this method has shown to be a powerful tool in the elucidation of 
aggregation processes74-77 as well as for the determination of rotational correlation times τR.78 
As the paramagnetic gadolinium(III) is not suitable for such measurements, the diamagnetic 
yttrium(III) analogue was used. Yttrium(III) is an appropriate substitute for gadolinium(III) in 
such systems as it has an almost identical ion radius and all involved interactions are almost 
exclusively electrostatic. The diffusion coefficients D of the complexes YL1 and YL4 were 
determined in the same range of concentration as the concentration dependent relaxivity 
measurements, both in the absence and presence of Ca2+ ions at 25°C (Figure 12).  
 
Figure 12. Concentration-dependence of the diffusion coefficient D of YL1 (a) and YL4 (b) in 
the absence of Ca2+ (full symbols) and the presence of three equiv. Ca2+ (empty symbols) at 
11.75 T, 25 °C, pH 7.3 (HEPES buffer). 
As mentioned above, aggregation is a concentration dependent process. This means that for an 
infinitely diluted sample the determined diffusion coefficient D is that of the monomer, 
whereas in highly concentrated samples D corresponds to that of the aggregate. In samples 
with concentrations between those two extremes only an average D is determined, 
corresponding to mixtures of aggregated, partly aggregated and monomeric species. For the 
quantification of aggregation processes usually the viscosity independent hydrodynamic 
volume VH is used.76 VH can be calculated from the hydrodynamic radius rH which is, for 
spherical molecules, related to the diffusion coefficient D via the Stokes-Einstein equation 
(equation 3.1), where kB is the Boltzmann constant, T is the absolute temperature, η is the 
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viscosity, and rH is the hydrodynamic radius. Additionally, the rotational correlation time τR 
can be calculated from rH using equation 3.2. 
W = h=6Dj&? (3.1) 
4L = 4Dj&?]3h=  (3.2) 
Assuming dilute solutions where ηsolution = ηsolvent, values for rH, τR and VH were calculated 
from the obtained diffusion constants (Table 3). For comparison, D and the related values of 
compound 21 (Figure 13), where no aggregation is expected, were also ascertained. 
 
Figure 13. Y-DO3A-hexylamine 
In this study, the calculated values of rH, τR and VH should only be regarded as 
approximations and serve mainly for visualization purposes, as not all complexes and possible 
aggregates can be considered as spherical, making equation 3.1 valid only within certain 
limits. However, it is unambiguous that in the absence of Ca2+ ions the diffusion constants of 
YL1 are significantly higher than those of YL4. The calculated hydrodynamic volume VH of 
YL4 is about two-times the volume of YL1, whereas VH of YL1 is only slightly higher than 
that of the monomeric compound 21. This confirms the presence of aggregates for LnL4 
already in the absence of calcium(II). D of YL4 and all related values are therefore only 
average values over all forms of YL4 in solution. The aggregation process is also shown by 
the increase in VH of YL4 with higher complex concentrations, at which the equilibrium 
between aggregated and monomeric species is shifted towards the aggregate. As, on the other 
hand, the relaxivity of GdL4 is decreasing with increasing complex concentration (Figure 
11a), r1 of these aggregates must be smaller than r1 of the monomeric complex. 
The tendency of LnL1 to form aggregates is much lower resulting in the significantly smaller 
hydrodynamic volume. However, in contrast to the relaxivity measurements, VH of YL1 
shows a small dependence on complex concentration, especially at higher concentrations. 
Therefore it might be possible that a certain amount of weak aggregates is formed at higher 
NN
N N
O
O
O
O
O
O
21
Y3+
NH2
28 CALCIUM(II)-SENSITIVE MRI CONTRAST Agents 
concentrations of LnL1 but they do not seem to influence the relaxivity. 
Table 3. Diffusion coefficient D, hydrodynamic radius rH, hydrodynamic volume VH, and 
rotational correlation time τR at 25°C of 21 as well as of YL1 and YL4 in the absence and 
presence of three equivalents of calcium(II) as a function of the complex concentration. 
  Concentration 
 Complex 2.5 mM 5 mM 10 mM 20 mM 
D [m2s1] 
21 3.85 x 10-10 3.85 x 10-10 3.85 x 10-10 3.85 x 10-10 
YL1 3.53 x 10-10 3.50 x 10-10 3.46 x 10-10 3.30 x 10-10 
YL1 + 3 equiv. Ca2+ 3.45 x 10-10 3.11 x 10-10 2.93 x 10-10 2.38 x 10-10 
YL4 2.85 x 10-10 2.74  x 10-10 2.71 x 10-10 2.60 x 10-10 
YL4 + 3 equiv. Ca2+ 2.49 x 10-10 1.95 x 10-10 1.84 x 10-10 1.59 x 10-10 
rH [Å]a 
21 5.01 5.01 5.01 5.01 
YL1 5.47 5.52 5.57 5.84 
YL1 + 3 equiv. Ca2+ 5.60 6.21 6.58 8.10 
YL4 6.76 7.05 7.12 7.42 
YL4 + 3 equiv. Ca2+ 7.75 9.87 10.51 12.12 
VH [Å3]b 
21 528 528 528 528 
YL1 684 702 725 835 
YL1 + 3 equiv. Ca2+ 736 1003 1192 2228 
YL4 1295 1465 1511 1711 
YL4 + 3 equiv. Ca2+ 1953 4031 4867 7454 
τR [ps]a) 
21 145 145 145 145 
YL1 188 193 199 230 
YL1 + 3 equiv. Ca2+ 202 276 328 613 
YL4 356 403 416 471 
YL4 + 3 equiv. Ca2+ 537 1109 1339 2050 
aCalculated from equations 3.1 and 3.2 using j = 1.13 × 10-3 Pa × s for D2O. bCalculated from 
rH with l? = m] D&?] 
 
The addition of three equivalents of calcium(II) to LnL1 then clearly induces aggregation. VH 
of YL1 at c = 20 mM in the presence of Ca2+ ions (three equivalents) is about three-times 
higher than VH of YL1 in the absence of calcium(II). However, at c = 2.5 mM the 
hydrodynamic volume of YL1 with calcium(II) is only slightly larger than without 
calcium(II). This implies that calcium(II) does not significantly increase the amount of 
aggregates at this concentration, which is an explanation for the independence of r1 on the 
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calcium(II) concentration in the initial r1 measurements at a gadolinium(III) complex 
concentration of 2.5 mM. The ratio of the aggregated to non-aggregated complexes increases 
at higher concentrations of calcium(II) which in turn results in the observed decrease in 
relaxivity at [GdL1] = 18.5 mM (cf. Figure 11). 
In the case of YL4, the addition of Ca2+ ions increases the hydrodynamic volume even more 
than in the case of YL1. The VH of YL4 at c = 2.5 mM in the presence of Ca2+ is 1.5 times 
bigger than in its absence. As for LnL1, the increased formation of aggregates seems to be 
responsible for the decrease in relaxivity of LnL4. With increasing complex concentration the 
average size of the species in solution seems to further increase. However, no influence on the 
r1 was observed for GdL4 in the concentration dependent experiments (Figure 11b). 
The results indicate that calcium(II) generally amplifies the formation of aggregates of these 
systems. Up to a certain point, the formation of bigger aggregates results in the observed 
decrease in relaxivity. The formation of aggregates leads to a slower rotation (see τR in Table 
3). However, the relaxivity enhancing effect of the increased τR should not be strong at the 
applied high magnetic field (9.4 T)56 and in the cases where r1 decreases an opposite effect 
must be also operative. 
3.2.4 31P{1H} NMR Spectroscopy 
In order to understand whether the different tendencies to form aggregates are related to 
differences in the interaction of the phosphonate-containing side arms with the paramagnetic 
centre, 31P{1H} NMR experiments on EuL1 and EuL4 solutions (50 mM in D2O, pD 7.4) 
were performed. The complexes of europium(III) are usually used to obtain information on 
the coordination behaviour of the gadolinium(III) analogues by NMR spectroscopy due to 
their favourable ratio between paramagnetic induced shift and line broadening. The 31P{1H} 
NMR spectrum of EuL4 measured at 298 K (Figure 14a) shows only one signal at 6.8 ppm. 
As this is nearly at the same position as the 31P signal of the free ligand (6.6 ppm at pD 7.4), 
the phosphonate groups of LnL4 are most likely not coordinated to the lanthanide ion. When 
the 31P{1H} NMR spectrum is measured at 273°K (Figure 14b) the signal becomes more 
narrow and is split into two resonances (7.0 ppm and 6.3 ppm), indicating inequivalent 
phosphonates. However, as a coordination to the lanthanide should have a more significant 
influence on the chemical shift, the inequivalency most likely arises from aggregation where 
the phosphonates become chemically inequvalent. This cannot be observed at higher 
temperatures due to an increased dynamic or a stronger paramagnetic influence on the 
transverse relaxation time from the europium(III) ion. 
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Figure 14. 31P{1H} NMR spectra of EuL4 at 298 K (a) and 273 K (b). *Impurity from the 
ligand synthesis, being hardly visible in solutions of the free ligand, but more intense in these 
spectra as it experiences only a weak paramagnetic influence. 
The addition of calcium(II) then results in a broadening of the signal but not in a change of 
the chemical shift. As for LnL4 neither of the phosphonate groups binds to the lanthanide(III) 
ion, both groups can interact with calcium(II).  
In the case of EuL1, the 31P{1H} NMR spectrum measured at 298 K (Figure 15) shows three 
resonances. The signal at 3.1 ppm matches to the chemical shift of the free ligand indicating 
the presence of phosphonate species which are not coordinated to the paramagnetic center. 
However, the observation of two strongly upfield shifted resonances at -102.3 and 
-109.6 ppm, respectively, suggests an interaction of phosphonate groups with the 
paramagnetic Eu3+ ion, as well.79 
 
Figure 15. 31P{1H} NMR spectra of EuL1 at different temperatures. *Impurity from the 
ligand synthesis (see above). 
*
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The two upfield shifted signals of EuL1 merge into one broadened peak when the temperature 
is increased to 318 K, which can be explained by the existence of two different coordination 
isomers at lower temperatures.69, 80 Moreover, when the temperature is further increased, the 
signals of the free and the coordinated phosphonates keep broadening and move closer to each 
other indicating an equilibrium between coordinated and non-coordinated phosphonates.  
The integration ratio between the signal at 3.1 ppm and the two upfield shifted signals is not 
1:1, but rather 3:2. Therefore, it is possible that the solution contains a mixture of species 
where in two cases one of the two phosphonates is coordinated and the other one is not 
coordinated resulting each in an upfield shifted signal and a signal in the range of the free 
ligand, and a small fraction where both phosphonates are non-coordinated which results only 
in a signal in the range of the free ligand. Since the diffusion measurements indicated a weak 
tendency to form aggregates at higher complex concentrations, as are necessary for the 
31P{1H} NMR measurements, an intermolecular interaction cannot be excluded, as well. 
Nevertheless, it is possible that both signals belong to the same complex with one coordinated 
and one non-coordinated phosponate group. The discrepancy between a therefore expected 
1:1 integration ratio and the observed 3:2 can be explained by the difficulty of correct 
integration in these paramagnetic systems as the paramagnetic influence can also determine 
the signal intensity. This is most obvious for the signal at about 16 ppm which belongs to a 
small impurity being already visible in the 31P{1H} NMR spectrum of the free ligand. Though 
there the signal is negligible, the ratio between the signal of the impurity and the signals of the 
complex is significantly increased in the spectra of the paramagnetic europium(III) complex. 
 
Figure 16. 31P{1H} NMR spectra of EuL1 at 298 K in the absence of calcium(II) (a) and in 
the presence of three equiv. calcium(II) (b). *Impurity from the ligand synthesis. 
After the addition of three equivalents of calcium(II), the 31P{1H} NMR spectrum of EuL1 
-100-500 ppm -100-500 ppm
* *
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(Figure 16b) shows a signal at 3.9 ppm and still two upfield shifted signals, now at -104.3 and 
-131.6 ppm, respectively. The addition of Ca2+ ions affects the chemical shift of the signals 
corresponding to coordinated phosphonate groups, which means that the 
aminobis(methylenephosphonate) group of LnL1 can interact with Ca2+ ions while one 
phosphonate group is still coordinated. In this case only one of the phosphonates is free to 
interact with calcium(II) resulting in smaller and less stable aggregates and explaining the 
lower affinity to form aggregates, as was observed in the diffusion measurements (see Table 3 
in chapter 3.2.3). By contrast, in the case of LnL4 where only species with two free 
phosphonate groups exist, the formation of more stable and larger aggregates involving one or 
even more Ca2+ ions is possible. 
3.2.5 Luminescence Spectroscopy  
Luminescence emission spectra of EuL1-EuL4 in aqueous media give further details about 
their coordination environment. An advantage of this technique is that it requires a much 
lower concentration of the complex than for 31P{1H} NMR spectroscopy, thereby giving the 
opportunity to observe concentration dependent changes. For EuL1, the coordination of a 
phosphonate group in the absence and presence of calcium(II), already observed in the 
31P{1H} NMR spectra for a complex concentration of 50 mM, could be confirmed for all 
measured complex concentrations (5 mM – 50 mM). The appearance of a distinctive band at 
625 nm and the form and splitting of the ∆J = 1 manifold in the luminescence emission 
spectrum of EuL1 (Figure 17a) is a clear evidence for the coordination of a phosphonate 
group to the europium(III) centre.79, 81  
 
 
 
 
 
 
 
 
Figure 17. Luminescence emission spectra of EuL1 (a) and EuL4 (b) in the presence and 
absence of three equiv. calcium(II) (5 mM, λex=395 nm, 25 °C, pH 7.3, HEPES). 
Since the coordination can be observed also at low complex concentrations where the 
diffusion measurements indicated no significant aggregation, it is much more likely that the 
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coordination to the lanthanide(III) ion is an intramolecular rather than an intermolecular 
process. This results in complexes, where one phosphonate is coordinated and the other one is 
free to interact with calcium(II). None of the luminescence emission spectra of EuL2-EuL4 
exhibit the characteristic pattern for a phosphonate coordination, neither in the absence nor in 
the presence of calcium (II). This confirms that the phosphonate groups of these complexes 
are not coordinated to the lanthanide(III) ion over the whole range of complex concentration. 
The spectrum of EuL4 is shown in Figure 17b as an example. 
3.2.6 Determination of the Hydration Number q 
The differences in the coordination behaviour of LnL1 and the other three complexes LnL2-
LnL4 can explain the differences in the tendency to form aggregates in the absence and 
presence of calcium(II), but do not give an explanation for the decrease in relaxivity. A 
possible reason for a lower r1 could be a reduction in the number of inner-sphere water 
molecules, q, accompanied with aggregation. This could overcompensate the positive effect 
of an increase in the rotational correlation time τR on the relaxivity and therefore lead to an 
overall drop in r1 (see equations 2.7 - 2.12 in chapter 2.3.1). 
The measurement of luminescence lifetimes in H2O and D2O solutions of the complexes 
offers a possibility to estimate the hydration number q. The method is based on the difference 
in the effectivity of O-H and O-D oscillators to act as a quencher of the excited state. O-H 
oscillators close to the europium(III) ion are about 200 times more efficient for non-radiative 
desactivation than O-D oscillators. q can then be calculated by using the empirical equation 
3.3.82 
5 = 1.2 × 	τ ?/o − τ 8/o − 0.25 (3.3) 
where 4?/ and 48/ are the luminescence lifetimes in H2O and D2O, respectively.  
Using this equation, the hydration number q of EuL1-EuL4 was determined in the absence 
and presence of calcium(II) (Table 4). 
Table 4. Luminescence emission lifetimes and estimated q values of EuL1-EuL4 (4-5 mM) in 
the absence and presence of Ca2+ ions (three equiv.). 
Complex 4?/[ms] 48/[ms] q Complex + Ca2+ 4?/[ms] 48/[ms] q 
EuL1 0.42 1.37 1.7 EuL1 + Ca2+ 0.54 1.75 1.2 
EuL2 0.58 1.55 1.0 EuL2 + Ca2+ 0.68 1.65 0.7 
EuL3 0.50 1.63 1.4 EuL3 + Ca2+ 0.84 1.60 0.4 
EuL4 0.65 1.66 0.8 EuL4 + Ca2+ 0.89 1.75 0.4 
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For EuL1, the only complex with a coordinated phosphonate group, a q value of 1.7 is 
obtained at 5 mM complex concentration in the absence of Ca2+ ions, suggesting the presence 
of dihydrated species. Since a coordination number of ten is unlikely for europium(III) 
complexes, this is only possible if the solution contains a fraction of species with non-
coordinated phosphonate groups allowing two inner-sphere water molecules. As mentioned in 
chapter 3.2.4, the presence of such species would not generally be in contradiction to the 
results of the phosphorous NMR study and can also not be excluded from the luminescence 
spectra. However, equation 3.3 is an empirical equation, working already for systems with no 
second sphere only with an error of ±0.5. Furthermore, it has been shown previously,83 that 
the non-consideration of additional oscillator(s) brought into the proximity of the 
europium(III) ion as in our case by the coordination of the aminobis(methylenephosphonate) 
group (Figure 18a) might increase the obtained q value, thereby suggesting two hydrated 
species where only monohydrated species exist. By contrast, for EuL2-EuL4, the q values are 
rather one than two in the absence of Ca2+ ions. This still agrees with the fact that no 
experimental evidence of the coordination of phosphonates to the paramagnetic centre is 
found, as it is known that non-polar moieties attached to the fourth cyclen nitrogen can reduce 
the overall coordination number in water (Figure 18b). 
 
Figure 18. Solution structures of LnL1 and LnL4 with possible oscillators (red) influencing 
the luminescence lifetimes of the europium complexes. 
The addition of three equivalents of calcium(II) to solutions of EuL1-EuL4 reduced q for all 
four complexes (Table 4). As Matczak-Jon et al.72 have shown that the coordination of 
calcium(II) by an aminobis(methylenephosphonate) does not involve the amino nitrogen, the 
N-H or N-D oscillator (see Figure 18) remains unchanged upon the addition of calcium(II) 
and has therefore no influence on the decrease in q. On the other hand, this means that even 
though the apparent q value might not represent the exact number of coordinated water 
molecules in the inner-sphere, in all cases the reduction of the apparent q values must be 
related to a decreasing number of water O-H and O-D oscillators, respectively. This can arise 
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from a lower number of inner-sphere water molecules, as well as from a reduction of second 
sphere water on the aminobis(methylenephosphonate) groups (see Figure 18). In both cases 
the observed reduction in the obtained q values explains the observed decrease in r1 for GdL2-
GdL4 at low CA concentrations, although the relation between q and r1 is not linear. This is 
most obvious in the case of LnL1 where a decrease of in q 0.5 results in hardly any r1 change 
at a complex concentration of 5 mM. By contrast, for EuL4 q decreases by only 0.4 whereas 
r1 of GdL4 for the same concentration decreases from 5.54 mM-1s-1 to 3.86 mM-1s-1(-30%). 
The hydration number q was also determined as a function of the complex concentration in 
the absence and presence of three equivalents of calcium(II) (Figure 19a and Figure 19b, 
respectively). Similar trends were observed as for the concentration-dependence of the 
relaxivities (see Figure 11 in chapter 3.2.2). 
 
Figure 19. Concentration-dependence of q for EuL1 (■), EuL2 (○), EuL3 (∆) and EuL4 (▼) 
in (a) the absence of Ca2+ and (b) the presence of three equiv. of calcium(II) at 25 °C, pH 7.3 
(HEPES buffer). 
In the systems where r1 was independent of the gadolinium(III)-complex concentration, q also 
remained unchanged. However, in all cases where r1 decreased with increasing complex 
concentration, the hydration number also dropped for the respective europium(III) complexes. 
It could be shown in chapter 3.2.3 that the decrease in relaxivity is accompanied with the 
formation of aggregates, thus the aggregation must lead to structures in which the water 
access to the inner and/or second sphere of the lanthanide ion is significantly hindered. The 
lower number of water molecules being able to interact with the paramagnetic centre, is then 
reflected in the reduced relaxivity. Similarly, Rojas-Quijano et al. reported a decrease of q 
with increasing complex concentration for the phosphonate containing Ln-PCTA-(ampOBu)3 
which was related to oligomer formation.84 
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3.2.7 17O NMR Spectroscopy 
In order to assess parameters characterising the water exchange and rotational dynamics on 
the gadolinium(III) complexes, variable temperature transverse and longitudinal 17O NMR 
relaxation rates and chemical shifts were measured at 11.7 T in aqueous solutions of GdL1-
GdL4 at concentrations of about 50 mM. A detailed discussion of this method can be found in 
ref. 1. A short summary involving all important equations is given in the experimental part 
(chapter 5.1.8) of this thesis. Therein the reduced 17O relaxation rates (1/T1,2r) and the reduced 
17O chemical shifts ∆ωr are defined as the following: 
+ 1, p, = 123 + 1, − 1, U, (3.4) 
∆Hp = 123 rH% − HUs (3.5) 
where Pm is the molar fraction of bound water molecules, 1/T1,2 is the longitudinal or 
transverse 17O NMR relaxation rate of the paramagnetic solution, 1/T1,2A is the longitudinal or 
transverse 17O relaxation rate of a reference and ωp and ωA are the 17O chemical shifts of the 
paramagnetic solution and the reference, respectively. 
 
Figure 20. Variable temperature reduced 17O transverse () and longitudinal () relaxation 
rates and chemical shifts () for GdL1. B = 11.75 T. The lines correspond to the least-squares 
fit as explained in the text. 
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For complexes GdL1 (Figure 20), GdL2 and GdL3 (Figure 21), the reduced 17O transverse 
relaxation rates (1/T2r) decrease with increasing temperature in the whole temperature range 
investigated, indicating that they are in the fast exchange region. In the fast exchange regime, 
the reduced transverse relaxation rate is defined by the transverse relaxation rate of the bound 
water oxygen 1/T2m, which is in turn influenced by the water exchange rate kex, the 
longitudinal electronic relaxation rate 1/T1e, and the scalar coupling constant A/ħ. The reduced 
17O chemical shifts ∆ωr are determined by A/ħ. Transverse 17O relaxation is governed by the 
scalar relaxation mechanism, thus contains no information on the rotational motion of the 
system. In contrast to 1/T2r, the longitudinal 17O relaxation rates 1/T1r, are determined by 
dipole-dipole and quadrupolar relaxation mechanisms, both related to rotation. The dipolar 
term depends on the gadolinium(III)-water oxygen distance rGdO, while the quadrupolar term 
is influenced by the quadrupolar coupling constant χ(1+η2/3)1/2. For GdL2 and GdL3, the 
experimentally measured paramagnetic 17O chemical shifts were considerably smaller than 
what would be expected for a gadolinium(III) complex with the given q value, which is why 
they have not been included in the final fitting. A diminution of the chemical shifts has been 
previously reported in systems with a significant second sphere contribution.85, 86  
The behaviour of GdL4 is unusual, as the 1/T2r values at high temperature start to increase 
(Figure 22). On the other hand, the 1/T1r values show only small temperature dependences. 
This can be related to the presence of the relatively large amount of aggregates even in the 
absence of Ca2+ ions, being observed in the PGSE NMR diffusion experiments (see Figure 
12b in chapter 3.2.3). The formation of such aggregates is likely temperature dependent. 
Therefore no further analysis of the 17O NMR data on GdL4 was performed. 
 
Figure 21. Variable temperature reduced 17O transverse () and longitudinal () relaxation 
rates for GdL2 (a) and GdL3 (b). B = 11.75 T. The lines correspond to the least-squares fit as 
explained in the text. q = 1 
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At the concentration used for the 17O NMR measurements, some aggregation is expected in 
the absence of calcium(II) for GdL1, based on the slight concentration-dependence of the 
diffusion NMR data on YL1 (see Figure 12a in chapter 3.2.3). However, the relaxivities of 
GdL1 (see Figure 11a in chapter 3.2.2) and the q values of EuL1 (Figure 19a in chapter 3.2.6) 
showed no dependence on the concentration. In the case of GdL2 and GdL3 stronger 
aggregation is expected, though, no unusual behaviour was observed for 1/T2r and 1/T1r. It was 
therefore
 
decided to further analyse the three systems. Nevertheless, one should be aware that 
changing the temperature might change the aggregation state and thereby the size and also the 
hydration number of the systems, which should be considered in the judgement of the 
obtained data. 
 
Figure 22. Variable temperature reduced 17O transverse () and longitudinal () relaxation 
rates for GdL4. B = 11.75 T. 
Even though a higher q value has been obtained for EuL1 from the luminescence lifetime 
measurements (Figure 19 in chapter 3.2.6) and the possibility of the existence of some 
dehydrated species with uncoordinated phosphonate groups cannot be excluded from the 
luminescence and 31P NMR data, the hydration number of GdL1 was fixed to one in this 
analysis, as q = 1 correlates better with the obtained values of the reduced chemical shifts ∆ωr 
than q = 1.7. This indicates that it is more likely that the luminescence data pretend an 
increased q value rather than the existence of dehydrated species. For GdL2 and GdL3 the 
increased formation of aggregates at 50 mM concentration might lead to a reduction of inner 
sphere water, which was indicated by a reduction in q to 0.7 in the concentration-dependent q 
measurements (Figure 19a in chapter 3.2.6). However, as the equation used in these 
measurements is not optimised for this system, the reduction can also only be due to a change 
in the second sphere and the number of inner sphere water molecules might still be one. 
Therefore, for GdL2 and GdL3 two fits of the 17O data were performed by assuming q = 0.7 
or q = 0.7 (Figure 21 shows the fit with q = 1). 
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The experimental data for GdL1-GdL3 were fitted according to the Solomon-Bloembergen-
Morgan theory of paramagnetic relaxation (see chapter 2.3) using the equations presented in 
the experimental part (chapter 5.1.8). In the fitting procedure, rGdO has been fixed to the 
common value of 2.50 Å.87 The quadrupolar coupling constant χ(1+η2/3)1/2 was set to the 
value for pure water, 7.58 MHz. For GdL2 and GdL3, the scalar coupling constant A/ħ, was 
fixed to  -3.6 MHz, the value obtained for GdL1. The electron spin relaxation rate 1/T1e, was 
fitted to a simple exponential function. Since it makes a negligible contribution to the 
transverse relaxation rates, the fit of parameters related to the zero-field splitting mechanism, 
as usually done, has very low confidence. The following parameters were adjusted: the water 
exchange rate kex298, or the activation entropy ∆S‡, the activation enthalpy for water exchange 
∆H‡, the rotational correlation time τRO298, and its activation energy ER, and the electron spin 
relaxation rate at 298 K 1/T1e298 as well as its activation energy ET. The values obtained for 
these parameters are presented in Table 5.  
Table 5. Parameters obtained from the fitting of the 17O NMR data at 11.75 T. 
 GdL1 GdL2 GdL3 Gd-DOTAb 
qa 1 1 0.7 1 0.7 1 
kex298 [106 s-1] 170±13 160±15 120±15 190±15 130±10 4.1 
∆H‡ [kJ mol-1] 27.2±0.5 16.8±0.4 16.3±0.4 13.4±0.5 13.4±0.5 49.8 
∆S‡ [J mol-1 K-1] 0±2 -32±2 -36±2 -42±2 -44±2 +48.5 
A/h [106 rad s-1] -3.6±0.3 -3.6a -3.6a -3.6a -3.6a -3.7 
τRO
298
 [ps] 290±10 390±10 540±10 380±10 550±20 90 
ER [kJ mol-1] 17.8±0.9 17.1±0.7 16.3±0.7 16.5±0.9 16.6±1.0 17 
a fixed in the fit. bRef. 88 
 
For 1/T1e298, for all three GdL1-GdL3 complexes values between (1.1-1.3)×107 s-1 were 
obtained, while ET was fixed to 1 kJ/mol, otherwise small negative values were obtained. It is 
noticeable that the electron spin relaxation 1/T1e makes a limited contribution in any of the 
three systems, representing maximum 10 % in the correlation time τc governing the relaxation 
rate of the bound water oxygen, 1/T2m (1/τc = kex + 1/T1e). Therefore, the water exchange rate 
can be obtained with a very good certitude. 
The second sphere water molecules that are present around the phosphonate groups might 
affect the 17O longitudinal relaxation rates, governed by dipolar and quadrupolar interactions. 
However, this effect is difficult to describe quantitatively, which is why no second sphere 
effect was included in the fit. On the other hand, 17O T2 relaxation is mainly driven by the 
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scalar contribution, thus it is not sensitive to rotation and consequently to the presence of a 
second hydration shell. Consequently, the water exchange rates calculated are not influenced 
by second sphere effects.  
The water exchange rate is very high on all the three gadolinium(III) complexes. It is in the 
same order of magnitude as for the [Gd(H2O)8]3+ aqua ion (kex298 = 8×108 s-1), and this 
dependents only to a very small extent on the q value assumed for GdL2 and GdL3. As 
already mentioned in chapter 2.3.1, DOTA- or DO3A-type complexes have in general much 
slower water exchange (kex298 = (4-10)x106 s-1) though one example of a very fast water 
exchange has been reported on the gadolinium(III) complex of a Gd-DO3A complex bearing 
an N-linked CH2CH2NHCO–pyridyl moiety (kex298 = 1.1×108 s-1).89 For GdL2 and GdL3, the 
fast water exchange can be likely related to the associative nature of the exchange mechanism. 
Indeed, the strong negative values of the activation entropy obtained for GdL2 and GdL3 are 
clearly indicative of an associative activation mode, in contrast to the large positive value 
reported for Gd-DOTA (1), with a dissociatively activated water exchange. As mentioned 
above, for GdL2 and GdL3, an overall coordination number of eight with the participation of 
seven donor groups of the ligand and one inner sphere water molecule (cf. Figure 18b in 
chapter 3.2.6) is assumed for q = 1 or even partly seven-fold coordination in the case of q = 
0.7. Since the common coordination numbers for gadolinium(III) are eight or nine, eight- and 
seven-coordinate gadolinium(III) complexes typically undergo associative water exchange. 
The associative character, as indicated by the activation entropy of zero, is less important for 
GdL1. A plausible explanation for this difference between GdL1 and GdL2/GdL3 is the 
existence of an overall coordination number of nine in the case of LnL1 due to the 
coordination of one phosphonate group to the lanthanide(III) ion and one inner-sphere water 
molecule. In this case, the fast exchange can be rather related to the presence of the 
coordinated phosphonate group. Indeed, the phosphonate coordinating group has been often 
recognized to induce fast water exchange on the Gd3+ complexes.16 One should note that even 
if the hypothesis of q = 1 was not correct for GdL1, the water exchange would be fast (if we 
assume q = 2, we calculate kex298 = 3.4×108 s-1). However, for a dehydrated complex where no 
phosphonate group is coordinated to the gadolinium(III) ion the observed fast water exchange 
is hard to explain. 
The rotational correlation time of the gadolinium(III)-water oxygen vector, τRO298, as obtained 
from the analysis of the longitudinal 17O relaxation rates for GdL1, is similar to that 
calculated from the NMR diffusion experiments for the y analogue (see Table 3 in chapter 
3.2.3). It is longer than τRO298 of Gd-DOTA (1) which can be explained in terms of a less 
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compact structure brought by the side-chain and the high number of water molecules 
hydrogen-bound to the bisphosphonate group which will considerably increase the 
hydrodynamic radius of the complex and the existence of a small fraction of aggregated 
species at this concentration. The rotational correlation times of GdL2 and GdL3 depend on 
the q assumed, but in any case, they are longer than that for GdL1, indicative of stronger 
aggregation. For GdL1, the longitudinal 17O relaxation rates were also measured in the 
presence of three equivalents of calcium(II). The 1/T1r values were higher than in the absence 
of Ca2+ ions, being in accordance with a longer rotational correlation time and indicating 
again the calcium(II)-induced aggregation. 
3.3 Conclusions 
A series of novel DO3A-type gadolinium(III) complexes, having alkylaminobis(methylene-
phosphonate) moieties were extensively investigated towards their relaxivity response to the 
presence of calcium(II). At low complex concentrations (2.5 mM), the longitudinal relaxivity 
of GdL2-GdL4 decreased after addition of calcium(II), whereas GdL1 had no calcium(II) 
dependence. Concentration-dependent relaxivity and PGSE 1H diffusion measurements 
showed that calcium(II)-induced aggregation is responsible for the observed changes in 
relaxivity. GdL1 has a lower tendency to form aggregates in the presence of calcium(II) than 
GdL2-GdL4, resulting in a calcium(II) dependent relaxivity change only at high complex 
concentrations. This is attributed to a different coordination behaviour of the phosphonate 
groups in GdL1 as compared to GdL2-GdL4. 31P{1H} NMR spectroscopy and luminescence 
measurements on the europium(III) analogues indicated coordination of a phosphonate group 
to the lanthanide(III) ion for GdL1, but not for GdL2-GdL4. Since the coordination in the 
case of GdL1 can be observed also at low complex concentrations where the diffusion 
measurements indicated no significant aggregation, it is much more likely that the 
coordination to the lanthanide(III) ion is an intramolecular rather than an intermolecular 
process. Form the obtained 31P{1H} NMR and luminescence data, it cannot be clarified 
whether exclusively complexes with one coordinated and one uncoordinated phosphonate 
group exist in solution or also a certain amount of species exists with no coordinated 
phosphonate group at all. However, according to the integration ratio of the 31P{1H} NMR 
spectrum, this amount is maximum 20 % and due to the problems with integration in the 
paramagnetic solutions it is likely even less. Therefore most or perhaps all GdL1 complexes 
have one coordinated and one free phosphonate group. Since the 31P{1H} NMR spectra show 
that the phosphonate group remains coordinated to the lanthanide(III) ion even after the 
interaction of the aminobis(methylenephosphonate) group with calcium(II), only one of the 
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phosphonates is free to interact with calcium(II). This results in smaller and less stable 
aggregates and is the reason for the lower affinity of GdL1 to form aggregates. In contrast, for 
GdL2-GdL4, where no coordination of a phosphonate group to the lanthanide(III) ion is 
observed, both phosphonate groups can be involved in the calcium(II)-induced aggregate 
formation, resulting in larger and more stable aggregates. In these aggregates, the water 
access to the inner and/or the second sphere is significantly hindered, shown by a reduction in 
the apparent hydration number q, which therewith explains the observed decrease in 
relaxivity. A still remaining question is the high apparent hydration number q of GdL1 in the 
absence of calcium(II). The luminescence lifetime measurements resulted in q values between 
1.7 and 1.6 for complex concentrations between 5 and 50 mM. If one assumes a mixture of 
monohydrated complexes with one coordinated phosphonate group and dihydrated complexes 
with two uncoordinated phosphonate groups, a q value of 1.7 would refer to a mixture of 
30 % monohydrated and 70 % dehydrated complexes (40 to 60 % for q = 1.6). However, this 
is in contradiction to the results from the 31P{1H} NMR measurements which allowed 
maximum 20 % dehydrated species. Therefore it is very likely that the used equation is not 
valid for this system due to the additional oscillators brought in the proximity of the 
lanthanide(III) ion and a q value of about one is a more realistic reflection of the hydration 
state in a solution of GdL1 than a q of 1.7. This is also supported by the better correlation of q 
= 1 with the obtained values of the reduced chemical shifts ∆ωr in the variable temperature 
17O NMR measurements as compared to q = 1.7. 
Furthermore, the 17O NMR measurements revealed an extremely high water exchange rate 
kex298 for these complexes, being in the same order of magnitude as that of the [Gd(H2O)8]3+ 
aqua ion. All these physico-chemical data show that structurally relatively simple lanthanide 
complexes might have unexpected and complicated solution chemistry behaviour. 
In terms of potential MRI applications, both GdL3 and GdL4 show a relaxivity increase upon 
decrease in calcium(II) concentration (at low GdLn concentration), thus the drop in 
extracellular calcium(II) associated to brain activity would result in increased image intensity. 
However, the complexity of their solution behaviour would prevent any practical use: the MR 
signal intensity and the calcium response would be also influenced by their aggregation state 
thereby making data analysis extremely complicated. Nevertheless, the obtained results 
demonstrate that the quest for responsive CAs can be enriched with novel approaches. 
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4 Silsesquioxane-based MRI Contrast Agents 
4.1 Introduction 
4.1.1 High Sensitivity MRI Contrast Agents 
Since the development of the first gadolinium(III)-based CA for MRI, there has been a quest 
for improving the efficiency e.g. the longitudinal relaxivity r1 of the agents. Two reasons are 
mainly responsible for this ambition. The first reason is that due to their low relaxivity, most 
commercial CAs are only effective at high concentrations. The smallest change in the 
observed relaxation rate 1/T1obs necessary to be detected as a change in contrast is about 
0.15 s-1.90 For Dotarem™ (1), having the typical low relaxivity of 3.4 mM-1s-1 at 37°C and a 
proton Larmor frequency of 20 MHz,9 this means a CA concentration of at least 0.044 mM 
(cf. equation 2.4 in chapter 2.3). To achieve a satisfying contrast enhancement usually 
concentrations of more than 0.1 mM are applied.91 For certain applications like MR 
angiography, which is the visualisation of blood vessels, even double and triple this dose is 
sometimes used. The high dose, but also the related longer exposure of the body to the CA, 
increase the risk of a release of free gadolinium(III).17 Compounds with high relaxivity can be 
detected at lower doses, or provide greater contrast at equivalent doses as compared to 
compounds with lower relaxivity. The second reason to develop high sensitivity CA is the 
desire to detect molecular targets by MRI. This so called molecular imaging has the aim to 
locate certain types of cells or biomolecules within the body in order to visualise molecular 
events occurring at cellular levels. This would represent a breakthrough in clinical settings as, 
in addition to provide early diagnosis, it would allow the assessment of the underlying 
therapy. The early knowledge of processes on the molecular level will largely anticipate the 
time currently required for assessment based on anatomical changes and thereby reduce the 
time required to decide whether a chosen therapy is going to provide the expected effects or 
another approach might be more promising. However, to locate such biomarkers they must 
coordinate or at least interact with an appropriate CA and in order to visualise this event via 
MRI, the concentration of the respective cell or biomolecule must be in the range of the CA. 
As outlined above, this would require a biomarker concentration of at least 0.044 mM, better 
0.1 mM or more for the typical commercially available CAs, which strongly limits the 
number of potential biological targets. 
The parameters mainly determining the relaxivity were introduced in chapter 2.3 and are 
namely the number of coordinated water molecules q, the water exchange rate kex, the 
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rotational correlation time τR, the electronic properties of the gadolinium(III) ion 1/T1e and the 
external field expressed by the proton Larmor frequency ωI. It was already mentioned in 
chapter 2.4.2 that an increase in the hydration number q can provide a significant increase in 
relaxivity independently from the other parameters. However, as this involves a reduction in 
ligand denticity, it is often accompanied with an unwanted decrease in complex stability. 
Furthermore, the existence of more than one free coordination site can allow reversible oxy-
anion binding under physiological conditions which in turn can lead to the complete loss of 
inner sphere water.32, 33 As described in chapter 2.3.1 the dependence of the relaxivity on the 
other parameters is more complicated. For an optimal relaxivity, equation 4.1 needs to be 
fulfilled, which would require the simultaneous optimisation of all three parameters 
depending on the magnetic field desired for the particular application. 
14G = 14L + 1K + hK = H- (4.1) 
However, it could be shown, that kex and τR of the currently used CAs are generally too slow 
and too short, respectively at any field strengh. Some useful empirical relationships have 
emerged which influence water exchange rates of CAs. Replacing an acetate oxygen donor 
with an amide oxygen donor will result in a slower water exchange rate. As most of the 
studied complexes undergo dissociative water exchange, increasing the steric bulk will 
increase the water exchange rate. For example replacing an acetate oxygen donor with the 
larger phosphonate oxygen donor increases the exchange rate (see also chapter 3.2.7).92 
However, the development of CAs with faster water exchange rates is not straight forward, 
and changes in the coordination sphere can be accompanied with a loss in stability. 
Furthermore, at the mostly used field strength of 1.5 T the short rotational correlation time τR 
is the most limiting factor of current CAs and kex becomes only important when rotational 
motion is slowed down.91  
The influence of the applied magnetic field on the optimal values of the parameters 
determining the relaxivity of a CA can be identified from the equations of the Solomon-
Bloembergen-Morgen theory in chapter 2.3. A bit more graphical is the measurement of so 
called 1H nuclear magnetic relaxation dispersion (NMRD) profiles. In a 1H NMRD profile the 
relaxivity of a CA is measured as a function of the magnetic field expressed by the proton 
Larmor frequency. The 1H NMRD profile of Gd-DOTA (Dotarem™) (1) together with the 
range of magnetic fields currently used in clinical MR scanners is shown in Figure 23. By 
using the Solomon-Bloembergen-Morgan equations in a simultaneous fitting of this profile 
together with 17O NMR (cf. chapter 3.2.7) and electron paramagnetic resonance (EPR) data 
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Powell et al. determined the values of the relevant parameters described above.88  
Figure 23. 1H NMRD profile (black squares) of Gd-DOTA (1) at 312 K (39°C) (data from 
Ref. 88). Range of magnetic fields (grey area) currently used in clinical MR scanners (1-3 T).  
In order to visualise the effect of a slower rotational motion, the so obtained values can be 
used in simulated 1H NMRD profiles where only the value of the rotational correlation time 
τR is varied and all other parameters remain fixed (Figure 24).  
Figure 24. Simulated 1H NMRD profiles (for 37°C) on the basis of the parameter values 
obtained for Gd-DOTA (1) and varying only τR. 
From Figure 24 it is obvious, that τR of Gd-DOTA (1) is with only 77 ps far too short. A 
prolongation of τR results generally in an increase in r1, but most interesting is the appearance 
of a so called “high field peak” being especially effective in the magnetic field range of 
interest for clinical use. All these aspects make the prolongation of the rotational correlation 
time τR the prior aim in the development of high sensitivity CAs for MRI. 
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4.1.1.1 Macromolecular contrast agents 
Several approaches have been reported in order to optimise the rotational motion. The 
Guerbet group developed a molecule called gadomelitol (also called P792 or Vistarem™) that 
can be described as Gd-DOTA (1) with large hydrophilic groups appended to each of the α-
carbons on the acetate arms.93 Although there is flexibility within the hydrophilic arms, the 
Gd-Hwater vector cannot rotate independently of the entire molecule, which results in a 
remarkably high relaxivity (r1 = 39.0 mM-1s-1 at 37°C, 0.47 T). Fulton et al. showed that the 
rotational effect can be modulated by adjusting the size of the hydrophilic “arms”.94 
The approach of Livramento et al. to slow down the rotational motion by self-assembly of 
2,2’-bipyridine functionalised gadolinium(III) complexes binding around an iron(II) ion was 
outlined already in chapter 3.1.1.3. Another promising type of self-assembled macromolecular 
CAs are amphiphilic gadolinium(III) chelates which form micelles in aqueous media.95, 96 
Additional to the increase in τR, the self-assembly of functionalised gadolinium(III) 
complexes to a micelle results in a higher local gadolinium(III) concentration, which 
multiplies the efficiency when used as a target specific CA. Furthermore, the increased size 
can prevent a leakage of the CAs into the interstitium and slows down the renal clearance 
from the body, thus allowing more efficient blood pool and tumor angiogenesis imaging.97, 98 
However, for micellar aggregates it is essential to maintain the monomer concentration in the 
body above the critical micelle concentration, which might prevent the application of lower 
concentrations of the CA in certain cases.99  
The grafting of many low molecular weight gadolinium(III) complexes to one macromolecule 
would be a concentration independent way to obtain higher local gadolinium(III) 
concentration and slower rotational motion. Numerous approaches have been reported in this 
direction. The noncovalently binding of MS-325 (7) to HSA as an example for increasing τR 
by conjugation to biomolecules was already described in chapter 2.4.1. Linear polymeric CAs 
from the conjugation of Gd-DTPA (2) to poly-L-lysine chains were reported by Spanoghe et 
al..100 Other examples of this type of CA include alternating copolymers of DTPA-class 
gadolinium(III) conjugates, linked by α,ω-alkyldiamides101, 102 or a modified dextran polymer 
with DO3A-monoamide chelates with a total molecular weight of 52 kDa.103 However, the 
increase in relaxivity of these linear polymers is usually much smaller than expected. The 
lower relaxivity can be attributed to anisotropic local rotational motions of the bound 
paramagnetic moiety with components rapid as compared to the overall motion of the 
macromolecule itself. The local motion may be rapid because the linkage between the 
gadolinium(III) complex and the macromolecule is highly flexible or because of rapid local 
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motion of the macromolecule itself, particularly if the gadolinium(III) complex is bound to a 
highly flexible linear polymer.91, 101 Furthermore, their random morphology can lead to 
inconsistent and unpredictable pharmacokinetics, which may limit experimental repeatability. 
Dendrimers are large molecules with well-defined chemical structures, with a regular and 
highly branched three-dimensional scaffold. Their structure can be separated in three major 
components, namely the core, the branches and the end groups. The synthesis of dendrimers is 
a process using a series of repetitive steps starting with the central initiator core. Each 
subsequent step represents a new “generation” of the dendrimer with a larger molecular 
diameter, doubles in general the number of reactive surface sites, and approximately doubles 
the molecular weight from that of the preceding generation. Unlike classical polymers, 
dendrimers therefore have a high degree of molecular uniformity, narrow molecular weight 
distribution, specific size characteristics, and a highly functionalised surface. Numerous types 
of dendrimeric CAs with various types of gadolinium(III) complexes, dendrimeric cores, 
branches and generations were reported over the last 15 years. The most often used type of 
dendrimer for the development of macromolecular CAs are so called polyamidoamino 
(PAMAM) dendrimers (G2-PAMAM dendrimer (22) is depicted in Figure 25).86, 104-109  
 
Figure 25. G2-polyamidoamino (G2-PAMAM) dendrimer. 
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The high-generation versions of these water soluble dendrimers are generally accepted to be 
globular molecules, with the core and interior being almost completely shielded owing to the 
numerous terminal surface groups. 
Other examples of dendrimers being used for MRI CAs, are diaminobutane (DAB)-based 
dendrimers,106 and dendrimers having poly-L-lysine branches on a polyethylene glycol (PEG) 
core110 or a trimesoyl triamide core.111 In contrast to linear polymeric CAs, in these 
dendrimeric CAs the effect of the increased molecular weight on relaxivity is more realised as 
the dendritic structure imposes a more isotropic rotational dynamic allowing higher 
relaxivities.91 Nevertheless, the large systems are often relatively flexible and medium-sized 
dendrimeric contrast agents may no longer have a well defined three-dimensional spherical 
structure. To minimize nonspecific interactions with healthy tissues and lower systemic 
accumulation, however, a compact and globular shaped CA would be preferred. 
An important drawback of very large CAs is also their slow excretion from the body, which 
increases the possibility to release toxic gadolinium(III) from the complexes, e.g. by 
transmetallation.9, 14, 17, 20 The kidneys, being the exclusive excretion organ of most MRI CAs, 
possess a filtration system, called glomerulus, which has small pores with an effective radius 
of 3-5 nm.112, 113 Everything that is small enough can freely diffuse through those pores and is 
rapidly cleared from the body. However, most of the large macromolecular CAs have sizes in 
the range of these pores or even higher and therefore need to diffuse through so called “shunt 
pathways” being significantly lower in number than small pores,113 which slows down the 
excretion rate. 
4.1.2 Silsesquioxanes 
Silsesquioxanes are all structures with the formula [RSiO1.5]n, where R is hydrogen or any 
alkyl, alkylene, aryl, arylene, or organofunctional derivative of alkyl, alkylene, aryl, or 
arylene groups. They were first discovered by D.W. Scott in 1946 when he was investigating 
the thermal rearrangement of the co-hydrolysis product of dimethyldichlorosilane and silicon 
tetrachloride.114 Since then silsesquioxanes have found an ever increasing number of 
applications. Most of these applications are in the field of materials science where differently 
functionalised silsesquioxanes are used as additives, polymers and precursors for 
inorganic/organic hybrid materials.115-118 The silsesquioxanes used in these applications 
include random polymeric structures (23), ladder structures (24) and cage structures (25-27) 
(see Figure 26).115, 117, 119 The cage structures are called polyhedral oligosilsesquioxanes 
(POSS) and their nomenclature Tn refers to the number of Si-OR’ functions (T: three oxygens 
attached to the silicon)120 and to the number of silicons n involved in the cage. POSS 
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compounds embody a truly hybrid (inorganic–organic) architecture, which contains an inner 
inorganic framework made up of silicon and oxygen that is externally covered by organic 
substituents. By functionalisation of these substituents, especially the symmetric T8-POSS 
(26) has already shown its potential as dendrimeric core.121, 122 Owing to its three-dimensional 
structure and the generally accepted nontoxic properties of silica compounds,123 T8-POSS 
cubes could therefore be ideal building blocks for the development of dendrimeric CAs which 
possess already a compact globular shape at low numbers of generations. 
 
Figure 26. Structures of various silsesquioxanes. 
4.1.3 Aim of this project 
From Figure 24 in chapter 4.1.1 it is obvious that the maximum achievable relaxivity r1 
increases with increasing τR, however, the maximum of the resulting high field peak shifts 
towards lower field strength. This is easily understandable from equation 2.9 in chapter 2.3.1. 
Once ωΙ2τc12 in the “3-term” becomes larger than one, the relaxation rate becomes slower and 
disperses with increasing frequency (field). An increased τR, increases τc1 and therefore 
ωΙ
2τc1
2
 > 1 is already fulfilled at a lower proton Larmor frequency. To achieve a high 
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relaxivity at field strength currently used in clinical MRI, novel macromolecular CAs should 
therefore be only of moderate size. Due to the Debye-Stokes equation (equation 3.2 in chapter 
3.2.3) for example a rotational correlation time τR of 10 ns, being the longest τR used in Figure 
24, belongs to a hydrodynamic radius rH of about 2 nm in water. 
As outlined in chapter 4.1.1.1, for an acceptable excretion rate of the CA from the body it is 
also essential to keep the hydrodynamic radius of the CA below the effective radius of the 
small pores of the glomerular filtration system. 
On the other hand, for the development of target specific CAs, large CAs with a high number 
of gadolinium(III) ions are favourable, as each paramagnetic centre on the CA which locates a 
biomolecule in the body serves as a multiplier, allowing the detection of lower concentrated 
biomarkers.  
CAs based on T8-polyhedral oligosilsesquioxanes could be the ideal compromise, as T8-POSS 
cubes form a precast three-dimensional platform for the synthesis of compact globular CAs, 
loaded with a high number of gadolinium(III) complexes already at the lowest possible 
number of dendrimeric generations. 
The aim of this project is therefore the development of synthetic strategies to functionalise T8-
silsesquioxanes with eight appropriate gadolinium(III) complexes each. Once a working 
protocol is established, novel potential CAs shall be synthesised and fully characterised. All 
aspects of their solution behaviour shall be investigated by means of various analytical 
techniques in order to optimise their properties as a CA. 
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4.2 Results and Discussion 
4.2.1 Synthesis of T8-Silsesquioxanes 
Two differently functionalised T8-silsesquioxanes were prepared to serve as the building 
block for macromolecular silsesquioxane-based CAs, an amino-functionalised one for the 
coupling of carboxylic acid-functionalised ligand systems and a carboxylic acid-
functionalised silsesquioxane for the binding of amino-functionalised ligand systems. 
4.2.1.1 Synthesis of an amino-functionalised T8-silsesquioxane 
Aminopropyl-functionalised T8-silsesquioxanes can be directly obtained by hydrolytic 
condensation of γ-aminopropyltriethoxysilane in methanol-conc. hydrochloric acid (Scheme 
5).124 
 
Scheme 5. 
Following the literature procedure, octa(3-chloroammoniumpropyl)silsesquioxane (29) could 
be synthesised in 39 % yield. All analytical data were in agreement with those reported in the 
literature.124 29 needs to be isolated as the octaammonium chloride salt, since the octaamine 
species is marginally stable in solution and decomposes rapidly when the solvent is removed. 
At least two different pathways for the decomposition of the silsesquioxane cage of the 
octaamine species were proposed. The most rapid one probably involves the formation of 
hydroxide ions via reaction of water with the free amine. Support for this pathway was given 
from the observation that other silsesquioxane frameworks are slowly decomposed by 
exposure to amine bases (e.g. Et3N) in wet solvents and the fact that decomposition is much 
slower in anhydrous solvents (e.g. MeOH over 3 Å sieves). However, as decomposition still 
occurs when solutions of the octaamine species are prepared in dimethylsulfoxide (DMSO) 
and stored over molecular sieves a second mechanism must be operative that does not require 
water. It is believed that this mechanism involves the nucleophilic attack of the amino 
nitrogen on the silicon on which it is bound to.124 
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4.2.1.2 Synthesis of a carboxylic acid-functionalised T8-silsesquioxane 
So far, there is no method for direct hydrolytic condensation of acid-functionalised T-silicon 
monomers. Therefore a two step route, developed in our group by D. Ruiz-Abad,125 was used 
for the synthesis of carboxylic acid-functionalised T8-silsesquioxanes. In the first step, 
octavinylsilsesquioxane (31) was synthesised by the hydrolytic condensation of CH2CHSiCl3 
(30) in an excess of methanol containing acidic Amberlite IR-120, following the method 
reported by Dare et al. (Scheme 6).126 The synthesis of pure product 31 in 15 % yield was 
confirmed by the agreement of the analytical data with those reported in the literature. In the 
second step the so obtained octavinylsilsesquioxane (31) was treated with mercaptopropionic 
acid (32) in the presence of azobisisobutyronitrile (AIBN) as a radical initiator in toluene 
(Scheme 7). This radical addition yielded selectively the octa(3-(ethylmercapto)propionic 
acid) silsesquioxane (33) as the anti-Markovnikov product in an excellent yield of 98 %. All 
analytical data were in full accordance with those reported in the literature.125 
 
Scheme 6. 
 
Scheme 7. 
4.2.2 Introduction of Macrocyclic Ligands via their tert-Butyl protected Form 
It was discussed in detail in chapter 2.4.2, that CAs based on macrocyclic DOTA-type ligand 
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systems are a much safer alternative as compared to the open chained linear systems, as their 
higher inertness significantly slows down the leaking of toxic free gadolinium(III) ions from 
the ligand systems. As was reinvestigated recently in the context of the gadolinium(III)-
related decease NSF,9, 14, 17, 20 this can be essential for the development of macromoleclar CAs 
being designed to remain longer in the body than their low molecular derivatives. It was 
therefore decided to use macrocyclic DOTA-type ligand systems for the development of 
silsesquioxane-based CAs. 
4.2.2.1 Synthesis of DOTA(tBu)3 
The most common way to introduce DOTA-type ligands into macromolecular systems is to 
use the monoreactive prochelator DOTA(tBu)3 (4,7,10-tricarboxymethyl-tert-butyl ester 
1,4,7,10-tetraazacyclododecane-1-acetic acid (36), Scheme 9), which can be coupled to e.g. 
amino-functionalised systems via its free carboxylic acid group. Furthermore, Feher et al. 
already demonstrated the octafunctionalisation of octa(3-chloroammoniumpropyl)-
silsesquioxane (29) with N-protected amino acids and N-protected di- and tri-peptides under 
standard peptide coupling conditions.127 
Divergent from the literature method which starts with the monoalkylation of cyclen,128 
DOTA(tBu)3 (36) was synthesised in two steps from tri-tert-butyl 1,4,7,10-
tetraazacyclododecane-1,4,7-triacetate (DO3A(tBu)3 (34)). In the first step the secondary 
nitrogen of 34 was alkylated by benzyl bromoacetate (Scheme 8).  
 
Scheme 8. 
The successful synthesis of 4,7,10-tri-tert-butyl-1-benzyl-1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetate (DOTA(tBu)3Bn (35)) in 87 % yield could be shown by the appearance 
of new signals in the aromatic region of the 1H NMR spectrum in the correct ratio of integrals 
and the agreement of the analytical data with those reported in the literature.128 Deprotection 
of the benzyl ester was accomplished by catalytic hydrogenation using palladium on charcoal 
(Scheme 9). 36 was isolated in 87 % yield and the obtained analytical data agreed with that 
reported in the literature.128 Due to their hygroscopic properties no elemental analysis was 
carried out for the macrocyclic ligands. 
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Scheme 9. 
4.2.2.2 Coupling of DOTA(tBu)3 to octa(3-aminopropyl)silsesquioxane 
Following the procedure reported by Feher et al.127 for the attachment of N-protected amino 
acids, octa(3-aminopropyl)silsesquioxane (29) was treated with an excess of ligand 36 in the 
presence of classical peptide coupling reagents and a base. Analogous to Feher et al. O-
(benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium tetrafluoroborate (TBTU)129 (38) and 1-
hydroybenzotrialzol (HOBt) (44) were used as coupling reagents and diisopropylethylamine 
(DIPEA) was used as base. The proposed mechanism for such reactions is depicited in 
Scheme 10.130 It involves the in situ formation of the highly reactive hydroxybenzotriazol 
ester 42, which reacts with the amino component 43 to yield the amide 45. 
 
Scheme 10. 
NN
N N
O
O
O
O
O
O
H2, Pd/C
35
O
O MeOH NN
N N
O
O
O
O
O
O
36
O
OH
N
N
N
ON
N
BF4
R O
O
38
37 -BF4
N
N
N
O
_
R O
O
40
39
N
N
N N
O
_
N
N
N
O
41
O
R
42
N
N
N
HO
_
R' NH2
43
44
R N
H
O
45
R'
SILSESQUIOXANE-BASED MRI CONTRAST AGENTS 55 
Feher et al. carried out their syntheses in dimethylformamide (DMF) or DMSO and allowed 
the solutions to stir for one day at room temperature. As 29 needs to be available in its 
deprotonated form a large excess of DIPEA was used. When DOTA(tBu)3 (36) was reacted 
with 29 under the conditions decribed by Feher et al. in both dry DMF and dry DMSO, a 
yellowish crude product could be isolated. The 1H and 13C{1H} NMR spectra of the crude 
products measured in DMSO-d6 showed the signals corresponding to the tert-butyl protected 
DOTA-type ligand systems and also the signals of the propyl groups attached to the 
silsesquioxane core. Furthermore, the 1H NMR spectra showed the changes in chemical shift 
of the resonances of the propyl groups (SiCH2: δ 0.71 → 0.59 ppm, SiCH2CH2: δ 1.71 → 
1.60 ppm, NCH2: δ 2.75 → 3.19 ppm), being characteristic for the amide formation on 29.127 
The deprotonation of the ammonium group as the source for the observed changes in the 
chemical shift could be excluded, as the 1H NMR spectrum of 29 in DMSO-d6 did not show 
such changes after the addition of excess DIPEA. This clearly shows the successful 
attachment of 36. However, no resonance could be observed in the 29Si{1H} NMR spectra of 
the crude products. A possibility why no signal was observed could be the broadness of the 
signal due to hindered rotation, leading to a low signal intensity. Moreover, it is also possible 
that the silsesquioxane cage partly decomposes during the long reaction time. As was already 
mentioned in chapter 4.2.1.1, silsesquioxane frameworks can slowly decompose by exposure 
to amine bases in wet solvents. Even though dry solvents were used for the attachment of 36 
to 29, HOBt was added as its monohydrate, allowing the formation of hydroxide ions which 
in turn can destroy the cage. 
In order to investigate the stability of the silsesquioxane cage under the used conditions and to 
exclude that the loss of the silicon signal is due to hindered rotation accompanying the 
successful reaction, octa(3-aminopropyl)silsesquioxane (29) was dissolved in dry DMSO-d6 
and transferred in an screw capped NMR tube under argon atmosphere and 29Si{1H} NMR 
spectra were recorded (Figure 27). Due to the cubic symmetry of 29, the spectrum shows only 
one resonance at -66.5 ppm which is in the typical range of T3 groups.120 After 145 minutes 
the equivalent amount of DIPEA as used in the coupling reactions was added and another 
spectrum was recorded. After further 240 minutes and 20 h additional spectra were recorded. 
As was mentioned earlier, it was reported, that the deprotonation of the ammonium groups of 
29 leads to the decomposition of the silsesquioxane cage, however, in this study no decrease 
in signal intensity was observed. Only the addition of a small amount of water (about five 
times the amount that would have been included in HOBt·H2O) to the solution resulted in a 
fast decrease in signal intensity with an almost complete disappearance of the signal already 
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after 110 minutes. For comparison the same investigation was carried out with the carboxylic 
acid functionalised octa(3-(ethylmercapto)propionic acid) silsesquioxane (33). In this case the 
signal also decreased only after the addition of water. However, the loss in signal intensity 
was significantly slower than for 29 resulting in a noticeable decrease only after 27 hours. The 
longer alkyl chain in the case of 33 might hinder the approach of the hydroxide ions. The 
reason why no new signals appear in the spectra is probably the reduced symmetry of the 
partly degraded cages, which generates numerous magnetically inequivalent 29Si nuclei in 
poor concentrations circumventing their detection in a reasonable time. 
 
Figure 27. 29Si{1H} NMR spectra of 29 in dry DMSO-d6, without base, directly after the 
addition of DIPEA, 240 min and 20 h after the addition of DIPEA and 25 and 110 min after 
additional addition of water. 
HOBt (44) is usually added in peptide coupling reactions as it improves the stereocontrol by 
preventing racemisation. However, in the coupling of 36 to 29 racemisation is not an issue 
and therefore it was omitted in further reactions. Moreover, the reaction was reset in a screw 
capped NMR tube under argon atmosphere and monitored by 1H NMR spectroscopy to 
optimise the reaction time. It could be shown, that almost immediately after the addition of 
DIPEA, which was the last component added, the resonances became broad and were shifted 
in the characteristic way. Completeness of the reaction was indicated after about 20 minutes. 
This shows that a reaction time as long as used in the initial attempts is not required to 
achieve octafunctionalisation of the silsesquioxane. 
In a new attempt the octaammonium silsesquioxane 29 was therefore treated with an excess of 
DOTA(tBu)3 (36), TBTU (38) and DIPEA in dry DMSO under argon atmosphere and the 
without base 
addition of DIPEA
240 min after DIPEA
20 h after DIPEA
25 min after H O2
110 min after H O2
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mixture was stirred for only 30 minutes at room temperature (Scheme 11). Workup resulted in 
the desired product 46 in excellent yield. The 1H NMR spectrum of the obtained yellowish 
solid dissolved in CDCl3 showed the signals of the product in the correct ratio of integrals 
indicating a complete octafunctionalisation. Furthermore, according to the spectrum the 
yellowish solid contained mostly the product, however, a small amount of TBTU byproducts 
was also observed. This time the 29Si{1H} NMR spectrum revealed a single resonance at 
-66.9 ppm suggesting the intactness of the silsesquioxane core. 
 
Scheme 11. 
4.2.2.3 Deprotection of the carboxylic acid functions 
A typical way to cleave tert-butyl esters is their hydrolysis under acidic conditions, using 
formic acid or trifluoroacetic acid (TFA) in dichloromethane (DCM). Furthermore, Feher et 
al. used TFA in DCM to remove their Boc (tert-butoxycarbonyl) protecting groups without 
decomposition of the silsesquioxane cage under these acidic conditions.127 
Thus, 46 was stirred in TFA:DCM (1:2) for about eight hours, after which the volatile matter 
was removed under reduced pressure. The residue was precipitated from acetone after the 
addition of diethyl ether. The 1H NMR spectrum (Figure 28b) of the obtained crude product in 
D2O showed an almost complete disappearance of the resonance at about 1.4 ppm, belonging 
to the tert-butyl hydrogens. Unfortunately, the two signals of the methylene groups SiCH2CH2 
and SiCH2 of 46 at 1.6 and 0.6 ppm, respectively, also changed. The signal of the SiCH2 
methylene group, being adjacent to the silicon atom, split in several resonances. Due to the 
also measured 1H-13C HSQC NMR spectrum, at least three distinct resonances could be 
assigned. Together with the disappearance of the signal in the 29Si{1H} NMR spectrum, this 
indicated the decomposition of the silsesquioxane cage under the used conditions. The 
cleavage was therefore attempted using milder conditions. 46 was stirred in formic acid:DCM 
(1:1) for 16 hours at room temperature. In this case, the obtained product remained soluble in 
DCM and its 1H NMR spectrum revealed that the protecting groups had only partly been 
removed. However, also in this case the resonance at 0.6 ppm split, indicating again the 
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decomposition of the cage. 
 
Figure 28. 1H NMR spectra of (a) 46 in DMSO-d6 and (b) the crude product of the reaction 
of 46 with TFA:DCM, measured in D2O. 
As in the case of the coupling reaction, it is hard to explain why under the chosen conditions 
decomposition of the silsesquioxane cage takes place for these systems, but not for the 
systems described by Feher et al.. It is known that strong acids can break Si-O-Si bonds, even 
in the absence of water. Acids like HBF4/BF3, CF3SO3H or CH3SO3H are used for the 
selective cleavage of one corner from T8-silsesquioxanes.119, 131 Furthermore, it is possible 
that due to the hygroscopic nature of the DOTA moiety, water is introduced into the systems 
leading to acid catalysed hydrolysis. 
4.2.3 Introduction of Macrocyclic ligands via non tert-Butyl protected Forms 
As the deprotection of the tert-butyl protected carboxylic acids proved unsuccessful, two 
alternative ways to introduce macrocyclic ligands into silsesquioxane systems were explored 
contemporaneously. 
4.2.3.1 Synthesis of La-DO3A-hexylamine 
André et al. have shown that it is possible to directly couple functionalised gadolinium(III) 
DOTA-complexes to a designated molecule without using protecting groups, since the four 
DOTA-carboxylate groups are protected by the coordination to the gadolinium(III) ion.95 This 
would make a later deprotection and complexation unnecessary. For this approach initially the 
lanthanum(III) complex (48) of the in our lab available 1-aminohexyl-1,4,7,10-
tetraazacyclododecane-1,4,7-triacetic acid (DO3A-hexylamine) ligand65 (47) was prepared 
(Scheme 12). The successful coordination was confirmed by electrospray ionisation mass 
spectrometry (ESI-MS) (m/z: 582.4 ([M+H]+), 604,2 ([M+Na]+)). Lanthanum(III) was chosen 
1.5 1.0 0.5 ppm1.5 1.0 0.5 ppm
a) b) 
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as 139La is an NMR active nucleus whose chemical shift allows conclusions about the number 
of coordinated carboxyl and amino functions.132 This should indicate whether the hexylamino 
moiety is coordinated to the lanthanide(III) ion or not and hence is free to be coupled to the 
carboxylic acid functionalised silsesquioxane 33 or not. 
 
Scheme 12. 
Contrary to the 139La NMR spectrum (Figure 29) of La-DO3A (cf. compound 10 in chapter 
2.4.2), which showed a broad resonance at about 295 ppm corresponding to four coordinated 
nitrogen atoms and three negatively charged oxygen ions,132 the 139La NMR spectrum of 48 
did not show a signal corresponding to a coordinated lanthanide(III) ion. Due to the 
comparably large quadrupolar moment of 139La and the reduced symmetry as compared to the 
La3+aq ion, the signal of La-DO3A already has a line-width of about 8600 Hz. As no signal is 
observed for 48, the amino function terminating the hexyl chain is most likely not 
permanently coordinated to the lanthanum(III) ion. In solution the flexibility of the hexyl 
moiety rather allows the amino group to tumble, thereby sometimes approaching the 
lanthanum(III) ion. This increased dynamics can further broaden the 139La NMR signal 
leading to the non-observability of the resonance. 
 
Figure 29. 139La NMR spectrum of La-DO3A in D2O, pD 7.0, 65°C. 
Further evidence for the non-coordination of the hexylamine function comes from the 1H 
NMR spectrum of 48 (Figure 30). Due to the quadrupolar moment of the lanthanum nucleus 
and the hindered motion, the signals belonging to hydrogens on the DO3A moiety are 
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extremely broad. The further apart the nuclei are located from the lanthanum(III) and the 
higher the flexibility of the respective group is, the sharper is the line-width of the 
corresponding NMR signal. As the signals become narrower from 1 to 5 in Figure 30, the 
methylene group 5 is further apart from the lanthanum(III) ion than methylene group 1. This 
suggests a free amino group and enables the amino function to react with a carboxylic acid. 
Furthermore, when the amino group is not coordinated, it should be protonated under the used 
conditions and needs to be deprotonated prior the coupling. 
 
Figure 30. 1H NMR spectrum of 48 in D2O (pD 7.0). 1-5 are the resonances of the methylene 
groups of the alkylchain as shown. * is the solvent residual peak. 
4.2.3.2 Coupling of La-DO3A-hexylamine to the silsesquioxane 
The water was removed from complex 48 and the solid residue was dried at 50°C under 
reduced pressure over night in order to minimise the amount of remaining water in the 
systems. 48 was then coupled to the carboxylic acid functionalised octa(3-
(ethylmercapto)propionic acid) silsesquioxane (33) in dry DMSO using TBTU and DIPEA 
and stirring only for 30 minutes at room temperature. The mixture was then added drop-wise 
to a diluted acetic acid/sodium acetate buffer (pH 5.5) in order to purify the solution via 
diafiltration. Unexpectedly, an off-white solid precipitated during the addition. The precipitate 
was isolated by centrifugation. It turned out to be insoluble in acetone, chloroform, diethyl 
ether and DMF and could hardly be redissolved in DMSO. In solution, only a poor 1H NMR 
spectrum of the precipitate could be obtained using DMSO-d6 (Figure 31). Nevertheless, the 
spectrum contains signals corresponding to structural elements of the lanthanum(III) complex 
48 and of the silsesquioxane 33, indicating that the formed precipitate is the desired 
octalanthanum(III)-functionalised silsesquioxane 49 (Figure 32). 
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Figure 31. 1H NMR spectra of 49 (black) and 33 (grey) in DMSO-d6. * H2O, ** DMSO with 
satellite signals due to coupling to 13C. 
 
Figure 32. Structure of compound 49. 
As compound 49 was not sufficiently soluble in any tested solvent, solid state 13C and 29Si 
CP/MAS NMR spectra were recorded (Figure 33a and b, respectively). 
 
Figure 33. (a) 13C and (b) 29Si CP/MAS NMR spectra of compound 49. The rotation 
frequency was (a) 10000 Hz and (b) 1000 Hz. * residual acetone. 
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Due to the broadness and therefore overlapping of the signals in the 13C CP/MAS NMR 
spectrum (Figure 33a), not all signals corresponding to the former octa(3-
(ethylmercapto)propionic acid) silsesquioxane moiety and the hexylamine chain can be 
assigned unambiguously. However, the signal at 14 ppm clearly corresponds to the CH2Si 
group whereas the signals between 70 and 42 ppm belong to the La-DO3A moiety. The 
signals between 183 and 167 ppm can be assigned to the carboxylate and amide carbons. The 
29Si CP/MAS NMR spectrum (Figure 33b) of 49 shows a singlet at -67.5 ppm. This indicates 
again the octafunctionalisation and points out the intactness of the cage. However, as the 
signal is broad and the spectrum shows side-bands due to the low rotation frequency, this 
cannot finally be ascertained. 
Since compound 49 is insoluble in aqueous media at moderate pH, it is not suitable as a CA in 
MRI. When compound 49 was placed in D2O and the pD was decreased to 2-3 by adding 
conc. hydrochloric acid (HCl) to the stirred suspension, the compound slowly dissolved. At 
this pH the carboxylate groups become protonated and lanthanum(III) can be released, in turn 
leading to a protonation of the nitrogens. The introduced charge increases the solubility in 
water by improving the dipolar interaction with surrounding water molecules. The 1H NMR 
of the solution shows all signals expected for an DO3A-hexylamine moiety attached to a 
octa(3-(ethylmercapto)propionic acid) silsesquioxane (Figure 34). The release of quadrupolar 
lanthanum(III) is indicated by the much sharper signals of the DO3A moiety as compared to 
those in the spectrum of complex 48 (see Figure 30).  
 
Figure 34. 1H NMR spectrum of compound 49 in D2O after decreasing the pD to 2-3. 
* residual solvent peak, ** residual acetone 
The also measured 29Si{1H} NMR spectrum shows only one resonance at -67.8 ppm. 
However, the intensity is poor and therefore the cage might have started to slowly decompose. 
Nevertheless, the addition of NaOH(aq) up to pH 7 resulted again in a precipitation of the 
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compound. When the pH was further increased to about pH 12 the precipitate redissolved 
again. This time the increased solubility is most likely related to the decomposition of the 
silsesquioxane cage, as the subsequent decrease in pH no longer resulted in a precipitation. 
4.2.3.3 Synthesis of DOTA(Bn)3 
The second approach to introduce macrocyclic ligands into silsesquioxane systems without 
using acidic or basic cleaved protecting groups involved the attachment of benzyl protected 
ligands. Therefore the benzyl protected analogue of DOTA(tBu)3 (36) was synthesised. The 
synthesis of DOTA(Bn)3 (4,7,10-tricarboxymethyl-benzyl ester 1,4,7,10-tetraaza-
cyclododecane-1-acetic acid (53)) has already been reported by Anelli et al..133 Their route 
involved the monoalkylation of cyclen (50) with tert-butyl bromoacetate followed by the 
alkylation of the remaining three nitrogens using benzyl bromoacetate. For this study it was 
decided to first synthesise tri-benzyl 1,4,7,10-tetraazacyclododecane-1,4,7-triacetate 
(DO3A(Bn)3 (51)), the benzyl protected analogue of DO3A(tBu)3 (34). 51 should allow faster 
access to various carboxylic acid- or amino-functionalised DO3A(Bn)3-derivatives, once the 
attachment of gadolinium(III) complexes to silsesquioxanes via benzyl protected ligands 
proved successful. 51 was synthesised by alkylation of three of the cyclen (50) nitrogens 
using 2.8 equivalents benzyl bromoacetate (Scheme 13). 
 
Scheme 13. 
The synthesis resulted in a mixture of mono-, di-, tri- and tetra-alkylated cyclen derivatives. 
Mono- and di-alkylated species could almost completely be removed via filtration as their 
bromide salts are poorly soluble in acetonitrile. However, the separation of 51 from the tetra-
alkylated DOTA(Bn)4 could not be achieved by traditional separation techniques. The 
isolation of 51 was finally accomplished via elution from an Amberlite XAD1600 resin 
column using a water/acetonitrile gradient. Amberlite XAD1600 is a polystyrene resin, to 
which DOTA(Bn)4, due to its four aromatic groups, has a higher affinity than 51, which 
possesses only three aromatic groups. The product was characterised by multidimensional 1H 
and 13C NMR spectroscopy and ESI-MS. Unfortunately, with only 10 %, the yield remained 
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poor. 
In the next step the forth cyclen nitrogen of 51 was alkylated with tert-butyl bromoacetate in 
order to obtain 4,7,10-tri-benzyl-1-tert-butyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetate (DOTA(Bn)3tBu (52)) (Scheme 14). 
 
Scheme 14. 
The successful synthesis of 52 in 70 % yield could be shown by high resolution mass 
spectrometry (HR-MS) and by the appearance of a tert-butyl hydrogen signal at 1.43 ppm in 
the 1H NMR spectrum, being in the correct ratio of integrals to the signals in the aromatic 
region of the spectrum. Finally, deprotection of the tert-butyl protected carboxylic acid was 
achieved by stirring a solution of 52 in TFA:DCM (1:1) for 22 h at room temperature 
(Scheme 15). 
 
Scheme 15. 
The crude product was purified via elution from an Amberlite XAD1600 resin column using a 
water/methanol gradient, however DOTA(Bn)3 (53) only eluted at 100 % methanol. 53 was 
obtained in 43 % yield and was characterised by multidimensional 1H and 13C NMR 
spectroscopy and ESI-MS. 
4.2.3.4 Coupling of DOTA(Bn)3 to octa(3-aminopropyl)silsesquioxane 
Analogous to the synthesis described in chapter 4.2.2.2 for the coupling of DOTA(tBu)3 (36), 
DOTA(Bn)3 (53) was attached to octaammonium silsesquioxane 29 by treating 29 with an 
excess of 53, TBTU (38) and DIPEA in dry DMSO under argon atmosphere and stirring the 
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mixture for 30 minutes at room temperature (Scheme 16).  
 
Scheme 16. 
Workup afforded a dark yellow solid. The 1H NMR spectrum of a CDCl3 solution of the solid 
showed the signals of the desired product 54 (Figure 35). However, the spectrum reveals 
several peaks of residual solvents and TBTU byproducts, and most important the SiCH2CH2 
group shows not only the signal at 1.60 ppm, but also a small signal at 1.79 ppm. The 1H-29Si 
HSQC NMR spectrum shows that also the signal at 0.59 ppm in the 1H NMR spectrum 
consists of two resonances, a main peak at 0.58 ppm coupling to a 29Si signal at -67.0 ppm 
and a small proton signal at 0.63 ppm coupling to a silicon signal at -67.5 ppm.  
 
Figure 35. 1H NMR spectrum in CDCl3 of the crude product of the synthesis of 54. 
Since the chemical shifts of the signals further apart from the silsesquioxane core differ 
stronger, it is more likely that a certain amount of the octaaminopropylsilsesquioxane is not 
octafunctionalised rather than a degradation of the silsesquioxane cage. The ratio of 
integration of the signals at 1.60 and 1.79 ppm in the 1H NMR spectrum is about 8:1, 
indicating mostly incomplete functionalisation. Most likely the excess of ligand was not high 
enough to achieve full octafunctionalisation in the given time. Nevertheless, it was decided to 
initially use the obtained product to investigate the possibility of deprotection of these 
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systems. 
4.2.3.5 Cleavage of the benzyl esters 
As the obtained dark yellow solid turned out to be insoluble in methanol, the hydrogenolytic 
cleavage of the benzyl esters was attempted in DMF. The solid was dissolved in dry DMF, 
Pd/C (10 % Pd) was added and the solvent was degassed. The mixture was stirred under a 
dihydrogen atmosphere for 2.5 h at room temperature. However, after workup, the residual 
solid was insoluble in water, but still soluble in CDCl3. As the 1H NMR spectrum showed no 
cleavage of the benzyl esters, the reaction was reset in DMF with new catalyst and the 
mixture was stirred for two days. The 1H NMR spectrum of the reaction solution (Figure 36) 
showed only little toluene formation, indicating less than 30 % deprotection. Furthermore, the 
spectrum revealed the appearance of a new signal at 3.78 ppm, being in the intensity range of 
the solvent rather than the solutes (integration ratio of 0.5 as compared to the DMF signal at 
about 8 ppm).  
 
Figure 36. 1H NMR spectrum of the reaction solution of the attempted deprotection of 54. 
The signals of remaining benzyl esters are indicated by “Bn”, whereas the resonances of the 
formed toluene are labelled by “Tol”. * DMF. ** most likely dissolved dihydrogen. 
The 1H-13C HSQC NMR spectrum indicates that the hydrogens of this signal are not attached 
to a carbon and the 1H-1H COSY NMR spectrum shows no coupling of the hydrogen nuclei to 
other hydrogen nuclei. As anhydrous solvent was used, the signal corresponds most likely to 
dissolved dihydrogen. The small signal appearing at 0.8 ppm might belong to species with a 
decomposed silsesquioxane cage. As no complete octafunctionalisation was achieved in the 
previous reaction, free amine groups could destroy the cage as described in chapter 4.2.1.1. 
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An explanation for the extremely low reaction rates for the deprotection might be the large 
size of the functionalised silsesquioxane which could prevent a satisfactory interaction with 
the catalytic centres, leading to slow conversion rates. Even though comparably large amounts 
of Pd/C were used and the catalyst was renewed, it is also possible that sulphur compounds 
from residual DMSO poisoned the catalyst, thereby reducing its activity. In order to clarify 
this, the synthesis of 54 needs to be rerun in DMF using a larger excess of 53. Then the 
hydrogenolytic deprotection can be reattempted. However, the results from the 
simultaneously carried out attachment of La-DO3A-hexylamine (48) to octa(3-
(ethylmercapto)propionic acid) silsesquioxane (33) in chapter 4.2.3.2 pointed out the need of 
a charge to obtain sufficient water solubility of these highly symmetric systems. For this 
reason and because the direct introduction of the complexes turned out to be much more 
convenient, the benzyl protection approach was not pursued further. 
4.2.4 Introduction of Charged Macrocyclic Complexes 
4.2.4.1 Synthesis of DOTAGA 
The easiest way to introduce a charge in those systems is the use of charged complexes. Gd-
DOTA (1) itself is negatively charged due to the four carboxylate functions complexing the 
gadolinium(III) ion. However, for the attachment to a silsesquioxane an additional functional 
group is required. A relatively convenient way is the functionalisation of the methylene group 
of one of the acetic acids with an additional carboxylic acid. Eisenwiener et al. reported the 
synthesis of DOTAGA(tBu)4 (1-(1-carboxy- 3-carbo-tert-butoxypropyl)-4,7,10-(carbo-tert-
butoxymethyl)-1,4,7,10-tetraazacyclododecane, 55) (Figure 37).134 55 is an excellent 
prochelator which can be conjugated to amines and after deprotection and complexation 
results in a negatively charged monohydrated complex. 
 
Figure 37. Structure of DOTAGA(tBu)4 (55). 
Since the complex should be directly attached to the silsesquioxane in this study, the use of 
orthogonal protecting groups was not required. Therefore a new route for the synthesis of 
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DOTAGA (1,4,7,10-tetraazacyclododecane-1-glutaric-4,7,10-triacetic acid, 60) was 
developed (Scheme 17 and Scheme 18). In the first step glutamic acid (56) was converted into 
2-bromoglutaric acid (57) via diazotation analogous to the method described by Holmberg.135 
Following the method by Eisenwiener et al.,134 the crude acid, being about 85 % pure by 
NMR, was then directly treated with tert-butyl trichloroacetimidate (TBTA) in the presence of 
boron trifuoride ethyl etherate to afford the desired di-tert-butyl protected product 58 in about 
40 % yield. All steps were characterised by 1H and 13C{1H} NMR spectroscopy. 
 
Scheme 17. 
The obtained di-tert-butyl 2-bromoglutaric acid (58) was then used to alkylate the forth ring 
nitrogen of DO3A(tBu)3 (34) in order to obtain the penta-tert-butyl protected DOTAGA(tBu)5 
(59). The successful synthesis of 59 in 70 % yield was confirmed by two-dimensional 1H and 
13C NMR spectroscopy and HR-MS. 
 
Scheme 18. 
Finally, deprotection was accomplished by stirring a solution of 59 in TFA:DCM (3:2) for 
23 hours at room temperature. 60 was obtained as an off-white powder, which still contained 
a small amount of TFA. Rough titrations of the product at about pH 6 with a YCl3 solution 
and xylenol orange as the indicator yielded the equivalence point after the addition of about 
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0.85 equivalents of yttrium(III) referred to the molecular mass of the uncharged structure of 
60 as shown in Scheme 18. This corresponds to less than one equivalent TFA per ligand. The 
yield of complexing species was calculated to be 61 %. As 59, 60 was characterised by two-
dimensional 1H and 13C NMR spectroscopy and HR-MS. Due to their prolonged relaxation 
times and the coupling to the fluorine atoms the TFA carbons were not visible in the 13C{1H} 
NMR spectrum. 
Since the protection of 57 as its di-tert-butyl ester using the expensive TBTA resulted in only 
moderate yields and also the deprotection of 59 with TFA was not satisfying, an alternative 
route for the synthesis of DOTAGA (60) was evolved (Scheme 19). Instead of the di-tert-
butyl ester, the dimethyl ester of 57 was prepared. This could conveniently be accomplished 
in 75 % yield by treating the crude 57 with catalytic amounts of conc. sulphuric acid in 
methanol under reflux. The purity of the obtained dimethyl 2-bromoglutaric acid (61) was 
demonstrated by 1H and 13C{1H} NMR spectroscopy as well as by elemental analysis. 
 
Scheme 19. 
In analogy to the synthesis of DOTAGA(tBu)5 (59), DOTAGA(tBu)3(Me)2 (62) was obtained 
by alkylation of DO3A(tBu)3 (34) with 61 in the presence of a base. The successful synthesis 
of 62 in 71 % yield was also confirmed by two-dimensional 1H and 13C NMR spectroscopy 
and HR-MS. Complete deprotection of the ligand was achieved in excellent yield (about 
92 %) by refluxing its aqueous 6 N hydrochloric acid solution overnight. Following this route, 
60 was isolated as its ammonium chloride salt. Rough titration indicated also in this case the 
molecular mass of the uncharged structure of 60 to be 85 % of that of the obtained product. 
This would roughly correspond to DOTAGA·2.5HCl for the obtained product, however, as 
the product is slightly hygroscopic, some water can also contribute to the increased molecular 
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mass. Organic impurities are not possible as the 1H and 13C NMR spectra in D2O contained 
only signals of the desired product. Furthermore, both NMR spectroscopy and mass 
spectrometry data were in agreement with that obtained for 60 prepared by the other route. 
4.2.4.2 Synthesis of Gadoxane G 
Prior to attachment, the lanthanide complexes of 60 needed to be prepared. Therefore an 
aqueous solution of 60 was treated with aqueous solutions of LnCl3 (Ln = Gd3+, Y3+) while 
adjusting the pH to 6-7 using hydroxide as base (Scheme 20). Since the complexes are 
negatively charged, the counter ions have a large influence on the solubility of the systems. 
To increase the solubility in non-aqueous solvents as required for the following grafting to the 
silsesquioxane, tetra-n-butylammonium hydroxide was used as base. When the complexes 
were required for analytical studies and not for the attachment to silsesquioxanes, tetra-n-
butylammonium hydroxide was replaced by sodium hydroxide. Complete complexation was 
achieved by stirring the solutions for several hours at increased temperature. The solvent of 
the reaction mixture was then removed under reduced pressure and the residue was kept in 
vacuo for four to six days in order to remove most of the remaining water. 
 
Scheme 20. 
The covalent binding of 63 to octa(3-chloroammoniumpropyl)silsesquioxane (29) was 
achieved as for the other systems described above. The silsesquioxane was treated with an 
excess of the respective complex 63, TBTU (38) and DIPEA in dry DMSO. The tetra-n-
butylammonium salt of 63 is fairly soluble in DMSO, however the process is relatively slow. 
Once 63 is dissolved, the coupling to the silsesquioxane can be achieved quantitatively within 
several minutes. The reaction was quenched after 30 minutes by adding the reaction mixture 
to a strongly diluted acetic acid/sodium acetate buffer (pH 5.5). This time no precipitation was 
observed. 
Purification of the product was achieved via diafiltration using a membrane with a molecular 
weight cutoff of 3 K. Additionally to the separation of small molecules from larger molecules, 
diafiltration allows the exchange of counter ions. By using a sodium chloride solution in one 
step of the filtration process the tetra-n-butylammonium counter ion was fully replaced by 
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sodium to afford Gadoxane G (GG) (Figure 38) as its octasodium salt in about 37 % yield. As 
the obtained white solid can contain residual sodium chloride, the yield was determined by 
measuring the gadolinium(III) concentration in a known volume using the BMS method (see 
chapter 5.2.7.2). The yield can be improved by using a smaller cutoff, however, this goes at 
the expense of purity. 
 
Figure 38. Structure of Gadoxane G (GG). 
GG was characterised on the basis of its yttrium(III) complex by HR-MS as well as 
multinuclear (1H, 13C, 29Si) NMR spectroscopy. The absence of non-coordinated 
lanthanide(III) ions was confirmed by the xylenol test.136 The HR mass spectrum of the 
yttrium(III) complex (M = 5228.2 g/mol) is shown in Figure 39.  
 
Figure 39. HR-MS of the yttrium(III) complex of Gadoxane G (GG) [M]8-. 
The characteristic isotope pattern of the eight-times negatively charged [M]8- ion was well 
resolved and the m/z was determined to be 653.487015 (theor.: 653.487060). No signals 
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corresponding to less than eight-times substituted silsesquioxanes, partly hydrolysed or free 
Y-DOTAGA were detected. This shows that pure GG can be synthesised with an intact 
silsesquioxane core by this method. Furthermore, no hydrolysis products were observed in 
samples which were stored at -28°C for more than 10 months. 
The NMR spectra were measured in D2O at 25°C and pD 7.0. The 1H NMR spectrum is 
depicted in Figure 40. A complete assignment of the 1H and 13C NMR resonances to the 
structure of GG was achieved using two dimensional techniques. To reduce the acquisition 
time the 29Si NMR spectrum was also recorded via a 2D 1H-29Si HSQC experiment. It shows 
only one 29Si signal at -65.3 ppm which is again owed to the cubic symmetry of the 
undamaged silsesquioxane core. 
 
Figure 40. 1H NMR spectrum of the yttrium(III) complex of Gadoxane G (GG) in D2O 
(pD 7.0). *DMSO, **solvent residual peak. 
4.2.4.3 Synthesis of DOTAMA and DOTABA 
In order to synthesise derivatives of GG which posses a further reduced internal flexibility 
and therefore show little anisotropic local rotational motion (cf. chapter 4.1.1.1), two novel 
bifunctional ligands were designed (Figure 41).  
 
Figure 41. Structures of DOTAMA (64) and DOTABA (65). 
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Instead via an ethyl spacer as in DOTAGA (60) the additional carboxylate group is directly 
attached to the DOTA moiety in the case of DOTAMA (1,4,7,10-tetraazacyclododecane-1-
malonic-4,7,10-triacetic acid, 64) and via a phenyl ring in the case of DOTABA (1,4,7,10-
tetraazacyclododecane-1-(4-(carboxymethyl)benzoic)-4,7,10-triacetic acid, 65). 
In analogy to the synthesis of DOTAGA (60), the synthetic strategy for both novel ligands 
implies the alkylation of the secondary nitrogen of DO3A(tBu)3 (34) by an appropriate 
protected 2-bromodicarboxylic acid.  
Dimethyl 2-bromomalonate (67), for the synthesis of 64, was prepared in one step from 
dimethyl malonate (66) via radical bromination analogously to the method of Palmer and 
McWherter137 (Scheme 21). Repeated distillation under reduced pressure afforded 67 in 45 % 
yield. Due to its 1H NMR spectrum the final product was 98 % pure with 2 % of unreacted 66. 
 
Scheme 21. 
For the synthesis of DOTABA (65), methyl 4-((methoxycarbonyl)bromomethyl)benzoate (71) 
was synthesised in three steps from the commercially available methyl 4-(cyanomethyl)-
benzoate (68) (Scheme 22).  
 
Scheme 22. 
Following the procedure of Schaper et al.,138 68 was hydrolysed to afford 4-
(carboxymethyl)benzoic acid (69) in 84 % yield. Protection of the acid groups using thionyl 
chloride in methanol gave the dimethyl ester (70) in 95 % yield. The bottle neck of this route 
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was the bromination of 70. When 70 was refluxed with N-bromosuccinimide (NBS) and 
catalytical amounts of AIBN in carbon tetrachloride for five hours the conversion was only 
about 49 % due to 1H NMR spectroscopy. Readdition of AIBN and additional 17 hours 
heating to reflux were necessary to achieve at least 73 % conversion. Interestingly, much 
poorer conversion was obtained if the reaction time was directly prolonged to 24 hours. As a 
complete separation of 71 from unreacted 70 by column chromatography proofed 
unsuccessful, pure 71 could be obtained in only 48 % yield. All steps were characterised by 
1H and 13C{1H} NMR spectroscopy. The purity of 71 was additionally shown by elemental 
analysis. 
DO3A(tBu)3 (34) was then treated with the two obtained dimethyl 2-bromodicarboxylates 67 
or 71 in the presence of a base, to afford 72 and 73 as the protected forms of DOTAMA and 
DOTABA, respectively (Scheme 23). Both alkylations could be carried out in excellent yields 
of 84 % and 86 % for 72 and 73, respectively. The yield of the analogous alkylation reactions 
in the syntheses of DOTAGA (60) were with 70 % and 71 % significantly lower. This might 
be explained by possible eliminations as side reactions in these cases, whereas this is 
impossible in the synthesis of 72 and 73. 72 and 73 were both characterised by two-
dimensional 1H and 13C NMR spectroscopy and HR-MS. Noteworthy is the hindered rotation 
of the dimethyl malonate moiety of 72 leading to two distinct signals (52.4 and 52.7 ppm) for 
the methyl groups in the 13C{1H} NMR spectrum. 
 
Scheme 23. 
The deprotection of 74 was carried out analogously to that of DOTAGA(tBu)3(Me)2 (62) by 
refluxing its aqueous 6 N hydrochloric acid solution overnight (Scheme 24). The successful 
synthesis of 74 in 90 % yield was confirmed by two-dimensional 1H and 13C NMR 
spectroscopy and HR-MS. The ligand was again obtained as its ammonium chloride salt and 
rough titration of the product at about pH 6 with a YCl3 solution and xylenol orange as the 
indicator, showed also in this case the molecular mass of the uncharged structure of 65 to be 
85 % of that of the obtained product. This would correspond to about three HCl molecules per 
ligand. However, also for this ligand the additional inclusion of water molecules is more 
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likely than a triammonium salt as only about six equivalents of base were necessary in the 
following complexation reaction to neutralise the solution of the forming complex. 
 
Scheme 24. 
In the case of DOTAMA(tBu)3(Me)2 (72) deprotection of the malonic acid moiety under 
acetic conditions is not possible due to the instability of malonic acid derivatives at low pH. 
Therefore 72 was deprotected in two steps (Scheme 25). In the first step the tert-butyl esters 
were cleaved by stirring 72 in TFA:DCM (1:1) for 20 hours at room temperature. The 
cleavage was demonstrated by HR-MS and by the disappearance of the tert-butyl signals in 
the 1H and 13C{1H} NMR spectra. The signals of the methyl groups remain in both spectra, 
however, now also the 13C{1H} spectrum shows only one resonance for the methyl groups 
indicating free rotation of the dimethyl malonate moiety after removal of the bulky tert-butyl 
groups. 
 
Scheme 25. 
The deprotection of the malonic acid moiety was accomplished by stirring 75 in an alkaline 
aqueous solution for one day. When the obtained deprotected and deprotonated 
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DOTAMA (64*) was intended for the attachment of its complexes to a silsesquioxane, tetra-
n-butylammonium hydroxide was used as base, whereas when it was scheduled for the 
characterisation of 64* and its lanthanide complexes lithium hydroxide or sodium hydroxide 
was used. All three methods resulted in the fully deprotected 64* as was shown by two-
dimensional 1H and 13C NMR spectroscopy. 
4.2.4.4 Coupling of DOTAMA complexes to the silsesquioxane 
The complex formation of DOTAMA (64*) and the lanthanide(III) was carried out by treating 
the respective aqueous solution of 64* with an aqueous solution of LnCl3 (Ln = Gd3+, Y3+). 
Upon the addition of the lanthanide(III) chloride solution the pH dropped from about 13 to 
7.2±0.1 and a light precipitate was formed, independently of the counter ion. The precipitate 
is most likely lanthanide(III) hydroxide. After stirring overnight at room temperature, the 
precipitate had redissolved. Prior to coupling the complexes 76 to the octa(3-
chloroammoniumpropyl)silsesquioxane (29), the solvent of the reaction mixture was removed 
under reduced pressure and the residue was kept in vacuo for two days in order to remove 
most of the remaining water. The successful complexation was shown by HR-MS on the basis 
of the gadolinium(III) complex having sodium as the counter ion. 
 
Scheme 26. 
In a first attempt to couple 76 as its yttrium(III) complex to the silsesquioxane 29, the 
synthesis was performed in the same manner as for the preparation Gadoxane G (GG). Once 
76 was dissolved in dry DMSO, a DMSO solution of 29 and TBTU (38) as well as DIPEA 
were added under argon atmosphere. The reaction was quenched after 30 minutes by adding 
the reaction mixture to a strongly diluted acetic acid/sodium acetate buffer (pH 5.5). In order 
to purify the desired product, diafiltration with a 3 K molecular weight cutoff membrane was 
performed. Unfortunately after removal of the solvent, no product was obtained. In order to 
investigate why no product was obtained, the reaction was reattempted using dry DMSO-d6. 
Interestingly, the 1H-1H COSY NMR spectrum measured after 15 minutes showed the 
characteristic change in the chemical shift from 2.75 ppm to 3.09 ppm for the 
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SiCH2CH2CH2N group (see chapter 4.2.2.2 or ref. 127) indicating the completeness of the 
reaction. Therefore, the reaction was quenched after 40 minutes. However, workup afforded 
again no product. If a complete octafunctionalisation was really achieved, the product must 
have decomposed during diafiltration. In the octafunctionalised product (77, Figure 42) of this 
reaction, the hydrophilic lanthanide complexes are closer to the silsesquioxane core than in 
the case of GG. Therefore a hydrolytic cleavage of Si-O-Si bonds might occur significantly 
faster and thereby preventing the isolation of 77. 
 
Figure 42. Structure of the desired coupling product of Ln-DOTAMA (76) and octa(3-
chloroammoniumpropyl)silsesquioxane (29). 
4.2.4.5 Synthesis of Gadoxane B 
The lanthanide complexes of DOTABA (65) were also prepared by treating aqueous solutions 
of 65 with aqueous solutions of LnCl3 (Ln = Gd3+, Y3+) while adjusting the pH to 6-7 
(Scheme 27). When the complex 78 was intended for the attachment to the silsesquioxane 29, 
again tetra-n-butylammonium hydroxide was used as base, otherwise sodium hydroxide was 
used. Complete complexation was achieved by stirring the solutions for several hours at 
increased temperature.  
 
Scheme 27. 
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low, leading to a white precipitate once the complex has formed. With sodium as the counter 
ion the solubility of 78 is significantly higher, but still low compared to the complexes of 
DOTAGA (60) and DOTAMA (64). Nevertheless, the solvent of the respective reaction 
mixture was removed under reduced pressure after this time and the residue was kept in vacuo 
for four to six days in order to remove most of the remaining water. 
Despite the use of tetra-n-butylammonium as the counter ion, 78 is only poorly soluble also in 
DMSO. The residue was taken up in a significantly larger amount of dry DMSO than in the 
case of the other two systems, still a suspension remained after stirring for two days. 
Nevertheless, a DMSO solution of 29 and TBTU (38) as well as DIPEA were added. As the 
reaction had to be carried out in suspension, the reaction time was prolonged to three hours. 
The reaction was then quenched by adding the reaction mixture to the diluted acetic 
acid/sodium acetate buffer (pH 5.5). Upon addition the suspension dissolved. This allowed 
the purification of the product via diafiltration (3K membrane). During the filtration process 
the tetra-n-butylammonium counter ion was again fully replaced by sodium ions. In contrast 
to the coupling of Ln-DOTAMA (76), the octafunctionalised Gasdoxane B (GB) (Figure 43) 
could be isolated in about 30 % yield. Again the gadolium(III) concentration was determined 
by the BMS method (see chapter 5.2.7.2) in order to calculate the yield. The absence of non-
coordinated lanthanide(III) ions was confirmed by the xylenol test.136 
 
Figure 43. Structure of Gadoxane B (GB). 
Gadoxane B (GB) was characterised by multinuclear (1H, 13C, 29Si) NMR spectroscopy on the 
basis of its yttrium(III) complex and by HR-MS using the gadolinium(III) complex. The HR 
mass spectrum of the gadolinium(III) complex (M = 6159.3 g/mol) is shown in Figure 44. 
The characteristic isotope pattern of the eight-times negatively charged [M]8- ion was well 
resolved and the m/z was determined to be 769.881065 (theor.: 769.880308). No signals 
corresponding to less than eight-times substituted silsesquioxanes, partly hydrolysed or free 
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Y-DOTABA were detected, showing that pure GB can be synthesised with an intact 
silsesquioxane core by this method.  
 
Figure 44. HR-MS of the gadolinium(III) complex of Gadoxane B (GB) [M]8-. 
The NMR spectra were measured in D2O at 25°C and pD 7.0. The 1H NMR spectrum is 
depicted in Figure 45. Again two dimensional techniques were used to achieve a complete 
assignment of the 1H and 13C NMR resonances to the structure of GB. Furthermore, the 29Si 
NMR spectrum shows only one signal at -65.4 ppm due to the cubic symmetry of the 
undamaged silsesquioxane core. 
 
Figure 45. 1H NMR spectrum of the yttrium(III) complex of Gadoxane B (GB) in D2O 
(pD 7.0). *solvent residual peak. 
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4.2.5 The Molecular Size of Gadoxane G and B 
The importance of the molecular size of a CA was already pointed out in chapter 4.1.1.1 and 
4.1.3. The size of the CA is not only related to the rotational correlation time τR, it also 
influences the distribution of the CA within the body and its excretion rate. As described in 
chapter 3.2.3, PGSE diffusion 1H NMR spectroscopy is a powerful tool in determining the 
size and also the rotational correlation time of very small to extremely big molecules.75, 76, 78 
Using PGSE NMR spectroscopy, the translational self-diffusion coefficients D of the 
yttrium(III) complexes of GG and GB as well as of their corresponding monomeric 
complexes 63 and 78 were determined at 25°C. For spherical molecules, like the Gadoxanes 
and in good approximation also the monomers, the Stokes-Einstein equation (equation 3.1 in 
chapter 3.2.3) is valid and allows the calculation of reliable hydrodynamic radii rH. From rH 
the rotational correlation time τRDiff can be calculated applying equation 3.2 (chapter 3.2.3) 
and the hydrodynamic volume VH is obtained using equation 4.2: 
l? = 43 D&?] (4.2) 
As strongly diluted samples (2-3 mM of the Gadoxanes and 15-20 mM for the monomers) 
were used, rH, VH and τRDiff could be calculated from the diffusion constants assuming ηsolution 
= ηsolvent (Table 6).139 
Table 6. Translational diffusion coefficient D and resultant hydrodynamic radius rH, 
hydrodynamic volume VH, and rotational correlation time τRDiff at 25°C of GG, GB, 
Y-DOTAGA (63) and Y-DOTABA (78). 
Compound D [m2/s] rH [nm] VH [nm3] τRDiff [ps] 
Gadoxane G (GG) (1.373±8)x10-10 1.442±0.008 12.56±0.22 3370±60 
Gadoxane B (GB) (1.379±7)x10-10 1.436±0.007 12.40±0.19 3320±50 
Y-DOTAGA (63) (3.976±9)x10-10 0.499±0.001 0.52±0.00 139±1 
Y-DOTABA (78) (3.625±8)x10-10 0.547±0.001 0.68±0.01 183±1 
 
Evaluation of the diffusion data revealed almost identical hydrodynamic radii for GG and GB 
(about 1.44 nm), showing that the different linkers have no net effect on the size of the CAs. 
By contrast, in the case of the monomers, the replacement of the ethylene spacer by a phenyl 
ring leads to a significant increase in the hydrodynamic volume VH of about 30 % (0.52 nm3 
and 0.68 nm3 for Y-DOTAGA and Y-DOTABA, respectively). With hydrodynamic volumes 
of 12.56 nm3 and 12.40 nm3 the two Gadoxanes are thereby about 20-times larger than their 
respective monomers. This should result in a significantly increase in relaxivity, especially at 
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field strength currently used in clinical MRI (see chapter 4.1.3). 
Furthermore, the Gadoxanes are still considerably smaller than the small pores (r = 3-5 nm) of 
the glomerular filter in the kidneys (see chapter 4.1.1.1), which should allow a sufficiently 
fast clearance of the Gadoxanes from the body. 
4.2.6 The Stability of the Silsesquioxane Cage in Aqueous Media 
Silsesquioxanes are formed in a condensation reaction, therefore hydrolysis, being the reverse 
reaction, can be an issue in aqueous media. It has been reported that degradation of the 
silsesquioxane cage occurs in wet organic solvents in the presence of amine bases,124 which 
could be confirmed in this study (see chapter 4.2.2.2). However, as most of the so far reported 
silsesquioxanes are insoluble in water, not many data are available on their hydrolysis in 
aqueous media. Feher et al.124 referred the stability of octa(3-chloroammonium-
propyl)silsesquioxane (29) to be very high in neutral or acidic solutions, though no 
quantitative data were given. On the other hand, they reported the appearance of a prominent 
new set of resonances in the 29Si NMR spectrum of an alkaline D2O solution (pH 9) of 29 ten 
minutes after preparation. These resonances, which grow at the expense of the resonance for 
29, are believed to belong to a silsesquioxane cage, in which one Si-O-Si bond is cleaved. 
Attempts to achieve higher conversion then led to complete decomposition of the cage. 
4.2.6.1 Time-dependent 29Si NMR measurements 
In order to investigate the stability of the silsesquioxane cage of the Gadoxanes towards 
hydrolysis, initially 29Si NMR spectra of an aqueous solution (pD 7.0) of the yttrium(III) 
complex of Gadoxane G (GG) were measured at 25°C as a function of time. To reduce the 
acquisition time the 29Si NMR spectra were recorded via a 2D 1H-29Si HSQC experiment. The 
29Si projections are depicted in Figure 46. The spectrum measured directly after preparation of 
the solution shows, as already mentioned in chapter 4.2.4.2, only one signal in the typical 
range of T3 groups120 at -65.3 ppm, being owed to the cubic symmetry of the undamaged 
silsesquioxane core (trace 0 d). The solution was then kept at 25°C for two weeks during 
which further 1H-29Si HSQC NMR spectra were recorded. The intensity of the resonance at 
-65.3 ppm slowly decreased during this period of time, clearly indicating the hydrolysis of the 
silsesquioxane. This leads to various Tn (n = 1-3) species with much lower symmetry which 
generate numerous magnetically inequivalent 29Si nuclei in poor concentrations 
circumventing their detection in a reasonable time. 
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Figure 46. 29Si projections of 1H-29Si HSQC NMR spectra of the yttrium(III) complex of GG 
after 0 d, 4 d, 7 d, 14 d at 25°C (pD 7.0) and after additional 8 days at 75°C. 
After seven days a new signal appeared at -38.2 ppm which is in the range of T0 groups140 and 
thus is assigned to the fully hydrolysed species 80 (Scheme 28). After 14 days the intensity of 
this peak had further increased and a very small signal at -47.9 ppm could also be observed. 
As this resonance is in the range for T1 groups, it is assigned to the (OH)2RSi-O-SiR(OH)2 
fragment (81) (Scheme 28). To achieve complete hydrolysis, after 14 days at 25°C the 
solution was heated to 75°C. In a spectrum measured after two days the signal due to 81 had 
not vanished, but on the contrary, the intensities of both 80 and 81 strongly increased. The 
ratio between them remained unchanged even after the solution was kept at 75°C for 
additional six days, suggesting an equilibrium between the two species, 80 and 81. 
 
Scheme 28. 
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4.2.6.2 Time-dependent PGSE diffusion 1H NMR spectroscopy 
Simultaneously to the 29Si NMR measurements, the same solution was also used to determine 
the translational self-diffusion coefficient D of Gadoxane G (GG) and of its fragments by 
PGSE diffusion 1H NMR spectroscopy at 25°C (Figure 47). All fragments are measured with 
the same sensitivity than the undamaged species which makes PGSE NMR ideal for 
following decomposition processes. However, as the signals of GG and its fragments could 
not be separated in the proton NMR spectra, only an average diffusion coefficient of all 
species was obtained during decomposition of GG. 
 
Figure 47. Average translational diffusion coefficient D of Gadoxane G (GG) and its 
fragments at 25°C (pD 7.0) as a function of time. 
The sample was strongly diluted (the initial concentration of Gadoxane was about 2-3 mM), 
therefore rH, VH and τR were again calculated from the diffusion constants assuming ηsolution = 
ηsolvent (Table 7).139 For comparison, the data of Y-DOTAGA (63) is also included in the table. 
As already reported in chapter 4.2.5, 1.37x10-10 m2s-1 was obtained for the diffusion 
coefficient of the undamaged GG (Time = 0). The average diffusion coefficient of GG and its 
fragments then slowly increased with time (Figure 47 and Table 7). As not all fragments are 
supposed to be spherical, the Stokes-Einstein equation is in this case not generally valid and 
therefore the resulting average values of rH, VH and τR during decomposition (Table 7) can 
only be considered as approximations. It is still conspicuous that after 14 days the average VH 
had only decreased to about half the value of the undamaged Gadoxane. Although the 
corresponding 29Si NMR spectrum showed no resonances due to T3 and T2 groups after that 
time, this points out that a considerable amount of only partly degraded species still remains 
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under these conditions. Heating the solution to 75°C for additional eight days then changed D 
significantly, showing that higher temperatures are necessary to obtain mostly small 
fragments at neutral pH within a reasonable time. 
Table 7. Translational diffusion coefficient D, hydrodynamic radius rH, hydrodynamic 
volume VH, and rotational correlation time τR at 25°C of Gadoxane G (GG) (time = 0), 
Y-DOTAGA (63), and the average values during the decomposition of GG. 
Time [d] D [m2/s] rH [nm] VH [nm3] τR [ps] 
0 (GG) 1.37x10-10 1.44 12.56 3366 
0.375 1.39x10-10 1.42 12.00 3216 
1 1.43x10-10 1.38 11.05 2960 
2 1.43x10-10 1.39 11.14 2985 
3 1.48x10-10 1.34 10.01 2682 
4 1.47x10-10 1.34 10.17 2726 
5 1.51x10-10 1.32 9.54 2555 
7 1.54x10-10 1.28 8.83 2367 
14 1.64x10-10 1.21 7.38 1979 
+ 8d at 75°C 2.63x10-10 0.75 1.78 477 
Y-DOTAGA (63) 3.98x10-10 0.50 0.52 139 
 
4.2.6.3 Time-dependent ESI-MS measurements 
A possibility to follow the single steps of the hydrolysis in more detail is offered by ESI-MS. 
The gadolinium(III) complex of Gadoxane G (GG) was used for this investigation. As the 
reaction rate increases with temperature, the aqueous solution of GG was kept at 37°C and pH 
7.0. ESI mass spectra were recorded at the outset, after seven hours, 48 hours and 144 hours 
(Figure 48). With a molar mass of 5774.95 g/mol the eight-times negatively charged 
gadolinium complex has a m/z of 721.9. Unlike in the high resolution mass spectra, the 
isotopic pattern of this highly charged compound could not be resolved in the ESI mass 
spectra. Instead a broad signal appeared in the starting spectrum. Each breaking of a Si-O-Si 
moiety involves the addition of a water molecule (see Scheme 28 in chapter 4.2.6.1). For an 
eight-times negatively charged compound this corresponds to an increase in m/z of 2.25. The 
hydrolysis of the first Si-O-Si unit was observed after seven hours by the appearance of the 
signal at m/z = 724.1. After 48 hours the spectrum showed additional signals corresponding to 
two and three hydrolysed Si-O-Si moieties in the silsesquioxane core, but also the appearance 
of the isotope pattern of the fully degraded species 80 at m/z = 749.3. The signal 
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corresponding to the undamaged species had almost vanished when the solution was kept for 
additional 96 hours, whereas the isotope pattern of 80 was now clearly visible. Interestingly 
no signals corresponding to seven- to two-times negatively charged fragments could be 
observed by this method. 
 
Figure 48. ESI mass spectra of the gadolinium(III) complex of Gadoxane G (GG) and its 
fragments after 0 h, 7 h, 48 h and 144 h at 37°C and pH 7.0. 
4.2.6.4 Time-dependent relaxivity measurements 
The degradation rate of Gadoxane G (GG) under physiological conditions was tested via 
relaxivity measurements. Therefore various concentrated solutions of the gadolinium(III) 
complex of GG in typical cell culture media (20 mM HEPES, pH 7.4-7.6) with and without 
fetal calf serum (FCS) were incubated at 37°C, for different periods of time. T1-relaxation 
times of the solutions were measured at 3 T and room temperature. No significant differences 
between the serum containing and serum free solutions could be observed. Thus, for the 
further evaluations the data of both experiments were combined. The respective longitudinal 
relaxivities r1 were calculated from the T1 measurements (Figure 49). Without incubation a 
longitudinal relaxivity of 10.6 mM-1s-1 per gadolinium(III) ion was obtained. Within the first 
three to four hours of incubation r1 did not significantly change. This is understandable as the 
gadolinium(III) ion remains complexed safely and the initial breaking of Si-O-Si bonds 
should not have much influence on the size or rather the rotational correlation time τR. Further 
hydrolysis then leads to smaller fragments with a reduced average τR resulting in a decrease of 
r1. Fitting the period of decrease with a first order exponential decay showed a half-life t1/2 of 
about 15±3 hours. A plateau of 6.7 mM-1s-1 is reached after about 125 h. This relaxivity still 
belongs to an equilibrium between the fully hydrolysed 80 and fragment 81 (see Scheme 28 in 
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chapter 4.2.6.1). As 81 was not observable in the ESI-MS measurements this could not be 
directly verified. However, when the same measurements were performed in solutions of pH 
8.1 to 8.6 (without HEPES and gas exchange) the decay was much faster (t1/2 about 55 min), 
and, even more important, the plateau was significantly lower (5.4 mM-1s-1) showing that the 
increase in pH can further shift the equilibrium towards 80. 
 
Figure 49. Longitudinal relaxivity r1 (3 T, r.t.) during the degradation of GG under 
physiological conditions (cell culture media, 20 mM HEPES, pH 7.4-7.6). The inset 
highlights the first four hours of incubation. 
The degradation of the silsesquioxane core of Gadoxane B (GB) was also investigated by its 
effect on the longitudinal relaxivity r1. Since the water itself (or rather OH-) is responsible for 
the degradation of the silsesquioxane (see Scheme 28 in chapter 4.2.6.1) and no influence of 
serum, but a strong dependence on the pH was observed for GG, the measurements were 
carried out in HEPES buffered water (pH 7.4), where the pH can be adjusted more accurately. 
The sample was kept at 37°C and the longitudinal relaxation time T1 was measured at a proton 
Larmor frequency of 10 MHz after different periods of time. The longitudinal relaxivities 
were calculated from these data (Figure 50). As was observed for GG, r1 of GB also remained 
constant (14.14±0.08 mM-1s-1) within the first three hours and only then started to decrease. 
The decrease, starting after three hours, could also be fitted with a first order exponential 
decay. With a half-life t1/2 of 11.2±0.2 h the decay rate is comparable to that obtained for GG 
(t1/2 = 15±3 h). 
This result verifies the degradation of the silsesquioxane core also for GB. As mentioned 
earlier, the initial period of constant relaxivity can be explained by the negligible influence of 
the breaking of the first Si-O-Si bonds of the silsesquioxane core on the rotational correlation 
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time. Despite their degradation, the Gadoxanes should therefore allow the performance of 
MRI measurements with high reproducibility. 
 
Figure 50. Longitudinal relaxivity r1 of Gadoxane B (GB) under physiological conditions as 
a function of the time (37°C, pH 7.4, 10 MHz). The inset highlights the first six hours. 
4.2.7 Physico-chemical Characterisation of Gadoxane G and B 
The diffusion measurements revealed a rotational correlation time τRDiff of about 3.35 ns for 
both Gadoxanes (see chapter 4.2.5), which should result in highly efficient CAs. However, 
τRDiff reflects the rotational correlation time of the whole molecule, and, as was outlined in 
chapter 4.1.1.1, the major influence on the relaxivity of a macromolecular CA does not arise 
from the global rotational movement of the compound, but from the local tumbling of the 
attached gadolinium(III) complexes. The difference between the global and the local 
rotational dynamics is in turn based on the internal flexibility of the macromolecule. As 
mentioned in chapter 4.2.4.3, the phenyl ring in Gadoxane B (GB) was thus introduced, to 
replace the more flexible ethylene spacer in Gadoxane G (GG). 
In order to quantify the effect of the different rigidity of the linking groups on the rotational 
motion of the gadolinium(III) complexes in GG and GB, but also to determine the parameters 
describing water exchange and electronic relaxation, variable-temperature 17O NMR and 1H 
NMRD measurements were performed in aqueous solutions of the gadolinium(III) complexes 
of GG and GB as well as of their corresponding monomers Gd-DOTAGA (63) and Gd-
DOTABA (78). For both monomers, the 17O reduced transverse relaxation rates, 1/T2r, 
increase at lower temperatures, while above ~300 K they decrease with temperature (slow and 
fast exchange regions, respectively; Figure 51). As already mentioned in chapter 3.2.7, a 
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detailed discussion of variable-temperature 17O NMR measurements for the physico-chemical 
characterisation of CA, can be found elsewhere.1 The equations involved in the 17O NMR 
study are given in the experimental part (chapter 5.1.8) of this thesis. 
 
Figure 51. Temperature dependence of reduced transverse relaxation rates, 1/T2r, and 
chemical shifts, ∆ωr, of (a) Gd-DOTAGA (63) and (b) Gd-DOTABA (78). The lines 
represent the least-squares simultaneous fit of all data points. 
In the slow exchange region, the reduced transverse relaxation rate 1/T2r is given exclusively 
by the water exchange rate kex. In the fast exchange regime, 1/T2r is defined by the transverse 
relaxation rate of the bound water oxygen 1/T2m, which is in turn influenced by kex, the 
longitudinal electronic relaxation rate 1/T1e, and the scalar coupling constant A/ħ. The 17O 
reduced chemical shifts ∆ωr (Figure 51) are determined by A/ħ, and to a small extent by an 
outer-sphere contribution COS. Due to the significantly increased lability of the silsesquioxane 
core at higher temperatures, the 17O reduced transverse relaxation rates and 17O reduced 
chemical shifts ∆ωr of the Gadoxanes could only be obtained in a temperature range of 273-
320 K (Figure 52). Nevertheless, even in this limited temperature range, both the slow and 
fast exchange regimes are observable for Gadoxane G and B, evidencing that the water 
exchange rate kex on the gadolinium complexes is not significantly changed by the attachment 
to the silsesquioxane core. 
a) b) 
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Figure 52. Temperature dependence of reduced transverse relaxation rates, 1/T2r, and 
chemical shifts, ∆ωr, of (a) Gadoxane G (GG) and (b) Gadoxane B (GB). The lines represent 
the least-squares simultaneous fit of all data points. 
Since the transverse 17O relaxation is governed by the scalar relaxation mechanism, it contains 
no information on the rotational motion of the system. In contrast to 1/T2r, the longitudinal 
17O relaxation rates 1/T1r are determined by dipole-dipole and quadrupolar relaxation 
mechanisms, both related to the rotation of the molecules. The dipolar term depends on the 
Gd3+-water oxygen distance, rGdO, while the quadrupolar term is influenced by the 
quadrupolar coupling constant, χ(1+η2/3)1/2. The longitudinal relaxation rates have also been 
measured. However, the differences between the diamagnetic reference and the paramagnetic 
samples were too small because of the low gadolinium(III) concentration owed to the poor 
solubility of the complexes, in particular of 78. Therefore, the reduced longitudinal 17O 
relaxation rates have not been included in the analysis. The relatively poor quality of the 
chemical shifts should also be noted. Nevertheless, in accordance to related systems, the shifts 
confirm the hydration number of one for all four compounds. 
In recent years, it has become general practice to fit 17O NMR and NMRD data 
simultaneously, which is thought to yield physically more meaningful parameters.88 However, 
such an approach was not possible in the case of both Gadoxanes, as an acceptable fit of the 
1H relaxation profile could not be reconciled with the electronic relaxation parameters 
a) b) 
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obtained from the 17O NMR studies. This discrepancy is most probably related to an 
inadequate description of the electron spin relaxation, having a strong influence on both the 
low-field proton relaxivities and the transverse 17O relaxation rates in the intermediate and 
fast water exchange regimes. A new appropriate theory that is capable of describing the field 
dependence (low frequency part of the NMRD curve: <0.02 T; 17O data: 7.05 T) of electron 
spin relaxation rates by the inclusion of both transient and static zero-field splitting (ZFS) has 
been reported.141, 142 However, this theory is only applicable to small molecular weight 
chelates and not to larger compounds like Gadoxane G and Gadoxane B. Indeed, attempts to 
simultaneously fit 17O T2 and NMRD data failed in the case of the “intermediate” sized 
metallostar compound (cf chapter 3.1.1.3).55 
Therefore, for all four compounds the transverse 17O relaxation rates, which primarily give 
access to the water-exchange rate, were fitted together with the 17O chemical shifts using the 
traditional Solomon–Bloembergen–Morgan equations (see chapter 5.1.8). From these fittings 
the water exchange rate kex298, its activation entropy ∆S‡, and enthalpy ∆H‡ as well as the 
parameters of the electron spin relaxation, namely the correlation time for the modulation of 
the zero-field-splitting τv298 and the mean-square zero-field-splitting energy ∆2 have been 
adjusted. The values obtained for these parameters are presented in Table 8. 
Table 8. Parameters obtained from the independent fit of 17O NMR and 1H NMRD data. For 
each complex, the left and right semicolumns show the electron spin relaxation parameters 
calculated from 17O NMR and 1H NMRD, respectively. In the NMRD analysis, parameters of 
water exchange were fixed to values obtained by 17O NMR. 
 
Gd-DOTAGA Gadoxane G Gd-DOTABA Gadoxane B 
∆H‡ (kJ mol-1) 49.9±0.5 43.5±0.5 47.5±0.5 42.2±0.5 
∆S‡ (Jmol-1k-1) +52±2 +30±2 +43±2 +25±2 
kex298 (106 s-1) 5.9±0.3 5.3±0.5 5.4±0.3 5.5±0.5 
ElH (kJ mol-1) 17.2±0.3a) 23±0.8 19.7±0.3a) 20±0.8 
τlH
298
 (ps) 93±8a) 240±10 117±10a) 380±20 
EgR (kJ mol-1)  23±0.8  19.3±0.8 
τgR
298
 (ps) 
 
1500±400 
 
1900±400 
S2 
 
0.14±0.02 
 
0.21±0.02 
τv
298
 (ps) 6.6±0.3 6.5±0.3 3.9±0.4 30±8 9.7±0.7 7.0±0.4 4.5±0.3 31±8 
∆2 (1019 s-2) 5.1±0.3 3.9±0.4 5.0±0.4 0.7±0.1 5.0±0.3 3.9±0.4 5.0±0.3 0.6±0.1 
a)
 No Lipari-Szabo treatment; only a single τRΗ298 and ERH is calculated, respectively 
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The water exchange rates of all four compounds are higher than that reported for Gd-DOTA 
(1) (kex298 = (4.1±0.2)×106 s-1).88 Gd-DOTAGA (63) shows the strongest increase in kex298 as 
compared to 1 (about 40 %). The large activation enthalpies ∆H‡ and the positive activation 
entropies ∆S‡ suggest a dissociative mechanism for all compounds.143 In such a dissociative 
mechanism, the additional negatively charged (at neutral pH) carboxyl group in 63, being 
relatively close to the coordination cage, can favour the leaving of the coordinated water 
molecule, thus resulting in faster exchange. This was previously observed for Gd-DOTASA 
(82, Figure 53) (DOTASA = 1,4,7,10-tetraazacyclododecane-1-succinic-4,7,10-triacetic acid), 
where the carboxylate group is even closer to the coordination cage (kex298 = 
(6.3±0.2)×106 s-1).144  
 
Figure 53. Structure of Gd-DOTASA (82) 
Beside the effect of the negative charge of the carboxylate on the water exchange, the pending 
group might lead to a structural change and induce some sterical crowding in the inner 
coordination sphere of the complex with respect to Gd-DOTA (1). This might also contribute 
to the acceleration of the water exchange. This effect is expected to increase with increasing 
length and rigidity of the linker. It is likely operative for Gd-DOTABA (78), where the 
additional negative charge is farther away from the inner sphere, and becomes even more 
important for Gadoxane G and B. Indeed, the Gadoxane compounds do not have an additional 
negative charge and still present a faster water exchange than 1.  
In a second step, the NMRD profiles of all four compounds (Figure 54 and Figure 55) were 
analysed to yield primary information on the rotational dynamics. In these fittings the 
parameters describing the water exchange (kex298, ∆H‡) were fixed to the values obtained from 
the fit of the 17O NMR data. In addition, rGdH was set to the common value of 3.10 Å based on 
recent electron-nuclear double resonance (ENDOR) spectroscopic results,87, 145 and the 
distance of closest approach of an outer-sphere water proton to gadolinium(III), aGdH, to 
3.5 Å. The diffusion constant DGdH298 (23×10-10 m2 s-1 (63 and 78); 26×10-10 m2 s-1 (GG and 
GB)) used in the analysis of the proton NMRD data and the corresponding activation energy 
EGdH (22 kJ mol-1 (63 and 78); 20 kJ mol-1 (GG and GB)) were adjusted to reasonable values. 
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Figure 54. NMRD profile of (a) Gd-DOTAGA and (b) Gd-DOTABA at 25°C (■) and 37°C 
(▲). The lines represent the least-squares simultaneous fit of all data points. 
The 1H NMRD profiles of the monomers (Figure 54) were fitted according to the equations 
described in chapter 2.3 using a single rotational correlation time τRΗ298, corresponding to the 
rotation of the Gd-Hwater vector. It should be noted that due to the internal motion of the 
coordinated water molecules around the Gd-O axis, τRΗ298 is usually lower than the rotational 
correlation time of the Gd-Owater vector τRΟ298 (τRH/τRO = 0.65±0.2).146, 147 The obtained values 
for τRΗ298 and its activation energy ERH, as well as the parameters of the electron spin 
relaxation (τv298, ∆2) are depicted in Table 8.  
 
Figure 55. NMRD profiles of (a) Gadoxane G and (b) Gadoxane B at 25°C (■) and 
37°C (▲). The lines represent the least-squares simultaneous fit of all data points. 
For the two Gadoxanes, a satisfying fit of the experimental high filed NMRD data 
(> 10 MHz) (Figure 55) could only be obtained by using the Lipari-Szabo model-free 
approach,148, 149 previously applied to evaluate NMR relaxation data of numerous 
macromolecular systems (equations are given in chapter 5.2.7.5). The Lipari-Szabo approach 
a) b) 
a) b) 
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allows the separation of the two kinds of rotational motions influencing relaxation, the fast 
local motion being characterised by a correlation time τlR298 and its activation energy ElR, as 
well as the slower global motion with a correlation time τgR298 (activation energy EgR) (Table 
8). A measure for the spatial restriction of the local motion is given by the parameter S2. For 
an isotropic internal motion S2 = 0, while for a fully restricted motion S2 = 1 (Table 8).  
Table 9 shows proton relaxivity data and rotational correlation times of Gadoxane G and B 
and the monomeric complexes 63 and 78 together with a series of other DOTA-type 
gadolinium complexes of various sizes, previously reported in the literature. In the case of 
Gd-DOTASA (82), the rotational correlation time τRΗ298 is about 60 % larger than that of Gd-
DOTA (1). As referred to the increased molecular weight, one would only expect an increase 
in τRΗ298 of about 10 %. The significantly higher increase was explained by the ability of the 
negatively charged additional carboxylate to assemble water molecules in the second 
coordination sphere. They move together with the complex, thereby further increasing the 
rotational correlation time. The rotational correlation time τRΗ298 of Gd-DOTAGA (63) is also 
higher than that of 1, but with only 20 % the increase is significantly smaller than for 82. Due 
to the longer alkyl chain the hydrophobicity of the linker might increase, thereby preventing 
the formation of a large second sphere hydration layer. As was already observed in the 
diffusion NMR study (4.2.5), the larger linker of Gd-DOTABA (78) prolongs the rotational 
correlation time of 78. τRΗ298 of 78 is therefore again in the range of that of 82. The obtained 
values for the rotational correlation time of 63 and 78 by the analysis of the NMRD profiles, 
τRΗ
298
, are smaller than those obtained from the diffusion NMR studies, τRDiff298 (Table 9 and 
Table 6). As mentioned above, τRΗ298 corresponds to the rotation of the Gd-Hwater vector, 
being faster than that of the Gd-Owater vector due to the internal rotation of the water molecule. 
On the contrary, τRDiff298 should represent the global rotational motion of the whole complex. 
Indeed, if the τRΗ298 values of 63 and 78 are multiplied with the above mentioned relation to 
τRΟ
298
, values of 143±12 ps and 180±15 ps, respectively, are obtained. These values are in 
excellent agreement with the obtained τRDiff298 values of 139±1 ps and 183±1 ps for 63 and 78, 
respectively. As one can assume that the τRΟ298 of these monomeric complexes match with 
their global rotational correlation times, these results emphasise that PGSE diffusion 1H NMR 
spectroscopy is an appropriate method for determining the global rotational correlation time 
of such almost spherical compounds.  
The effect of the longer rotational correlation times of 63 and 78 is reflected in their higher 
relaxivities as compared to 1. At 25°C and a proton resonance frequency of 20 MHz the 
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relaxivity of 63 is 9 % higher and the relaxivity of 78 is even 24 % higher than that of 1. Since 
at this field and for such small molecular weight compounds, the relaxivities are exclusively 
limited by the rotational correlation time, the relaxivity of 78 is comparable to that of 82 
despite the faster water exchange rate of the latter. 
Table 9. Relaxivity r1 (at 25°C and 20 MHz) and parameters characterising the rotational 
tumbling of selected DOTA-type gadolinium complexes. 
Complex τlR298 [ps] τgR298 [ps] S2 τRDiff298 [ps] r1 [mM-1s-1] 
monomers 
     
Gd-DOTAGA (63) 93±8a) 
  
139±1 5.18 
Gd-DOTABA (78) 117±10a) 
  
183±1 5.87 
Gd-DOTASA (82)144 125±2a) 
   
5.93 
Gd-DOTA (1)88 77±4a) 
   
4.74 
dendrimers 
     
Gadoxane G (GG) 240±10 1500±400 0.14 3370±60 12.13 
Gadoxane B (GB) 380±20 1900±400 0.21 3320±50 17.11 
Gadomer 17111 760 3050 0.50 
 
16.46 
micelles 
     
Gd-DOTASA-C1295 920±40a)    18.03 
Gd-DOTA-C1296 430 1600 0.23  17.24 
a)
 No Lipari-Szabo treatment; a single τRΗ298 is calculated. 
 
The attachment of Gd-DOTAGA (63) and Gd-DOTABA (78) to the octa(amino-
propyl)silsesquoxane core results in the expected “high field” peak in the NMRD profiles 
(Figure 55) of Gadoxane G (GG) and Gadoxane B (GB) being typical for macromolecular 
CAs, where the rotation of the gadolinium(III) chelates is substantially slowed down (see 
chapter 4.1.1.1). However, especially in the case of GG the peak is not as distinctive as it 
could be for a CA of that size. At 25°C and a proton resonance frequency of 20 MHz, GG 
only revealed a relaxivity of 12.13 mM-1s-1. This reflects the still high flexibility of the 
ethylenecarboxyl linker on the Gd-DOTAGA moiety together with the aminopropyl group on 
the silsesquioxane part, resulting in a short local correlation time τlR298 of only 240 ps. 
Remarkably, the replacement of the ethyl spacer in the linking group of GG by a phenyl ring 
in GB increases τlR298 to 380 ps and, more important, it leads to a significantly higher 
relaxivity (17.11 mM-1s-1 at 25°C and 20 MHz). This points out that DOTABA (65) can be in 
general an extremely useful ligand for attaching stable DOTA-type complexes to 
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(bio)macromolecules and thereby achieving high relaxivities. The apparent global rotational 
correlation times of GG and GB calculated from the NMRD profiles are 2 and 1.5 times 
shorter, respectively, than those obtained from the diffusion measurements. This difference 
can be attributed to the still relatively high flexibility of the systems and hence the poor 
correlation (S2) between the local and the global motion. With a greater rigidity of the systems 
the global motion is better represented in the NMRD profiles. This is supported by the better 
consistency of the two obtained values (τgR298 and τRDiff298) for the global rotational correlation 
time of Gadoxane B (GB) compared to Gadoxane G (GG). As is evident from Table 9, the 
relaxivity of GB is comparable to other DOTA-type macromolecular dendrimers and 
micelles. The increase in relaxivity of more than 40 % from GG to GB, however shows the 
potential for even higher relaxivities by further increasing the rigidity of these systems. 
Note, that for GG and GB, the electron spin relaxation parameters obtained from 17O NMR 
data are significantly different from those obtained by the evaluation of the 1H NMRD data 
(Table 8). As this is related to the shortcomings of the electron spin relaxation theory used, 
the interpretation of these values in terms of physical meaning is not possible. 
4.3 Conclusions and Perspectives 
In order to obtain moderate sized macromolecular CAs, several approaches to 
octafunctionalise T8-silsesquioxane cages with gadolinium(III) complexes were carried out. 
First of all, an amino functionalised T8-silsesquioxane (29) and a carboxylic acid 
functionalised T8-silsesquioxane (33) were synthesised. These silsesquioxanes should allow 
the attachment of various protected macrocyclic ligands bearing an additional amino or 
carboxylate moiety in high yields by using classical peptide coupling reagents. Initially, the 
tri-tert-butyl protected DOTA ligand 36 was coupled to 29. An issue in these coupling 
reactions is the hydrolysis of the silsesquioxane cage under the used basic conditions in the 
presence of even small amounts of water. Complete octafunctionalisation without destruction 
of the silsesquioxane cage could be achieved by reducing the reaction time to 30 minutes and 
avoiding hydrated reagents. This points out the suitability of peptide coupling reagents to 
synthesise eight-fold functionalised silsesquioxanes without generating complicated mixtures 
with less functionalised systems. Nevertheless, this initial route turned out to be unsuitable for 
the synthesis of silsesquioxane-based CAs, as the cleavage of the tert-butyl esters of the 
octafunctionalised 46 could not be fulfilled without decomposition of the silsesquioxane cage. 
A route where the tert-butyl esters were replaced by benzyl esters to avoid the harsh 
conditions necessary for the cleavage of tert-butyl esters, also proved unsuccessful as a 
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complete deprotection could not be achieved under the used conditions. A much more 
promising and also much more convenient approach was the direct eight-fold grafting of the 
hexylamine functionalised DO3A-type complex 48 to 33. In this case, the carboxylate 
moieties of the macrocyclic ligand are protected by coordination to the lanthanide(III) itself. 
This makes a later deprotection and subsequent complexation unnecessary, which reduces the 
risk of destroying the silsesquioxane cage. Unfortunately, the obtained product 49 turned out 
to be insoluble in aqueous media at moderate pH, what makes it unsuitable as a MRI CA. 
However, 49 could be dissolved by reducing the pH to about 2-3. At this pH the carboxylate 
groups become protonated and the lanthanide(III) ion can be released, in turn leading to a 
protonation of the nitrogens. Since this suggested the need of a charge to obtain sufficient 
water solubility of these highly symmetric systems, macrocyclic ligands were synthesised 
which form charged lanthanide (III) complexes. The first of these systems was DOTAGA 
(60). 60 is a DOTA-type ligand having an additional ethylene carboxylate function on one of 
the methylene moieties for the coupling to 29. As the lanthanide (III) complexes (63) 
themselves were attached to 29, no orthogonal protecting group chemistry was required in the 
synthesis of 60. The counter ion of the negatively charged complexes 63 is an important 
factor for the solubility of 63. Thus, for the binding of the complexes to 29, tetra-n-butyl 
ammonium was used as the counter ion to increase the solubility in DMSO. Complete 
octafunctionalisation could be achieved within 30 minutes using TBTU (38) and DIPEA. The 
obtained product was purified by diafiltration. Diafiltration also allowed the exchange of the 
tetra-n-butyl ammonium counter ion by sodium to yield the water soluble silsesquioxane-
based CA, Gadoxane G (GG), as its octasodium salt. The yttrium(III) complex of GG was 
synthesised in order to allow its characterisation with multinuclear (1H, 13C, 29Si) NMR 
spectroscopy and HR-MS. The data showed, that pure GG can be synthesised by this method 
with a fully condensed silsesquioxane cage. Encouraged by this success, two novel ligand 
systems, DOTAMA (64) and DOTABA (65), were designed and prepared. In these systems 
the flexible ethylene spacer by which the additional carboxylate group is attached to the 
DOTA moiety in DOTAGA (60) is replaced by a rigid phenyl ring in the case of 65 and in the 
case of 64 the carbxylate group is directly attached to one of the methylene groups of the 
DOTA moiety. This should further reduce the internal flexibility of the system, resulting in 
higher relaxivities. Unfortunately, a silsesquioxane bearing eight Ln-DOTAMA complexes 
(76) could not be isolated, even though the 1H NMR spectrum of the reaction solution 
indicated the successful octafunctionalisation of 29. By contrast, the eight-fold grafting of 29 
with Ln-DOTABA (78) succeeded after allowing the reaction mixture to stir for three hours. 
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The longer reaction time was necessary as 78 was poorly soluble in DMSO and DMF, even as 
its tetra-n-butyl ammonium salt. Nevertheless, as in the case of GG, the desired Gadoxane B 
(GB) turned out to be water soluble and could be isolated after diafiltration as its octasodium 
salt. GB was also characterised by multinuclear (1H, 13C, 29Si) NMR spectroscopy and 
HR-MS. 
A key issue of the Gadoxanes is the stability of the silsesquioxane cage towards hydrolysis in 
aqueous media. This point was initially investigated at neutral pH on the basis of GG by 29Si 
NMR and PGSE diffusion 1H NMR spectroscopy as well as by ESI-MS. It could be shown 
that aqueous solutions of GG can be stored at -28°C for at least 10 months without any 
decomposition. However, already at 25°C and pH 7.0 a slow hydrolysis of the silsesquioxane 
core was observed, which accelerated by increasing the temperature. Additionally, these 
experiments showed that having a single resonance in the 29Si NMR spectrum is not 
necessarily a proof of an intact silsesquioxane core. In fact, several techniques should be used 
to fully describe the state of the silsesquioxane cage. Relaxivity measurements of GG and GB 
were then used to determine the degradation rate of the cage under physiological conditions 
(pH 7.4, 37°C) in the presence and absence of cell culture media and fetal calf serum. Since 
the water itself is responsible for the decomposition of the silsesquioxane, no significant 
effect of the added serum on the degradation rate was observed. Interestingly, the relaxivity of 
both compounds remained constant within the first three hours, before starting to decrease due 
to the shorter rotational correlation time of the fragments. The initial period of constant 
relaxivity can be explained by the negligible influence of the breaking of the first Si-O-Si 
bonds of the silsesquioxane core on the rotational correlation time. This time frame should be 
sufficient to perform MRI measurements with high reproducibility. With half-lives t1/2 of 
15±3 and 11.2±0.2 hours, the decay rates of GG and GB, respectively, are then already 
significantly faster than at neutral pH. The influence of the pH on the hydrolysis rate becomes 
obvious, when the same experiment is carried out at pH 8.1 to 8.6. In this case a half-life t1/2 
of only 55 minutes was observed for the degradation of GG. In terms of toxicity the 
degradation of the silsesquioxane core is a very crucial aspect. Since silica monomers are 
nontoxic,123 the hydrolysis of the core is not supposed to increase the toxicity by itself. 
However, if silsesquioxanes are used as the dendrimeric core, the stability of the 
gadolinium(III) complex must not depend on the intactness of the silsesquioxane, since then 
the risk of gadolinium related diseases increases. On the other hand, if appropriate 
gadolinium(III) chelators are applied, like DOTAGA (60) and DOTABA (65) in the case of 
GG and GB, the decomposition of the silsesquioxane core has no influence on the stability of 
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the gadolinium (III) complex. On the contrary, the lability of the silsesquioxane core may 
allow the development of even larger and still well defined macromolecular CAs for MRI, 
whose fragments are then readily excreted via the kidneys. 
However, with a hydrodynamic radius of about 1.44 nm, as obtained by PGSE diffusion 1H 
NMR spectroscopy, both GG and GB are still significantly smaller than the small pores of the 
glomerular filtration system and hence should be excreted relatively fast via the kidneys, even 
before a significant amount of the silsesquioxane cages is fragmented. 
PGSE diffusion 1H NMR spectroscopy revealed also rotational correlation times of about 
3.35 ns for both, GG and GB. Even though variable temperature 17O NMR measurements 
showed that both CAs have also almost identical water exchange rates, the longitudinal 
relaxivities of GB are significantly higher than those of GG (54 % at 37°C and 20 MHz) over 
almost the whole range of magnetic fields. The discrepancy arises from a different local 
rotational correlation time of the Gd-Hwater vector of GG and GB, due to the lower internal 
flexibility of GB towards GG, as was intended. Having already relaxivities in the range of 
other, larger macromolecular CAs, GB still possesses a fairly high internal flexibility. This, 
together with the observed strong effect of replacing an ethylene by a phenyl spacer on the 
relaxivity, points out the high potential of silsesquioxane-based CAs to become extremely 
efficient, once the rigidity is further improved and the water exchange rate is optimised. 
Furthermore, the introduction of additional functional groups into these systems, e.g. via 
functionalisation of the remaining methylene groups of the complexes, could allow their use 
in the targeting of biomolecules within the body.  
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5 Experimental Part 
5.1 Calcium(II)-sensitive MRI Contrast Agents 
5.1.1 General Remarks 
All LnL1-LnL4 complexes used in this part of the thesis were kindly provided by Dr. I. 
Mamedov, Max-Planck-Institute for Biological Cybernetics, Tübingen. pH and pD150 values 
of the aqueous solutions were measured using a Schott handylab pH12 pH-meter equipped 
with a Hamilton Spintrode or a Mettler-Toledo Inlab Micro glass electrode. The absence of 
the non-coordinated metal ions in the systems was confirmed by the xylenol test.136 The 
calcium(II) chloride stock solutions were prepared by dissolving an accurately weighed 
amount of the chloride salt in the appropriate volume of distilled water. The exact 
concentration was determined via complexometric titration with Titriplex III in a buffered 
indicator solution (Merck indicator buffer tablet / conc. ammonia).  
5.1.2 Relaxivity vs. Calcium(II) Concentration 
The relaxivity measurements were performed at 9.4 T, 25°C and pH 7.3-7.4 (maintained by 
HEPES buffer). A solution of calcium(II) chloride of known concentration was added 
stepwise to the respective complex solution and the longitudinal proton relaxation time T1 of 
the water peak was measured after each addition of the analyte. The initial gadolinium(III) 
concentration was determined by measuring the bulk magnetic susceptibility (BMS) shift of 
the solution (see chapter 5.2.7.2).151 The relaxivity r1 was calculated according to equation 2.4 
from chapter 2.3, using the respective gadolinium(III) concentration at each point of the 
titration. 
Table 10. Relaxometric calcium(II) titration of GdL1 at 25°C, pH 7.3 and 9.4 T. 
[Gd3+] (mM) [Ca2+] (mM) [Ca2+]/[CA] T1 (ms) r1 (mM-1s-1) 
2.490 0.000 0.00 56.869 6.915 
2.441 1.225 0.50 58.070 6.904 
2.394 2.404 1.00 58.217 7.022 
2.349 3.538 1.51 59.219 7.033 
2.306 4.630 2.01 61.075 6.943 
2.264 5.682 2.51 62.207 6.940 
2.223 6.696 3.01 63.405 6.929 
2.184 7.675 3.51 64.874 6.890 
2.147 8.621 4.02 66.457 6.839 
2.110 9.534 4.52 67.901 6.806 
2.075 10.417 5.02 69.336 6.774 
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Table 11. Relaxometric calcium(II) titration of GdL2 at 25°C, pH 7.3 and 9.4 T. 
[Gd3+] (mM) [Ca2+] (mM) [Ca2+]/[CA] T1 (ms) r1 (mM-1s-1) 
2.500 0.000 0.00 52.783 7.432 
2.451 1.225 0.50 54.596 7.324 
2.404 2.404 1.00 58.128 7.004 
2.358 3.538 1.50 61.672 6.720 
2.315 4.630 2.00 65.328 6.455 
2.273 5.682 2.50 68.027 6.307 
2.232 6.696 3.00 70.769 6.166 
2.193 7.675 3.50 72.075 6.160 
2.155 8.621 4.00 74.706 6.041 
2.119 9.534 4.50 76.659 5.984 
2.083 10.417 5.00 80.068 5.819 
Table 12. Relaxometric calcium(II) titration of GdL3 at 25°C, pH 7.3 and 9.4 T. 
[Gd3+] (mM) [Ca2+] (mM) [Ca2+]/[CA] T1 (ms) r1 (mM-1s-1) 
2.520 0.000 0.00 57.987 6.698 
2.471 1.225 0.50 62.942 6.283 
2.423 2.404 0.99 71.899 5.589 
2.377 3.538 1.49 82.757 4.929 
2.333 4.630 1.98 87.024 4.768 
2.291 5.682 2.48 92.989 4.534 
2.250 6.696 2.98 95.433 4.494 
2.211 7.675 3.47 98.422 4.431 
2.172 8.621 3.97 100.227 4.424 
2.136 9.534 4.46 102.642 4.391 
2.100 10.417 4.96 104.209 4.395 
Table 13. Relaxometric calcium(II) titration of GdL4 at 25°C, pH 7.3 and 9.4 T. 
[Gd3+] (mM) [Ca2+] (mM) [Ca2+]/[CA] T1 (ms) r1 (mM-1s-1) 
2.540 0.000 0.00 66.734 5.755 
2.490 1.225 0.49 72.389 5.400 
2.442 2.404 0.98 81.963 4.846 
2.396 3.538 1.48 95.151 4.233 
2.352 4.630 1.97 105.052 3.892 
2.309 5.682 2.46 109.725 3.788 
2.268 6.696 2.95 115.238 3.665 
2.228 7.675 3.44 118.426 3.626 
2.190 8.621 3.94 120.841 3.612 
2.153 9.534 4.43 123.108 3.604 
2.117 10.417 4.92 127.143 3.543 
5.1.3 Relaxivity vs. Complex Concentration 
Like the calcium(II) dependent relaxivity measurements, the complex concentration 
dependent measurements were performed at 9.4 T, 25°C and pH 7.3-7.4 (maintained by 
HEPES buffer). The initial gadolinium(III) concentration of each complex solution was 
determined by measuring the bulk magnetic susceptibility (BMS) shift of the solution (see 
chapter 5.1.2). From these solutions, two new solutions per complex were prepared, one 
without calcium(II) and the other one with three equivalents of CaCl2. The longitudinal proton 
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relaxation time T1 of the water peak was measured of these solutions and remeasured after 
each dilution step. Dilution was carried out by addition of appropriate amounts of dest. H2O 
and the gadolinium(III) concentration was calculated including the additional volume. The 
relaxivity r1 was calculated according to equation 2.4 from chapter 2.3, using the respective 
gadolinium(III) concentration. 
Table 14. Complex concentration dependent relaxivity of GdL1 at 25°C, pH 7.3 and 9.4 T. 
Without calcium(II) With three equivalence of calcium(II) 
[Gd3+] (mM) T1 (ms) r1 (mM-1s-1) [Gd3+] (mM) T1 (ms) r1 (mM-1s-1) 
18.25 8.032 6.802 18.55 9.584 5.605 
14.95 9.786 6.811 14.95 11.476 5.804 
12.25 12.027 6.758 12.20 13.656 5.972 
10.00 14.637 6.795 10.00 16.234 6.123 
7.50 19.327 6.850 7.50 20.998 6.301 
5.00 29.398 6.730 5.00 30.518 6.480 
2.50 57.117 6.857 2.50 56.766 6.900 
Table 15. Complex concentration dependent relaxivity of GdL2 at 25°C, pH 7.3 and 9.4 T. 
Without calcium(II) With three equivalence of calcium(II) 
[Gd3+] (mM) T1 (ms) r1 (mM-1s-1) [Gd3+] (mM) T1 (ms) r1 (mM-1s-1) 
19.58 8.179 6.226 18.13 11.331 4.848 
14.86 10.593 6.328 14.83 13.689 4.901 
12.21 12.657 6.441 12.20 16.081 5.067 
10.01 15.077 6.589 10.00 19.321 5.139 
7.51 19.854 6.658 7.50 24.576 5.377 
5.00 28.995 6.825 5.00 34.639 5.701 
2.50 54.301 7.220 2.50 64.59 6.047 
Table 16. Complex concentration dependent relaxivity of GdL3 at 25°C, pH 7.3 and 9.4 T. 
Without calcium(II) With three equivalence of calcium(II) 
[Gd3+] (mM) T1 (ms) r1 (mM-1s-1) [Gd3+] (mM) T1 (ms) r1 (mM-1s-1) 
18.54 12.987 4.133 19.88 11.61 4.314 
15.00 15.279 4.339 14.70 15.803 4.280 
12.19 17.258 4.723 12.21 18.381 4.426 
10.00 19.887 4.992 10.01 21.767 4.553 
7.50 24.632 5.364 7.51 29.988 4.392 
5.00 33.217 5.948 5.00 41.944 4.695 
2.50 58.844 6.651 2.50 83.545 4.641 
Table 17. Complex concentration dependent relaxivity of GdL4 at 25°C, pH 7.3 and 9.4 T. 
Without calcium(II) With three equivalence of calcium(II) 
[Gd3+] (mM) T1 (ms) r1 (mM-1s-1) [Gd3+] (mM) T1 (ms) r1 (mM-1s-1) 
17.19 11.891 4.871 17.16 14.659 3.954 
14.98 13.615 4.879 14.77 16.911 3.979 
12.22 16.374 4.968 12.17 20.891 3.903 
9.98 19.375 5.135 9.98 24.796 4.004 
7.50 25.185 5.245 7.50 34.485 3.818 
5.00 35.635 5.539 5.00 50.853 3.860 
2.50 66.662 5.854 2.50 100.918 3.817 
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5.1.4 PGSE Diffusion 1H NMR Spectroscopy 
Appropriate amounts of YL1 and YL4 were dissolved in D2O and in a solution of three 
equivalents of CaCl2, respectively. The samples were diluted stepwise while keeping the pD 
at 7.2-7.4. The measurements were performed by using the standard stimulated echo pulse 
sequence on a Bruker Avance II+ 500 MHz spectrometer equipped with a gradient unit and a 
multinuclear inverse probe with a Z-gradient coil. The temperature was 298 K and the sample 
was not spun. The shape of the gradient pulses was rectangular, their duration (t) was 
between 1.4 and 1.8 ms, depending on the sample and their strength (G) was varied during the 
experiments. The delay between the midpoints of the gradients (∆) was set to 200 ms. The 
spectra were recorded using 32 – 1K scans, 32K points, a relaxation delay of 1.4 – 3.8 s, a 
spectral width of 7500 Hz and were processed with a line broadening of 2. The intensity of 
the 1H resonances of the alkyl groups of the side chain was determined in all spectra. The 
plots of ln(I/I0) versus G2 were fitted using a linear regression algorithm to obtain the D 
values according to equation 5.1, where I = intensity of the observed spin-echo, I0 = intensity 
of the spin-echo without gradients,  = magnetogyric ratio, t = length of the gradient pulse, D 
= diffusion coefficient, ∆ = delay between the midpoints of the gradients and G = gradient 
strength. 
ln ww = −	t W 0∆ − t31   (5.1) 
5.1.5 31P{1H} NMR Spectroscopy 
Appropriate amounts of EuL1 and EuL4 were dissolved in D2O and the pD was adjusted to 
about 7.4. The 31P{1H} NMR spectra were recorded on a Bruker DRX 400 MHz and a Bruker 
Avance II+ 500 MHz spectrometer. The temperature was measured using an external 
thermocouple (PT 100). The signals were externally referenced to 1 % phosphoric acid in 
D2O via deuterium lock. Calcium(II) was added via an highly concentrated solution of 
CaCl2·6H2O in D2O while maintaining the pD at about 7.4. 
5.1.6 Luminescence Spectroscopy 
Solutions of EuL1-EuL4 were prepared in H2O (pH 7.3, HEPES) at various complex 
concentrations (5-50 mM) in the presence and absence of three equivalents of CaCl2. The 
luminescence steady-state emission spectra were performed at 25°C on a QuantaMasterTM 3 
PH fluorescence spectrometer from Photon Technology International, Inc., USA. 
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5.1.7 Luminescence Lifetime Measurements 
The decay experiments were performed on H2O and D2O (25°C, pH 7.3, HEPES) solutions of 
EuL1-EuL4 at concentrations ranging from 5 to 50 mM. As for the steady state spectra, a 
QuantaMasterTM 3 PH fluorescence spectrometer from Photon Technology International, Inc., 
USA was used. The europium(III) ion was directly excited at 395 nm and the emission 
intensity at 615 nm was recorded with 10 µs resolution. Excitation and emission slits were set 
to 15 and 5 nm bandpass respectively. Datasets are average of 25 scans and each reported 
value is the mean of three independent measurements. Obtained curves are fitted to the first 
order exponential decay with r2 = 0.99. The q values were calculated using equation 3.3 
described in chapter 3.2.6. 
Table 18. Emission lifetimes and estimated q values of EuL1 at 25°C and pH 7.3. 
Without calcium(II) With three equivalence of calcium(II) 
[EuL1] (mM) τH2O (ms) τD2O (ms) q [EuL1] (mM) τH2O (ms) τD2O (ms) q 
50 0.43 1.34 1.6 50 0.73 1.59 0.6 
25 0.43 1.36 1.6 25 0.65 1.71 0.8 
10 0.43 1.38 1.6 10 0.58 1.76 1.1 
5 0.42 1.37 1.7 5 0.54 1.75 1.2 
Table 19. Emission lifetimes and estimated q values of EuL2 at 25°C and pH 7.3. 
Without calcium(II) With three equivalence of calcium(II) 
[EuL2] (mM) τH2O (ms) τD2O (ms) q [EuL2] (mM) τH2O (ms) τD2O (ms) q 
50 0.66 1.45 0.7 50 0.77 1.45 0.4 
25 0.63 1.46 0.8 25 0.75 1.57 0.5 
10 0.60 1.48 0.9 10 0.72 1.64 0.6 
5 0.58 1.55 1.0 5 0.68 1.65 0.7 
Table 20. Emission lifetimes and estimated q values of EuL3 at 25°C and pH 7.3. 
Without calcium(II) With three equivalence of calcium(II) 
[EuL3] (mM) τH2O (ms) τD2O (ms) q [EuL3] (mM) τH2O (ms) τD2O (ms) q 
50 0.67 1.50 0.7 50 0.86 1.45 0.3 
25 0.62 1.60 0.9 25 0.86 1.48 0.3 
10 0.55 1.64 1.1 10 0.85 1.53 0.3 
5 0.50 1.63 1.4 5 0.84 1.60 0.4 
Table 21. Emission lifetimes and estimated q values of EuL4 at 25°C and pH 7.3. 
Without calcium(II) With three equivalence of calcium(II) 
[EuL4] (mM) τH2O (ms) τD2O (ms) q [EuL4] (mM) τH2O (ms) τD2O (ms) q 
50 0.69 1.52 0.6 50 0.88 1.57 0.3 
25 0.67 1.59 0.7 25 0.88 1.61 0.3 
10 0.66 1.65 0.8 10 0.88 1.70 0.4 
5 0.65 1.66 0.8 5 0.89 1.75 0.4 
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5.1.8 17O NMR Spectroscopy 
The 17O NMR experiments were performed on a Bruker Avance 500 spectrometer (11.75 T, 
67.8 MHz). The longitudinal (1/T1) and transverse (1/T2) 17O NMR relaxation rates were 
measured for complexes GdL1-GdL4 in the temperature range of 275–350 K. The 
concentration of the samples was about 50 mM and the pH of the solutions was adjusted to 6 
using KOH/HCl. To improve the sensitivity in 17O NMR, 17O-enriched water (10 % H217O, 
CortecNet) was added to the solutions to yield about 1 % 17O enrichment. The exact 
gadolinium(III) concentration was determined using the BMS method described in chapter 
5.1.2. The samples were sealed in glass spheres in order to eliminate the influence of the bulk 
magnetic susceptibility.152 The exact temperature was calculated according to previous 
calibration with ethylene glycol and methanol.153 The 1/T1-data were obtained by the 
inversion recovery method, while the 1/T2-data were measured by the Carr–Purcell–
Meiboom–Gill spin-echo technique. Acidified water (HClO4, pH 3.3) was used as external 
reference. The least-squares fit of the 17O NMR data was performed by using Micromath 
Scientist version 2.0 (Salt Lake City, UT, USA). The reported errors correspond to one 
standard deviation obtained by the statistical analysis. 
The least-squares fits were carried out using the following equations based on the Solomon-
Bloembergen-Morgan theory (cf. chapter 2.3). 
As outlined in chapter 3.2.7, the reduced relaxation rates, 1/T1r, 1/T2r, can be calculated from 
the measured 17O NMR relaxation rates of the paramagnetic solutions, 1/T1, 1/T2, and of the 
reference, 1/T1A, 1/T2A, by using equations 5.2 and 5.3, where Pm is the molar fraction of 
bound water, 1/T1m, 1/T2m are the relaxation rates of the bound water and ∆ωm is the chemical 
shift difference between bound and bulk water. 
0 1p1 = 123 0 1 − 1U1 = 13 + 43 (5.2) 
0 1 p1 = 123 0 1 − 1 U1 = 143  3
o + 43o 3o + RH3 	43o +  3o + RH3  (5.3) 
∆ωm is determined by the hyperfine interaction between the gadolinium(III) electron spin and 
the 17O nucleus. Therefore, the hyperfine or scalar coupling constant A/ħ can be directly 
obtained from the chemical shifts measured for the paramagnetic sample, ωp, referred to the 
chemical shift of the reference, ωA, through equations 5.4 and 5.5. 
∆Hp = 123 rH% − HUs = RH3	1 + 43 3o + 43 RH3  (5.4) 
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∆H3 = ;<=A	A + 13h= Jℏ (5.5) 
where ∆ωr is the reduced 17O chemical shift, B represents the magnetic field, S is the electron 
spin and g is the isotropic Landé g factor. 
The 17O longitudinal relaxation rate of the coordinated water molecules, 1/T1m, is governed by 
quadrupolar and dipolar mechanisms, 1/T1q and 1/T1d, respectively, with the quadrupolar term 
being the major contribution. The terms are given in equation 5.6-5.9, where γS is the electron 
and γI is the nuclear gyromagnetic ratio (γS  = 1.76×1011 rad s-1 T -1, γI=-3.626×107 rad s-1 T-1), 
r is the effective distance between the electron charge and the 17O nucleus, I is the nuclear 
spin (5/2 for 17O), χ2 is the quadrupolar coupling constant and η is an asymmetry parameter: 
13 = 1x + 1$  (5.6) 
1x = 3D
 10 + 2w + 3w 	2w − 1, y 	1 + j 3 4L/ (5.7) 
1$ = 115 B<4DE
 +ℏ - . &>$/@ , A	A + 1 +64$ + 14 4$1 + H. 4$  , (5.8) 
where:  
14$, = 14L/ + 1, K + 143 (5.9) 
The rotational correlation time of the Gd-Owater vector, τRO, is assumed to have a simple 
exponential temperature dependence with the activation energy ER as follows: 
4L/ = 4L/ z{Z
| }~LY 01 − 1298.151 (5.10) 
Note that due to the internal motion of the coordinated water molecules around the Gd-O axis, 
the rotational correlation time of the Gd-Hwater vector, τRΗ298, is usually lower than τRΟ298 
(τRH/τRO = 0.65±0.2).146, 147 
Since the oxygen is directly coordinated to gadolinium(III), in the 17O transverse relaxation 
rate of coordinated water molecules, 1/T2m, the scalar contribution, 1/T2sc, is the most 
important (equation 5.11). In this equation, 1/τs1 is the sum of the exchange rate constant and 
the electron spin relaxation rate (equation 5.12).  
1 3 ≅ 1 #G = A	A + 13 0Jℏ1
 4# (5.11) 
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14# = 143 + 1K (5.12) 
The inverse binding time (or exchange rate kex) of water molecules in the inner sphere is 
assumed to obey the Eyring equation (equation 5.13), where ∆S‡ and ∆H‡ are the entropy and 
enthalpy of activation for the exchange, and kex298 is the exchange rate at 298.15 K. 
143 = hK = h=ℎ Z
| RA
Y − ReY  = hK z{298.15 Z
| ReY 0 1298.15 − 11 (5.13) 
The electron spin relaxation rate, 1/T1e, has been fitted to a simple exponential equation: 
1K = 1K z{ Z
| }~Y 01 − 1298.151 (5.14) 
Table 22. Variable temperature reduced longitudinal and transverse 17O relaxation rates and 
chemical shifts of a GdL1 solution with cGd = 0.0509694 mol/L, B =11.75 T and using q = 1. 
T (K) T1A (ms) T2A (ms) ωA (ppm) T1 (ms) T2 (ms) ω (ppm) ln(1/T1r) ln(1/T2r) ∆ωr (Hz) 
278.1 3.990 3.972 1.566 3.080 0.904 -0.532 11.30 13.74 -9.74E+05 
283.1 4.652 4.632 1.389 3.537 1.088 -0.849 11.21 13.55 -1.04E+06 
293.1 6.092 6.052 0.761 4.754 1.612 -1.435 10.83 13.11 -1.02E+06 
300.8 7.663 7.464 0.45 5.804 2.172 -1.624 10.73 12.78 -9.63E+05 
308.1 9.436 9.142 0.139 7.032 2.804 -1.721 10.58 12.50 -8.64E+05 
318.2 11.633 11.408 -0.312 8.699 3.830 -1.971 10.36 12.15 -7.70E+05 
328.1 13.829 13.656 -0.935 10.701 5.112 -2.539 10.04 11.80 -7.45E+05 
338.2 16.508 16.424 -1.203 12.767 6.756 -2.612 9.87 11.46 -6.54E+05 
348.1 19.548 19.242 -1.697 14.906 8.402 -2.905 9.76 11.20 -5.61E+05 
Table 23. Variable temperature reduced longitudinal and transverse 17O relaxation rates and 
chemical shifts of a GdL2 solution with cGd = 0.0540287 mol/L, B =11.75 T and using q = 1. 
T (K) T1A (ms) T2A (ms) ωA (ppm) T1 (ms) T2 (ms) ω (ppm) ln(1/T1r) ln(1/T2r) ∆ωr (Hz) 
278.1 3.924 3.870 2.212 2.819 1.144 0.669 11.44 13.26 -6.14E+05 
288.1 5.257 5.162 1.791 3.769 1.342 0.157 11.16 13.15 -6.51E+05 
300.8 7.673 7.462 0.871 5.151 1.808 -0.88 11.00 12.88 -6.97E+05 
308.1 9.307 8.674 0.626 6.227 2.186 -1.045 10.81 12.68 -6.65E+05 
318.2 11.299 11.070 0.34 7.549 2.736 -1.299 10.62 12.46 -6.53E+05 
328.1 13.833 13.686 -0.484 9.419 3.588 -2.002 10.36 12.17 -6.05E+05 
338.2 16.496 16.424 -0.618 11.309 4.568 -2.039 10.17 11.90 -5.66E+05 
348.1 19.418 18.784 -1.1 13.747 5.762 -2.069 9.90 11.63 -3.86E+05 
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Table 24. Variable temperature reduced longitudinal and transverse 17O relaxation rates and 
chemical shifts of a GdL3 solution with cGd = 0.0632339 mol/L, B =11.75 T and using q = 1. 
T (K) T1A (ms) T2A (ms) ωA (ppm) T1 (ms) T2 (ms) ω (ppm) ln(1/T1r) ln(1/T2r) ∆ωr (Hz) 
278.1 3.924 3.870 2.212 2.753 1.134 1.255 11.20 12.95 -2.76E+05 
288.1 5.257 5.162 1.791 3.753 1.522 0.858 10.85 12.65 -2.69E+05 
300.8 7.673 7.462 0.871 4.814 1.758 -0.307 10.87 12.59 -3.39E+05 
308.1 9.307 8.674 0.626 5.740 2.139 -0.502 10.72 12.38 -3.25E+05 
318.2 11.299 11.070 0.34 7.184 2.728 -0.618 10.44 12.14 -2.76E+05 
328.1 13.833 13.686 -0.484 8.872 3.402 -1.472 10.22 11.91 -2.84E+05 
338.2 16.496 16.424 -0.618 10.985 4.238 -1.295 9.93 11.68 -1.95E+05 
348.1 19.418 18.784 -1.1 13.202 4.582 -1.63 9.70 11.62 -1.53E+05 
Table 25. Variable temperature reduced longitudinal and transverse 17O relaxation rates and 
chemical shifts of a GdL4 solution with cGd = 0.0540287 mol/L, B =11.75 T and using q = 1. 
T (K) T1A (ms) T2A (ms) ωA (ppm) T1 (ms) T2 (ms) ω (ppm) ln(1/T1r) ln(1/T2r) ∆ωr (Hz) 
278.1 3.990 3.972 1.566 3.182 1.772 1.121 11.09 12.68 -1.95E+05 
283.1 4.652 4.632 1.389 3.699 2.004 0.901 10.95 12.58 -2.14E+05 
293.1 6.092 6.052 0.761 4.882 2.502 0.236 10.64 12.39 -2.30E+05 
300.8 7.663 7.464 0.45 5.926 2.974 -0.124 10.58 12.25 -2.51E+05 
308.1 9.436 9.142 0.139 7.096 3.560 -0.233 10.49 12.08 -1.63E+05 
318.2 11.633 11.408 -0.312 8.64 4.110 -0.66 10.33 11.98 -1.52E+05 
328.1 13.829 13.656 -0.935 10.226 4.466 -1.362 10.17 11.95 -1.87E+05 
338.2 16.508 16.424 -1.203 12.217 4.656 -1.624 9.99 11.97 -1.84E+05 
348.1 19.548 19.242 -1.697 14.164 4.564 -2.069 9.90 12.05 -1.63E+05 
Table 26. Variable temperature reduced longitudinal and transverse 17O relaxation rates and 
chemical shifts of a GdL1 solution in the presence of three equivalents of calcium(II) with 
cGd = 0.0540287 mol/L, B =11.75 T and using q = 1. 
T (K) T1A (ms) T2A (ms) ωA (ppm) T1 (ms) T2 (ms) ω (ppm) ln(1/T1r) ln(1/T2r) ∆ωr (Hz) 
278.1 2.750 1.154 1.328 3.924 3.870 2.212 11.68 13.40 -4.11E+05 
300.8 5.098 2.328 0.181 7.673 7.462 0.871 11.18 12.68 -3.20E+05 
318.2 6.589 3.102 -0.16 11.299 11.070 0.34 11.14 12.44 -2.32E+05 
338.2 9.398 4.660 -0.831 16.496 16.424 -0.618 10.82 12.03 -9.89E+04 
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5.2 Silsesquioxane-based MRI Contrast Agents 
5.2.1 Materials and General Remarks 
(3-Aminopropyl)-triethoxysilane (99%), boron trifluoride ethyl etherate, lanthanum 
trichloride heptahydrate (99.999 %), yttrium trichloride hexahydrate (99.99 %), xylenol 
orange and methyl 4-(cyanomethyl)-benzoate (96 %) were purchased from Aldrich. 
Vinyltrichlorosilane (techn, 97%), azobisisobutyronitrile (AIBN), benzyl bromoacetate 
(purum, 97%), dimethyl sulfoxide (DMSO), purris. absolut, over molecular sieves), Amberlite 
IR-120, tert-butyltrichloroacetimidate (TBTA) were obtained from Fluka. Mercaptopropionic 
acid, palladium on charcoal (Pd/C, 10% Pd), O-(benzotriazol-1-yl)-N,N,N’,N’-
tetramethyluronium tetrafluoroborate (TBTU, ≥ 98 %), 1-hydroybenzotrialzol hydrate 
(HOBt), diisopropylethylamine (DIPEA), trifluoroacetic acid (TFA), L-glutamic acid, 
dimethylacetamide (DMA), N-bromosuccinimide (NBS), carbon tetrachloride, dimethyl 
malonate, tetra-n-butylammonium hydroxide (20 % in water) were purchased from Merck. 
Acetonitrile (extra dry, over molecular sieves, water <50 ppm) and tert-butyl bromoacetate 
(99%) were bought from Acros Organics. Amberlite XAD 1600 was obtained from Rohm and 
Haas. 1,4,7,10-tetraazacyclododecane (cyclen, 98%) was purchased from CheMatech. 
Gadolinium trichloride hydrate (99.99 %) was obtained from Chempur. Dihydrogen (purity 
5.0) and argon (purity 5.0) was bought from Air Liquide. DO3A(tBu)3 and DO3A-hexylamine 
were kindly provided by Dr. I. Mamedov, Max-Planck-Institute for Biological Cybernetics, 
Tübingen. All reagents not mentioned were obtained from the chemicals store at the 
University of Tübingen. 
The lanthanide(III) chloride stock solutions were prepared by dissolving an accurately 
weighted amount of the chloride salt in the appropriate volume of distilled water. The exact 
concentration was determined via complexometric titration with the disodium salt of EDTA in 
an acetic acid / sodium acetate buffer (pH 5.8) using xylenol orange as indicator. 
Reactions under inert conditions were performed in an argon atomosphere applying standard 
Schlenk techniques. Column chromatography was performed using silicagel 60. The absence 
of non-coordinated metal ions in the solutions of GG, GB, Gd-DOTAGA (63) and Gd-
DOTABA (78), used in the analytical studies, was confirmed by the xylenol test.136 
5.2.2 Diafiltration 
Diafiltration was carried out on a Pall Minimate™ Tangential Flow Filtration System using a 
Pall Minimate™ TFF Capsule with an Omega™ 3K PES ultrafiltration membrane. 
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5.2.3 pH-metric Measurements 
pH and pD150 values of aqueous solutions were measured using a Schott handylab pH12 pH-
meter equipped with a Mettler-Toledo Inlab Micro glass electrode. 
5.2.4 Mass Spectrometry 
HR mass spectra were recorded on a Bruker Daltonics 4.7 T APEX II FT-ICR instrument 
equipped with an ESI source. In the positive mode appropriate polyethylene glycol molecules 
were used for internal calibration and perfluoroheptanoic acid, perfluorooctanoic acid, 
perfluorodecanoic acid and perfluorododecanoic acid were used in the negative mode. 
ESI mass spectra were recorded on a Bruker Daltonics esquire3000plus mass spectrometer 
(quadrupolar ion-trap) with an ESI interface.  
5.2.5 Elemental Analysis 
Elemental analysis was performed on an Elementar vario MICRO cube elemental analyser. 
5.2.6 Solid-State NMR Spectroscopy 
The solid state 13C and 29Si CP/MAS NMR spectra were recorded on a Bruker DSX 200 MHz 
spectrometer in a 4 mm ZrO2 rotor and on a Bruker ASX 300 MHz spectrometer in a 7 mm 
ZrO2 rotor, respectively. Magic angle spinning was performed at 1 KHz for the 29Si NMR 
spectrum and at 10 KHz in the case of the 13C NMR spectrum. The 13C NMR spectrum was 
recorded at 50.33 MHz and the 29Si NMR spectrum was recorded at 59.62 ppm 
5.2.7 Solution NMR Spectroscopy 
5.2.7.1 NMR spectroscopy for structural analysis 
1H and 13C{1H} NMR spectra were recorded on a Bruker Avance II 400 MHz or a Bruker 
Avance II+ 500 MHz spectrometer at room temperature, unless specified otherwise. 1H and 
13C resonances were assigned using standard 2D techniques (1H-1H COSY, 1H-13C HSQC, 
1H-13C HMBC).29Si{1H} NMR spectra were recorded on a Bruker Avance II+ 500 MHz 
spectrometer at room temperature via 2D 1H-29Si HSQC experiments or using a DEPT45 
sequence. 139La NMR spectra were recorded on a Bruker Avance II+ 500 MHz spectrometer 
operating at 65°C. The NMR spectra were recorded at the following frequencies: 1H NMR: 
400.13 and 500.13 MHz; 13C NMR: 100.61 and 125.76 MHz; 29Si NMR: 99.36 MHz; 139La 
NMR: 77.66 MHz. Except for 1H NMR spectra measured in D2O, which were referenced to 
the residual HDO peak (δ = 4.79), all 1H, 13C{1H} and 29Si{1H} NMR spectra were externally 
referenced to 1% TMS in CDCl3 via deuterium lock.154 139La NMR spectra were externally 
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referenced to 10 mM LaCl3 in D2O via deuterium lock. 
5.2.7.2 Bulk magnetic susceptibility shift measurements 
The gadolinium(III) concentration in water can be determined by measuring the bulk 
magnetic susceptibility (BMS) shift of the solution, independent of the state of coordination 
of the gadolinium(III).151 For the BMS measurements a small amount of tert-butanol (5 µL) 
was added to the respective solution and the chemical shift of its 1H NMR resonance was 
measured relative to a reference (internal capillary with tert-butanol/H2O). The concentration 
was then calculated according to equation 5.15: 
[Gd]`g  = 02.847.941
 3∆4D  (5.15) 
where ∆χ = BMS chemical shift in ppm and T = absolute temperature. 
5.2.7.3 PGSE diffusion 1H NMR spectroscopy 
1H PGSE diffusion NMR measurements were performed by using the standard Bruker 
stimulated echo pulse sequence on a Bruker Avance II+ 500 MHz spectrometer equipped with 
a gradient unit and a multinuclear inverse probe with a Z-gradient coil. Solutions of the 
yttrium(III) complexes of GG, GB, Y-DOTAGA (63) and Y-DOTABA (78) were prepared in 
D2O having a pD of 7.0 ± 0.1. The concentrations were estimated from the BMS 
measurements of the analogous gadolinium(III) complexes (2-3 mM of the Gadoxanes and 
15-20 mM for the monomeric complexes). The temperature during the measurements was 
298 K and the sample was not spun. Rectangular gradient pulses with durations (t) of 1.5 and 
1.6 ms for the monomers and 2.4 and 3.0 ms for the Gadoxanes were applied. Their strength 
(G) was varied during the experiments. The delay between the midpoints of the gradients (∆) 
was set to 150 ms for the monomers and 200 ms for the Gadoxanes. ∆ was also kept at 
200 ms during the degradation of GG. The spectra were recorded using 32 to 256 scans, 32K 
points, a relaxation delay of 1.6-3.5 s, a spectral width of 7500 Hz and were processed with a 
line broadening of 2 Hz. The intensities of the 1H resonance of the following moieties were 
determined in each spectrum: CHCH2 for Y-DOTAGA (63), Ar-2-H and Ar-6-H for Y-
DOTABA (78), CH2Si for the GB as well as for GG and its fragments. The plots of ln(I/I0) 
versus G2 were fitted using a linear regression algorithm to obtain the D values according to 
equation 5.16: 
ln ww = −	t W 0∆ − t31   (5.16) 
where I = intensity of the observed spin-echo, I0 = intensity of the spin-echo without 
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gradients,  = magnetogyric ratio, t = length of the gradient pulse, D = diffusion coefficient, 
∆ = delay between the midpoints of the gradients and G = gradient strength. 
5.2.7.4 Relaxivity measurements 
Relaxivity measurements during the degradation of GG were performed at room temperature 
(~21 ˚C) in a 3 T (123 MHz) human MR scanner (MAGNETOM Tim Trio, Siemens 
Healthcare, Germany), using a 12-channel RF Head coil and slice selective measurements 
from a slice with a thickness of 1 mm positioned through the samples. The samples (0.8 ml) 
were freshly prepared for each time point (0-200 h) by making dilutions of GG at 0, 12.5, 25, 
37.5, and 50 µM gadolinium(III) (1.56, 3.12, 4.69 und 6.25 µM GG) in culture medium 
(Dulbecco´s modified Earle´s medium, ± FCS, ± HEPES) in tubes and incubating them at 
37°C and 10% CO2 with or without gas exchange. The samples were then split into two 
0.65 mL tubes prior to the MR relaxivity measurements. The pH of the solutions was 
estimated after the MR measurements. Solutions containing HEPES buffer had a pH in the 
range of 7.4-7.6 whereas the samples without HEPES and no gas exchange during the 
incubation period had pH values between 8.1 and 8.6. T1 was measured using an inversion-
recovery sequence, with an adiabatic inversion pulse followed by a turbo-spin-echo readout. 
Between 10 and 15 images were taken, with the time between inversion and readout varying 
from 23 to 3000 ms. With a repetition time of 10 s, 15 echoes were acquired per scan and 
averaged six times. All experiments scanned 2562 voxels in a field-of-view of 110 mm in both 
directions resulting in a voxel volume of 0.43 × 0.43 × 1 mm3. Data analysis was performed 
by fitting to relaxation curves with self-written routines under MATLAB 7.1 R14 (The 
Mathworks Inc., United States). The series of T1 relaxation data were fitted according to 
equation 5.17 with varying t = TI: 
A =  A +1 − Zo , + A +Zo , (5.17) 
Nonlinear least-squares fitting of three parameters S0, S(TI = 0), and T1 was done for manually 
selected regions-of-interest with the Trust-Region Reflective Newton algorithm implemented 
in MATLAB. The quality of the fit was controlled by visual inspection and by calculating the 
mean errors and residuals. The obtained relaxation times T1obs were used to evaluate the 
relaxivity r1 according to equation 2.4 in chapter 2.3. The r1 values were plotted vs. the 
incubation time and fitted by a first order exponential decay function to get the degradation 
kinetics of Gadoxane. In case of the incubation at higher pH a fit assuming a second order 
decay gives a better result indicating to a very fast initial degradation of the silsequioxane 
core at pH > 8. 
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The degradation of the silsesquioxane core of GB was studied by measuring the longitudinal 
relaxation rates (1/T1obs) of water protons of an aqueous solution of GB (c(Gd3+) = 1.99 mM, 
pH 7.4 (HEPES buffer)) on a Stelar SMARtracer Fast Field Cycling NMR relaxometer at 
10 MHz and 37°C after different periods of time. During the first 36 h the sample was kept in 
the relaxometer, then the sample was kept in a water bath (37°C) between the measurements. 
The longitudinal relaxation rates were measured using an inversion-recovery sequence. The r1 
values were calculated from the obtained 1/T1obs values according to equation 2.4 in chapter 
2.3. Then the r1 values were plotted versus the time and fitted by a first order exponential 
decay function using ORIGIN™ (Microcal, USA). The reported errors correspond to one 
standard deviation obtained by the statistical analysis. 
Table 27. Longitudinal relaxivity r1 of Gadoxane B (GB) under physiological conditions as a 
function of the time (37°C, pH 7.4, 10 MHz). 
Time (h) T1 (s) T1 (s) T1 (s) Mean T1 (s) r1 (mM-1s-1) 
0 0.03479 0.03492 0.03503 0.03491 14.14 
1 0.03475 0.03488 0.03482 0.03481 14.18 
2 0.03503 0.03466 0.03453 0.03474 14.21 
3 0.03517 0.03513 0.03503 0.03511 14.06 
4 0.03596 0.03623 0.03591 0.03603 13.70 
5 0.03693 0.03707 0.03698 0.03699 13.34 
6 0.03759 0.03788 0.03779 0.03775 13.06 
7 0.03897 0.03922 0.03926 0.03915 12.59 
8 0.04050 0.04013 0.04055 0.04039 12.20 
9 0.04100 0.04161 0.04116 0.04126 11.94 
10 0.04211 0.04236 0.04226 0.04224 11.66 
12 0.04454 0.04501 0.04485 0.04480 10.98 
14 0.04655 0.04619 0.04705 0.04660 10.55 
24 0.05535 0.05555 0.05590 0.05560 8.81 
27 0.05831 0.05825 0.05861 0.05839 8.38 
29 0.05943 0.05962 0.05987 0.05964 8.20 
32 0.06079 0.06118 0.06101 0.06099 8.02 
35 0.06231 0.06265 0.06260 0.06252 7.82 
37 0.06345 0.06364 0.06401 0.06370 7.67 
48 0.06723 0.06724 0.06729 0.06725 7.25 
57 0.06775 0.06792 0.06764 0.06777 7.20 
72 0.06960 0.06944 0.06984 0.06963 7.00 
96 0.07136 0.07167 0.07192 0.07165 6.80 
120 0.07205 0.07260 0.07198 0.07221 6.74 
 
EXPERIMENTAL PART  113 
Table 28. Longitudinal relaxivity r1 (3 T, r.t.) during the degradation of GG under 
physiological conditions (cell culture media, 20 mM HEPES, pH 7.4-7.6) with and without 
fetal calf serum (FCS). 
 r1 (mM-1s-1) 
Time (h) With serum Without serum Mean value 
0 10.62 10.59 10.60 
0.5 10.15 9.79 9.97 
1 10.54 9.88 10.21 
2 10.74 - 10.74 
4 10.49 9.80 10.15 
6 9.29 10.29 9.79 
19 8.23 8.34 8.28 
45 7.52 7.51 7.52 
200 6.90 6.54 6.72 
 
5.2.7.5 Variable temperature 17O NMR and 1H NMRD measurements 
The transverse and longitudinal 17O relaxation rates (1/T1,2) and the chemical shifts were 
measured in the aqueous solutions of the gadolinium(III) complexes in the temperature range 
275–361 K for the monomeric complexes (63, 78) and 275–320 K for the Gadoxanes, on a 
Bruker Avance II 300 MHz (7.05 T, 40.69 MHz) spectrometer with a 10 mm broad band 
probe. The gadolinium(III) concentration of the samples was between 9.9 and 16.6 mM and 
the pH of the solutions was 6.7 (HEPES buffer). To improve the sensitivity in 17O NMR, 17O-
enriched water (10 % H217O, CortecNet) was added to the solutions to yield about 3 % 17O 
enrichment. The exact gadolinium(III) concentration was determined using the BMS method 
(chapter 5.2.7.2). The temperature was determined by measuring the chemical shift of neat 
ethylene glycol.155 An acidified water solution was used as reference (HClO4, pH 3.0). The 
samples were sealed in glass spheres fitted into 10 mm NMR tubes, to eliminate susceptibility 
corrections to the chemical shifts.152 Longitudinal 17O relaxation times (T1) were measured by 
the inversion-recovery pulse sequence, and the transverse relaxation times (T2) were obtained 
by the Carr-Purcell-Meiboom-Gill spin-echo technique. 
Proton NMRD profiles were recorded on a Stelar SMARtracer Fast Field Cycling NMR 
relaxometer (0.01–10 MHz) and a Bruker WP80 NMR electromagnet (20, 40, 60 and 
80 MHz) adapted to variable field measurements and controlled by the SMARtracer PC-NMR 
console. The temperature was controlled by a VTC91 temperature control unit and maintained 
by a gas flow. The temperature was determined according to previous calibration with a Pt 
resistance temperature probe. The relaxivities at 250, 400 and 500 MHz was measured on a 
Bruker DRX 250 MHz, a Bruker Avance II 400 MHz and a Bruker Avance II+ 500 MHz 
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spectrometer using an inversion-recovery sequence. The temperature was determined with 
ethylene glycol.155 The least-squares fits of the 17O NMR and 1H NMRD data were performed 
by using Micromath Scientist version 2.0 (Salt Lake City, UT, USA). The reported errors 
correspond to one standard deviation obtained by the statistical analysis. 
The equations involved in the analysis of the 17O NMR measurements were already reported 
in chapter 5.1.8. For the analysis of the 1H NMRD profiles the equations of the modified 
Solomon-Bloembergen-Morgan theory as given in chapter 2.3 were used. The electronic 
correlation time for the modulation of the zero-field-splitting interaction, τν, in equations 
2.13-2.15 and the sum of the diffusion coefficients DI and DS of water and the gadolinium(III) 
complex, DIS, were thereby assumed to have simple exponential dependence versus 1/T 
(equations 5.18 and 5.19). 
4 = 4 z{Z
| }~Y 01 − 1298.151 (5.18) 
W-. = W-. z{Z
| }~-.Y 0 1298.15 − 11 (5.19) 
where Eν and EIS are their respective activation energies. 
For the two Gadoxanes, the Lipari-Szabo approach was applied. In this model two statistically 
independent rotational motions are distinguished: A rapid local motion of the Gd-Hwater vector 
with a correlation time τlH and a slower global motion of the entire molecule with a correlation 
time τgR. Supposing the global molecular reorientation is isotropic, equation 2.9 in chapter 2.3 
is written as the following: 
188 = 215 +-
 ; <= &>$?@ , A	A + 1 B<4DE
 	7	H.; 49  + 3	H-; 49 (5.20) 
where 
	H.; 49  = A 4G 1 + H. 4G  + 	1 − A
 4G 1 + H. 4G   (5.21) 
	H-; 49 = A 4G 1 + H- 4G + 	1 − A
 4G 1 + H- 4G  (5.22) 
with 
14G,  = 14L + 1, K + 143 (5.23) 
14G,  = 14? + 1, K + 143 (2.24) 
EXPERIMENTAL PART  115 
The general order parameter S2 describes the degree of spatial restriction of the local motion. 
If the local motion is isotropic, S2 = 0; if the rotational dynamics is only governed by the 
global motion, S2 = 1.  
Table 29. Variable temperature reduced longitudinal and transverse 17O relaxation rates and 
chemical shifts of a Gd-DOTAGA (63) solution with cGd = 0.01655 mol/L, B =7.05 T and 
using q = 1. 
T (K) T1A (ms) T2A (ms) ωA (ppm) T1 (ms) T2 (ms) ω (ppm) ln(1/T1r) ln(1/T2r) ∆ωr (Hz) 
275.5 3.544 3.522 4.292 3.059 1.944 4.000 11.92 13.56 -2.51E+05 
286.0 5.109 5.092 6.550 4.312 1.736 6.355 11.71 14.06 -1.67E+05 
299.1 7.387 7.416 3.131 6.346 1.578 2.947 11.22 14.33 -1.58E+05 
309.7 9.304 9.426 5.416 8.030 1.692 4.931 10.96 14.30 -4.16E+05 
328.1 13.969 13.94 1.757 12.263 2.874 1.215 10.42 13.74 -4.65E+05 
342.8 17.858 17.318 3.894 15.465 4.486 3.428 10.28 13.23 -4.00E+05 
360.8 23.207 22.816 0.333 20.089 8.078 -0.082 10.02 12.50 -3.56E+05 
 
Table 30. Variable temperature reduced longitudinal and transverse 17O relaxation rates and 
chemical shifts of a Gd-DOTABA (78) solution with cGd = 0.01248 mol/L, B =7.05 T and 
using q = 1. 
T (K) T1A (ms) T2A (ms) ωA (ppm) T1 (ms) T2 (ms) ω (ppm) ln(1/T1r) ln(1/T2r) ∆ωr (Hz) 
275.8 3.457 3.500 7.064 3.205 2.154 6.883 11.52 13.59 -2.06E+05 
286.0 5.127 5.032 6.632 4.567 2.228 6.341 11.58 13.92 -3.31E+05 
297.5 7.325 7.522 6.056 6.513 2.060 5.694 11.23 14.27 -4.12E+05 
309.7 9.515 9.548 5.475 8.320 2.116 5.164 11.12 14.31 -3.54E+05 
319.4 11.654 11.592 5.008 10.338 2.474 4.624 10.79 14.16 -4.37E+05 
342.8 17.485 17.452 4.035 15.772 4.768 3.593 10.23 13.43 -5.03E+05 
360.8 23.495 22.996 3.088 21.443 8.806 2.665 9.81 12.65 -4.81E+05 
 
Table 31. Variable temperature reduced longitudinal and transverse 17O relaxation rates and 
chemical shifts of a Gadoxane G (GG) solution with cGd = 0.01285 mol/L, B =7.05 T and 
using q = 1. 
T (K) T1A (ms) T2A (ms) ωA (ppm) T1 (ms) T2 (ms) ω (ppm) ln(1/T1r) ln(1/T2r) ∆ωr (Hz) 
275.8 3.575 3.592 6.855 3.091 2.196 6.800 12.15 13.55 -6.08E+04 
286.0 5.109 5.092 6.550 4.328 2.338 6.406 11.94 13.82 -1.59E+05 
297.5 7.318 7.334 5.895 6.203 2.372 5.629 11.57 14.03 -2.94E+05 
309.7 9.304 9.426 5.416 7.959 2.596 5.074 11.27 14.00 -3.78E+05 
319.4 11.612 11.500 5.009 9.942 3.050 4.628 11.04 13.86 -4.21E+05 
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Table 32. Variable temperature reduced longitudinal and transverse 17O relaxation rates and 
chemical shifts of a Gadoxane B (GB) solution with cGd = 0.00994 mol/L, B =7.05 T and 
using q = 1. 
T (K) T1A (ms) T2A (ms) ωA (ppm) T1 (ms) T2 (ms) ω (ppm) ln(1/T1r) ln(1/T2r) ∆ωr (Hz) 
275.8 3.457 3.500 7.064 2.981 2.344 6.904 12.46 13.58 -2.29E+05 
286.0 5.127 5.032 6.632 4.207 2.586 6.393 12.38 13.86 -3.42E+05 
297.5 7.325 7.522 6.056 5.960 2.644 5.773 12.07 14.13 -4.04E+05 
309.7 9.515 9.548 5.475 7.686 2.970 5.232 11.85 14.08 -3.47E+05 
319.4 11.654 11.592 5.008 9.536 3.270 4.659 11.58 14.02 -4.99E+05 
 
Table 33. NMRD data of Gd-DOTAGA (63) at 25°C and 37°C. (cGd = 2.02 mM for 
ν(1H) ≤ 10 MHz and cGd = 2.49 mM for ν(1H) > 10 MHz). 
ν(1H) (MHz) r1 (mM-1s-1) at 25°C r1 (mM-1s-1) at 37°C 
500 4.19 3.23 
400 4.64 3.52 
250 5.18 3.86 
80 4.64 3.59 
60 4.81 3.73 
40 4.86 3.78 
20 5.17 4.14 
10.001 6.69 5.53 
6.951 7.40 6.17 
4.833 8.36 7.10 
3.360 9.38 7.84 
2.336 10.52 8.60 
1.623 11.27 9.13 
1.129 11.81 9.47 
0.785 11.93 9.67 
0.546 12.07 9.77 
0.379 12.26 9.82 
0.264 12.26 9.90 
0.183 12.28 9.93 
0.128 12.38 9.92 
0.089 12.20 9.95 
0.062 12.34 9.87 
0.043 12.25 9.91 
0.030 12.23 9.93 
0.021 12.35 9.94 
0.014 12.49 9.96 
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Table 34. NMRD data of Gd-DOTABA (78) at 25°C and 37°C. (cGd = 2.00 mM for 
ν(1H) ≤ 10 MHz and cGd = 2.01 mM for ν(1H) > 10 MHz). 
ν(1H) (MHz) r1 (mM-1s-1) at 25°C r1 (mM-1s-1) at 37°C 
500 4.46 3.55 
250 5.70 4.15 
80 5.39 4.19 
60 5.41 4.45 
40 5.53 4.34 
20 5.87 4.73 
10.001 6.95 5.68 
6.951 7.48 6.23 
4.833 8.62 7.16 
3.360 9.72 8.00 
2.336 10.90 8.97 
1.623 11.88 9.61 
1.129 12.47 10.17 
0.785 12.82 10.38 
0.546 13.02 10.57 
0.379 13.19 10.62 
0.264 13.22 10.66 
0.183 13.29 10.66 
0.128 13.25 10.78 
0.089 13.34 10.67 
0.062 13.30 10.65 
0.043 13.35 10.72 
0.030 13.30 10.78 
0.021 13.37 10.72 
0.014 13.18 10.79 
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Table 35. NMRD data of Gadoxane G (GG) at 25°C and 37°C. (cGd = 2.00 mM for 
ν(1H) ≤ 10 MHz and cGd = 1.99 mM for ν(1H) > 10 MHz). 
ν(1H) (MHz) r1 (mM-1s-1) at 25°C r1 (mM-1s-1) at 37°C 
500 4.99 4.17 
400 5.93 5.17 
250 8.03 6.70 
80 11.20 9.13 
60 11.55 9.38 
40 12.19 9.58 
20 12.13 9.58 
10.001 11.87 9.52 
6.951 11.73 9.51 
4.833 12.08 10.14 
3.360 12.95 10.87 
2.336 14.49 12.34 
1.623 16.01 13.56 
1.129 17.06 14.48 
0.785 17.83 15.17 
0.546 18.23 15.58 
0.379 18.57 15.73 
0.264 18.76 15.93 
0.183 18.73 15.96 
0.128 18.96 16.03 
0.089 18.83 16.00 
0.062 18.97 16.12 
0.043 18.76 16.12 
0.030 18.98 15.98 
0.021 18.98 16.13 
0.014 19.04 16.32 
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Table 36. NMRD data of Gadoxane B (GB) at 25°C and 37°C. (cGd = 1.99 mM for 
ν(1H) ≤ 10 MHz and cGd = 2.00 mM for ν(1H) > 10 MHz). 
ν(1H) (MHz) r1 (mM-1s-1) at 25°C r1 (mM-1s-1) at 37°C 
500 4.46 4.20 
250 7.70 7.31 
80 14.04 12.73 
60 15.61 13.83 
40 16.73 14.56 
20 17.11 14.76 
10.001 16.53 14.28 
6.951 15.58 13.55 
4.833 15.35 13.30 
3.360 15.51 13.64 
2.336 17.07 15.45 
1.623 18.85 17.13 
1.129 20.31 18.53 
0.785 21.19 19.50 
0.546 22.01 20.49 
0.379 22.48 20.83 
0.264 22.83 21.08 
0.183 22.69 21.22 
0.128 22.95 21.20 
0.089 23.05 21.38 
0.062 23.13 21.34 
0.043 22.98 21.37 
0.030 23.01 21.47 
0.021 23.05 21.38 
0.014 22.97 21.45 
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5.2.8 Syntheses 
5.2.8.1 Synthesis of octa(3-chloroammoniumpropyl)silsesquioxane (29) 
29 was synthesised according to the literature121 procedure in 39 % yield. 
5.2.8.2 Synthesis of octa(3-(ethylmercapto)-propionic acid)silsesquioxane (33) 
Synthesis of octavinylsilsesquioxane (31) 
31 was synthesised from vinyltrichlorosilane according to the literature125, 126 in 15 % yield. 
Synthesis of octa(3-(ethylmercapto)-propionic acid)silsesquioxane (33) 
33 was prepared from 31, mercaptopropionic acid and AIBN as the radical initiator according 
to the literature125 in 98 % yield. 
5.2.8.3 Synthesis of DOTA(tBu)3 (36) 
Synthesis of DOTA(tBu)3Bn (35) 
Under argon atmosphere DO3A(tBu)3 (34) (500 mg, 0.973 mmol) was dissolved in dry 
acetonitrile (35 mL) and benzyl bromoacetat (246 mg, 1.071 mmol) was added followed by 
K2CO3 (202 mg, 1.460 mmol). The mixture was stirred for 19 h at 70°C. After cooling to 
room temperature the solid was filtered off and the solvent removed under reduced pressure. 
The crude product was purified on a silica gel column (DCM, increasing the ratio of MeOH to 
15%) resulting in a yellow oil (564 mg, 87 %). 
1H NMR (500.13 MHz, CDCl3): δ = 7.39-7.28 (m, 5H, Ar-H), 5.11, (s, 2H, CH2Ph) 3.91-1.95 
(br m, 24H, NCH2), 1.46, 1.43 (s, 27H, C(CH3)3). 13C{1H} NMR (125.76 MHz, CDCl3): δ = 
173.7 (COOBn), 173.2, 173.1 (COOtBu), 135.3 (Ar-C), 128.7, 128.6, 128.5 (Ar-CH), 82.0, 
81.9 (C(CH3)3), 66.9 (CH2Ph), 55.9, 55.7, 55.2, 51.9, 51.0, 50.6 (NCH2), 28.1, 28.0 
(C(CH3)3). 
Synthesis of DOTA(tBu)3 (36) 
Pd/C (10 % Pd, 200 mg) was added to a solution 35 (280 mg, 0.422 mmol) in dry degassed 
methanol (25 mL). The mixture was stirred vigorously under a dihydrogen atmosphere 
(balloon) for 3 h. The catalyst was filtered off and the solvent removed under reduced 
pressure to afford a pale yellow solid (210 mg, 87 %). 
1H NMR (500.13 MHz, CDCl3): δ = 3.93-1.95 (br m, 24H, NCH2), 1.44, 1.43 (s, 27H, 
C(CH3)3). 13C NMR (125.76 MHz, CDCl3): δ = 174.5 (COOH), 172.3 (COOtBu), 82.5, 82.2 
(C(CH3)3), 56.1, 55.9, 55.6, 53.6-51.8 (br), 49.5-48.0 (br) (NCH2), 28.2, 27.9 (C(CH3)3). 
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ESI-MS: [M+H]+ calc. 573.4 , found 573.5. 
5.2.8.4 Synthesis of compound 46 
Method 1: Under argon atmosphere 29 (50 mg, 4.26×10-5 mol) and 36 (295 mg, 
5.11×10-4 mol) were dissolved in dry DMSO (4 mL). HOBt (77 mg, 5.11×10-4 mol) and 
TBTU (160 mg, 5.11×10-4 mol) were added followed by DIPEA (750 µL, 4.38×10-3 mol). 
The mixture was stirred for 20 h at room temperature and then added drop-wise to distilled 
water (10 mL) at ~ 0°C while a yellow precipitate was formed. The precipitate was filtered off 
and dissolved in methanol (30 mL). Removal of the solvent under reduced pressure resulted 
in a pale yellow solid (219 mg). No signal in the 29Si NMR spectrum. Destruction of the 
silsesquioxane core. 
Method 2: Under argon atmosphere 29 (10 mg, 8.51×10-6 mol) and 36 (59 mg, 1.02×10-4 mol) 
were dissolved in dry DMSO (500 µL) and TBTU (33 mg, 1.02×10-4 mol) was added 
followed by DIPEA (100 µL, 5.84×10-4 mol). The mixture was stirred for 30 min at room 
temperature and then added drop-wise to distilled water (10 mL) in a centrifuge tube which 
was kept in an ice bath. The formed precipitate was centrifuged, washed four-times with cold 
water and dissolved in methanol (1 mL). Removal of the solvent under reduced pressure 
resulted in a pale yellow solid (43 mg, 95 %). 
1H NMR (500.13 MHz, CDCl3): δ = 3.75-1.92 (192H, Cyclen NCH2, CH2CO), 3.19 (br, 8H, 
NCH2CH2), 1.60 (br, 8H, NCH2CH2), 0.59 (br, 8H, CH2Si), 1.43 (s, 216H, C(CH3)3). 13C{1H} 
NMR (125.76 MHz, CDCl3): δ = 173.3-170.7 (br, CO), 81.2 (br, C(CH3)3), 56.4-46.1 (br 
Cyclen NCH2, CH2CO), 41.5 (br, NCH2CH2), 27.5 (C(CH3)3), 22.4 (br, NCH2CH2), 9.4 (br, 
CH2Si). 29Si{1H} NMR (99.36 MHz, CDCl3): δ = -66.9. 
5.2.8.5 Attempted deprotection of compound 46 
Method 1: To a solution of 46 (36 mg, 6.768×10-6 mol) dissolved in DCM (0.5 mL) 
trifluoroacetic acid (0.25 mL) was added drop-wise. After stirring for 8 h at room temperature 
the volatile matter was removed under reduced pressure. The residue was taken up into a 
small amount of acetone. The addition of diethyl ether resulted in an off-white precipitate. 
The precipitate was dried in vacuo. 1H NMR of the product in D2O indicated an almost 
complete deprotection but a decomposition of the silsesquioxane core, as well. 
Method 2: To a solution of 46 (36 mg, 6.768×10-6 mol) dissolved in DCM (0.5 mL) conc. 
formic acid (0.5 mL) was added drop-wise. After stirring at room temperature for 16 h the 
solvent was evaporated under reduced pressure. To remove the excess of formic acid, DCM 
and methanol were added and evaporated off, twice. The product remained soluble in DCM. 
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1H NMR of the product in CDCl3 revealed incomplete deprotection and also the 
decomposition of the silsesquioxane core. 
5.2.8.6 Synthesis of compound 49 
DO3A-hexylamine (47) (54 mg, 1.214×10-4 mol) was dissolved in distilled water (0.36 mL) 
and a stock solution of LaCl3 (1.1 equiv.) was added. The pH was adjusted to 7 using a 1 M 
solution of NaOH. The mixture was heated to 60°C for 3 h. After cooling to room 
temperature, the pH was verified to be 7.0 and the solvent was evaporated and the remaining 
solid residue was dried in vacuo at 50°C over night. 
Under argon atmosphere, the residue was then dissolved in dry DMSO (4 mL) and a solution 
of 33 (60 mg, 4.048×10-5 mol), TBTU (156 mg, 4.856×10-4 mol), HOBt (76 mg, 
4.856×10-4 mol) and DIPEA (160 µL, 9.344×10-4) in dry DMSO (2 mL) was added. After 
stirring at room temperature for 30 min, the reaction mixture was added drop-wise to an acetic 
acid/sodium acetate buffer (buffer capacity of 10 mmol/L, pH 5.5, 50 mL). The formed 
precipitate was centrifuged, washed four-times with cold water (10 mL), followed by four-
times acetone (10 mL) and one-times diethyl ether (10 mL) and dried in vacuo (off-white 
solid, 170 mg).  
13C CP/MAS (50.33 MHz): δ = 183-167 (COO-, CON), 70-58 (CH2COO-), 57-42 (CH2N), 
41-33 (CH2NCO, NOCCH2CH2S), 32-19 (alkyl CH2, CH2SCH2), 14 (CH2Si). 29Si CP/MAS 
(59.62 MHz): δ = -67.5. 
5.2.8.7 Synthesis of DOTA(Bn)3 (53) 
Synthesis of DO3A(Bn)3 (51) 
Under argon atmosphere cyclen (50) (4.31 g, 25 mmol) and NaHCO3 (6.30 g, 75 mmol) were 
suspended in dry acetonitrile (50 mL). At 0°C tert-butyl bromoacetat (10.98 mL, 70 mmol) 
dissolved in dry acetonitril (200 mL) was added drop-wise over 6 h. The mixture was then 
allowed to reach room temperature and stirred for 3 day. The formed white precipitate was 
filtered off and the solvent was removed under reduced pressure. The solid residue was 
dissolved in a 10 % acetonitrile/water mixture (240 mL) and the pH was adjusted to 3 using 
HClaq. The solution was loaded onto a column of Amberlite XAD 1600 (200 mL), 
equilibrated with 10 % acetonitrile/water and eluted with a stepwise acetonitrile/water 
gradient. The product in a mixture with the undesired DOTA(Bn)4 eluted at 30 % 
acetonitrile/water. At higher ratios of acetonitrile DOTA(Bn)4 eluted exclusively. Removal of 
the solvent under reduce pressure resulted in about 9 g mixture and 5 g pure DOTA(Bn)4. The 
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mixture was again dissolved in 10 % acetonitrile/water mixture (200 mL) (pH 3) and loaded 
onto an Amberlite XAD 1600 column. The ratio of acetonitrile was slowly increased starting 
from 20 %. The pure product eluted at an acetonitrile ratio of 28-29 %. Removal of the 
solvent under reduced pressure resulted in a white powder (1.5 g, 10 %). 
1H NMR (500.13 MHz, CDCl3): δ = 7.37-7.16 (m, 15H, Ar-H), 5.15, (s, 2H, CH2Ph), 5.00 (d, 
2JHH = 11.4 Hz, 2H, CHHPh), 4.90 (d, 2JHH = 11.4 Hz, 2H, CHHPh), 4.58 (br, 2H, 
NCH2COO), 4.05, 3.72 (br m, 4H, Cyclen CH2), 3.57, 3.43 (br m, 4H, NCH2COO), 3.44, 3.30 
(br m, 4H, Cyclen CH2), 3.40, 2.98 (br m, 4H, Cyclen CH2), 3.37, 2.90 (br m, 4H, Cyclen 
CH2). 13C{1H} NMR (125.76 MHz, CDCl3): δ = 171.6, 166.4 (COOBn), 135.1, 134.1, 128.9, 
128.8, 128.75, 128.72, 128.6, 128.5 (Ar-C), 68.1, 67.3 (CH2Ph) 54.7, 53.3 (NCH2COO), 52.7, 
50.4, 48.2, 42.8 (Cyclen CH2). ESI-MS: [M+H]+ calc. 617.3 , found 617.5. 
Synthesis of DOTA(Bn)3tBu (52) 
Under argon atmosphere 51 (600 mg, 0.973 mmol) was dissolved in dry acetonitrile (35 mL) 
and tert-butyl bromoacetat (228 mg, 1.171 mmol) was added followed by K2CO3 (202 mg, 
1.459 mmol). The mixture was stirred for 23 h at 70°C. After cooling to room temperature the 
solid was filtered off and the solvent removed under reduced pressure. The crude product was 
purified on a silica gel column (CHCl3, increasing the ratio of MeOH to 15%) resulting in a 
sticky yellow solid (497 mg, 70 %). 
1H NMR (500.13 MHz, CDCl3): δ = 7.37-7.23 (m, 15H, Ar-H), 5.19-5.0, (br, 6H, CH2Ph), 
3.87-1.95 (br m, 24H, NCH2), 1.43 (s, 9H, C(CH3)3). 13C{1H} NMR (125.76 MHz, CDCl3): 
δ = 173.9, 173.8, 173.3 (COO), 135.3, 135.2 (br), 128.74, 128.71, 128.68, 128.6, 128.5 (Ar-
C), 82.3 (C(CH3)3), 67.07, 67.06 (CH2Ph), 56.0, 55.4, 55.3 (NCH2COO), 53.9-46.3 (br, 
Cyclen CH2), 28.1 (C(CH3)3). HRMS (FTICR): [M+H]+ calc.: 731.40144, found: 731.40083. 
Synthesis of DOTA(Bn)3 (53) 
52 was dissolved in DCM (10 mL) and trifluoroacetic acid (10 mL) was added carefully. 
After stirring for 22 h at room temperature the volatile matter was removed under reduced 
pressure. To remove the excess of trifluoroacetic acid, DCM (10 mL) was twice added and 
evaporated off. The solid residue was dissolved in 10 % MeOH/water (60 mL) and the pH 
was brought to 2 using HClaq. The solution was loaded onto a column of Amberlite XAD 
1600133 (160 mL), equilibrated with 10 % MeOH/water and eluted with a stepwise 
MeOH/water gradient. The product only eluted at 100 % MeOH. Evaporation of the solvent 
under reduced pressure resulted in a yellow solid (205 mg, 47 %). 
1H NMR (400.13 MHz, CDCl3): δ = 7.36-7.27 (m, 15H, Ar-H), 5.10, (s, 4H, CH2Ph), 5.09, (s, 
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2H, CH2Ph), 3.68 (s, 2H, CH2COOH), 3.57 (s, 2H, CH2COOBn), 3.50 (m, 4H, Cyclen CH2), 
3.42 (s, 4H, CH2COOBn), 2.98 (m, 4H, Cyclen CH2), 2.73 (m, 4H, Cyclen CH2), 2.73 (m, 
4H, Cyclen CH2). 13C{1H} NMR (100.61 MHz, CDCl3): δ = 171.2, 170.5 (COOBn), 170.5 
(COOH), 135.5, 135.3, 128.68, 128.62, 128.52, 128.44, 128.42, 128.32 (Ar-C), 66.6, 66.4 
(CH2Ph), 56.1 (CH2COOH), 55.9, 55.6 (CH2COOBn), 53.5, 53.3, 50.5, 48.3 (Cyclen CH2). 
ESI-MS: [M+Na]+ calc. 697.3, found 697.3. 
5.2.8.8 Synthesis of compound 54 
Under argon atmosphere 29 (10 mg, 8.51×10-6 mol) and 53 (64 mg, 9.48×10-5 mol) were 
dissolved dry DMSO (500 µL) and TBTU (33 mg, 1.02×10-4 mol) was added followed by 
DIPEA (100 µL, 5.84×10-4 mol). The mixture was stirred for 30 min at room temperature and 
then added drop-wise to distilled water (12 mL) in a centrifuge tube which was kept in an ice 
bath. The formed precipitate was centrifuged and washed four-times with cold water. The 
residue was dissolved in chloroform (0.4 mL) and transferred into a schlenk tube, (rinsed with 
0.4 mL chloroform). Removal of the solvent under reduced pressure resulted in a dark yellow 
solid (44 mg, 86 %). Due to the 1H and 29Si NMR data no complete octafunctionalisation was 
achieved. 
Data of the octafunctionalised species: 
1H NMR (400.13 MHz, CDCl3): δ = 7.40-7.23 (m, 120H, Ar-H), 3.67-2.40 (192H, Cyclen 
NCH2, CH2CO), 3.11 (br, 8H, NCH2CH2), 1.58 (br, 8H, NCH2CH2), 0.57 (br, 8H, CH2Si). 
13C{1H} NMR (100.61 MHz, CDCl3): δ = 171.6-170.7 (br, CO), 135.9, 128.7, 128.4 (br, Ar-
C), 66.1 (br, CH2Ph), 57.1-47.3 (br Cyclen NCH2, CH2CO), 42.1 (br, NCH2CH2), 22.7 (br, 
NCH2CH2), 9.5 (br, CH2Si). 29Si NMR (99.36 MHz, CDCl3): δ = -67.0. 
5.2.8.9 Attempted deprotection of compound 54 
54 (44 mg, ~7.16×10-6 mol) was dissolved in dry DMF (1 mL). Pd/C (10 % Pd, 10 mg) was 
added and the solvent was degassed. The mixture was stirred vigorously under a dihydrogen 
atmosphere for 2.5 h at room temperature. The catalyst was filtered off, and the solution was 
added drop-wise to diethyl ether (11 mL) in a centrifuge tube which was kept in an ice bath. 
The formed precipitate was centrifuged, washed with diethyl ether and dried under reduced 
pressure. The residual solid was insoluble in water, but still soluble in CDCl3. As the 1H NMR 
spectrum showed no cleavage of the benzyl esters, the reaction was reset. Therefore the solid 
residue was dissolved in dry DMF (1 mL) and Pd/C (10 % Pd, 12 mg) was added. After 
degassing the solvent, the mixture was stirred vigorously under a dihydrogen atmosphere for 
2 days at room temperature. The 1H NMR spectrum of the reaction solution showed only little 
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toluene formation, indicating less than 30 % deprotection. 
5.2.8.10 Synthesis of DOTAGA (60) 
Route 1: 
Synthesis of 2-bromoglutaric acid (57) 
To a stirred solution of L-glutamic acid (56) (16.50 g, 112 mmol) and sodium bromide 
(40.00 g, 389 mM) in aqueous 2 N hydrobromic acid (100 mL) cooled to 0°C sodium nitrite 
(14.00 g, 203 mM) was added gradually over 2 h. About 10 min after the last addition conc. 
sulphuric acid (6 mL) was added. The mixture was extracted three times with diethyl ether. 
The combined organic phases were washed with brine and dried over magnesium sulfate. 
Removal of the solvent under reduced pressure resulted in a yellow oil (11.13 g, 47%, about 
85 % pure due to 1H NMR). 
1H NMR (400.13 MHz, CDCl3): δ = 9.99 (br s, 2H, COOH), 4.42 (dd, 3JHH = 7.3 Hz, 3JHH = 
6.2 Hz, 1H, CHBr), 2.73-2.60 (m, 2H, CH2COOH), 2.49-2.27 (m, 2H, CHBrCH2). 13C{1H} 
NMR (100.61 MHz, CDCl3): δ = 178.8 (CH2COOH), 175.0 (CHBrCOOH), 44.1 (CHBr), 
31.3 (CH2COOH), 29.3 (CHBrCH2). 
Synthesis of di-tert-butyl 2-bromoglutarate (58) 
The crude 2-bromoglutaric acid (57) (3.20 g, ~13 mmol) was dissolved in CHCl3 (40 mL) 
under argon atmosphere. A solution of tert-butyltrichloroacetimidate (TBTA) (13.25 g, 
60.66 mmol) in cyclohexane (40 mL) was added drop-wise over 15 min. The formed white 
precipitate was dissolved by the addition of dimethylacetamide (DMA) (12 mL). Boron 
trifluoride ethyl etherate (600 µL) was added as catalyst and the solution was stirred for three 
days at room temperature. The mixture was concentrated and the remaining DMA phase was 
extracted three times with hexane (50 mL). The combined hexane phases were washed three 
times with brine, dried over magnesium sulfate and the solvent was removed. The crude 
product was purified on a silica gel column (n-hexane:ethyl acetate 15:1) resulting in a 
colorless oil (1.69 g, 40 %). 
1H NMR (400.13 MHz, CDCl3): δ = 4.23 (dd, 3JHH = 8.4 Hz, 3JHH = 6.0 Hz, 1H, CHBr), 2.44-
2.36 (m, 2H, CH2COOtBu), 2.35-2.13 (m, 2H, CHBrCH2), 1.48 (s, 9H, COOC(CH3)3), 1.45 
(s, 9H, COOC(CH3)3). 13C{1H} NMR (100.61 MHz, CDCl3): δ = 171.6 (CH2COOtBu), 168.6 
(CHBrCOOtBu), 82.8 (COOC(CH3)3), 81.0 (COOC(CH3)3), 47.0 (CHBr), 33.0 
(CH2COOtBu), 30.1 (CHBrCH2), 28.3 (COOC(CH3)3), 81.0 (COOC(CH3)3).  
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Synthesis of DOTAGA(tBu)5 (59) 
DO3A(tBu)3 (34) (1200 mg, 2.332 mmol) was dissolved in dry acetonitrile (50 mL) under 
argon atmosphere and 58 (820 mg, 2.565 mmol) was added followed by K2CO3 (483 mg, 
3.498 mmol). The mixture was stirred for 16 h at 70°C. After cooling to room temperature the 
solid was filtered off and the solvent removed under reduced pressure. The crude product was 
purified on a silica gel column (pure CHCl3, gradually increasing the ratio of MeOH to 10%) 
resulting in a yellow solid (1.228 mg, 70 %). 
1H NMR (500.13 MHz, CDCl3): δ = 3.45 (dd, 3JHH = 9.9 Hz, 3JHH = 1.7 Hz, 1H, 
NCHCOOtBu), 3.38 (d, 2JHH = 17.3 Hz, 1H, NCHHCOOtBu), 2.78 (d, 2JHH = 17.3 Hz, 1H, 
NCHHCOOtBu), 3.36 (d, 2JHH = 17.2 Hz, 1H, NCHHCOOtBu), 2.78 (d, 2JHH = 17.2 Hz, 1H, 
NCHHCOOtBu), 3.34 (d, 2JHH = 17.5 Hz, 1H, NCHHCOOtBu), 2.78 (d, 2JHH = 17.5 Hz, 1H, 
NCHHCOOtBu), 3.22, 2.10 (br m, 2H, Cyclen CH2), 3.20, 2.13 (br m, 2H, Cyclen CH2), 3.19, 
2.10 (br m, 2H, Cyclen CH2), 3.03, 2.47 (br m, 2H, Cyclen CH2), 2.50, 2.31 (br m, 2H, 
Cyclen CH2), 2.50, 2.34 (br m, 2H, Cyclen CH2), 2.49, 2.30 (br m, 2H, Cyclen CH2), 2.48, 
2.26 (br m, 2H, Cyclen CH2), 2.47, 2.42 (m, 2H, CH2CH2COOtBu), 1.95, 1.66 (m, 2H, 
CH2CH2COOtBu), 1.44 (s, 9H, C(CH3)3), 1.413 (s, 9H, C(CH3)3), 1.409 (s, 18H, C(CH3)3), 
1.39 (s, 9H, C(CH3)3). 13C{1H} NMR (125.76 MHz, CDCl3): δ = 174.9 (NCHCOOtBu), 173.0 
(NCH2COOtBu), 172.9 (2C, NCH2COOtBu), 172.2 (CH2CH2COOtBu), 82.3, 81.9, 81.8 (2C), 
80.5 (C(CH3)3), 59.9 (NCHCOOtBu), 55.9, 55.8, 55.6 (NCH2COOtBu), 52.7 (2C), 52.5, 48.7, 
48.6, 48.2, 47.2, 44.3 (Cyclen CH2), 33.6 (CH2CH2COOtBu), 28.1, 27.9, 27.8, (C(CH3)3), 
19.7 (CH2CH2COOtBu). HRMS (FTICR): [M+2H]2+ calc.: 379.26970, found: 379.26962. 
Synthesis of DOTAGA (60) 
59 (1.200 g, 1.585 mmol) was dissolved in dichloromethane (10 mL) and trifluoroacetic acid 
(15 mL) was added carefully. After stirring for 23 h at room temperature the volatile matter 
was removed under reduced pressure. To remove the excess of trifluoroacetic acid, methanol 
(20 mL) was twice added and evaporated off. The viscous residue was taken up in a minimum 
amount of methanol and added drop-wise to cold diethyl ether. The formed precipitate was 
filtered off and the procedure repeated with water-acetone. Again the precipitate was filtered 
off and dried in vacuo to yield the ammonium TFA salt of DOTAGA (containing about 85 % 
pure DOTAGA) as an off-white powder (541 mg, 61 %). 
1H NMR (400.13 MHz, D2O): δ = 3.99 (dd, 3JHH = 9.0 Hz, 3JHH = 3.8 Hz, 1H, NCHCOOH), 
3.95-2.90 (br, 22H, NCH2), 2.68 (m, 2H, CH2CH2COOH), 2.01 (m, 2H, CH2CH2COOH). 
13C{1H} NMR (100.61 MHz, D2O): δ = 177.4 (CH2CH2COOH), 175.2, 174.0, 170.4 (br, 
NCH2COOH), 59.6 (br, CHCOOH), 55.9, 53.8, 51.0, 48.5, 45.6, 44.3 (br, NCH2), 31.4 
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(CH2CH2COOH), 21.7 (CH2CH2COOH). HRMS (FTICR): [M+H]+ calc.: 477.21912, found: 
477.21900. 
Route 2: 
Synthesis of dimethyl 2-bromoglutarate (61) 
The crude 2-bromoglutaric acid (57) (5.00 g, ~20 mmol) was dissolved in a solution of conc. 
sulphuric acid (700 µL) in methanol (50 mL) and the mixture was heated to reflux for 1 h. 
The solution was allowed to reach room temperature and concentrated under reduced 
pressure. Diethyl ether was added and the organic phase was washed with aqueous NaHCO3 
(5%) followed by brine and dried over magnesium sulfate. After removal of the solvent under 
reduced pressure, the crude product was purified on a short silica gel column (n-hexane:ethyl 
acetate 9:1) resulting in a colorless oil (3.60 g, 75 %). 
1H NMR (400.13 MHz, CDCl3): δ = 4.32 (dd, 3JHH = 8.4 Hz, 3JHH = 5.8 Hz, 1H, CHBr), 3.72 
(s, 3H, CH2COOCH3), 3.63 (s, 3H, CHBrCOOCH3), 2.54-2.40 (m, 2H, CH2COOCH3), 2.38-
2.16 (m, 2H, CHBrCH2). 13C{1H} NMR (100.61 MHz, CDCl3): δ = 172.4 (CH2COOCH3), 
169.8 (CHBrCOOCH3), 53.0 (CH2COOCH3), 51.8 CHBrCOOCH3), 44.6 (CHBr), 31.2 
(CH2COOCH3), 29.7 (CHBrCH2). Anal. calc. for C7H11BrO4: C, 35.17, H, 4.64, found: C, 
35.13, H, 4.38. 
Synthesis of DOTAGA(tBu)3(Me)2 (62) 
Under argon atmosphere DO3A(tBu)3 (34) (470 mg, 0.913 mmol) was dissolved in dry 
acetonitrile (25 mL) and 61 (240 mg, 1.000 mmol) was added followed by K2CO3 (242 mg, 
1.749 mmol). The mixture was stirred for 16 h at 70°C. After cooling to room temperature the 
solid was filtered off and the solvent removed under reduced pressure. The crude product was 
purified on a silica gel column (pure CHCl3, gradually increasing the ratio of MeOH to 15%) 
resulting in a yellow solid (435 mg, 71 %). 
1H NMR (500.13 MHz, CDCl3): δ = 3.59 (s, 3H, NCHCOOCH3), 3.53 (s, 3H, 
CH2CH2COOCH3), 3.48 (dd, 3JHH = 10.3 Hz, 3JHH = 2.4 Hz, 1H, NCHCOOCH3), 3.32 (d, 
2JHH = 17.3 Hz, 1H, NCHHCOOtBu), 2.73 (d, 2JHH = 17.3 Hz, 1H, NCHHCOOtBu), 3.27 (d, 
2JHH = 17.6 Hz, 1H, NCHHCOOtBu), 2.74 (d, 2JHH = 17.6 Hz, 1H, NCHHCOOtBu), 3.27 (d, 
2JHH = 17.0 Hz, 1H, NCHHCOOtBu), 2.72 (d, 2JHH = 17.0 Hz, 1H, NCHHCOOtBu), 3.08, 
2.05 (br m, 6H, Cyclen CH2), 2.96, 2.37 (br m, 2H, Cyclen CH2), 2.49 (m, 2H, 
CH2CH2COOCH3), 2.43, 2.25 (br m, 4H, Cyclen CH2), 2.41, 2.25 (br m, 2H, Cyclen CH2), 
1.92, 1.68 (m, 2H, CH2CH2COOCH3), 1.34 (s, 9H, C(CH3)3), 1.33 (s, 9H, C(CH3)3), 1.31 (s, 
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9H, C(CH3)3). 13C{1H} NMR (125.76 MHz, CDCl3): δ = 175.9 (NCHCOOCH3), 173.2 
(CH2CH2COOCH3), 173.0, 172.9, 172.7 (NCH2COOtBu), 82.0, 81.90, 81.86 (C(CH3)3), 59.2 
(CHCOOCH3), 55.7, 55.6, 55.4 (NCH2COOtBu), 52.6, 52.5, 52.3, 48.5, 48.4, 48.0, 47.0, 44.6 
(Cyclen CH2), 52.1 (NCHCOOCH3), 51.5 (CH2CH2COOCH3), 31.6 (CH2CH2COOCH3), 
27.73, 27.72, 27.68, (C(CH3)3), 19.0 (CH2CH2COOCH3). HRMS (FTICR): [M+Na]+ calc.: 
695.42017, found: 695.42074. 
Synthesis of DOTAGA (60) 
62 (435 mg, 0.647 mmol) was dissolved in aqueous 6 N hydrochloric acid (30 mL) and 
refluxed for 18 h. The solution was allowed to reach room temperature, washed with diethyl 
ether and the solvent removed under reduced pressure to yield the ammonium chloride salt of 
DOTAGA (containing 85 % pure DOTAGA) as an off-white powder (333 mg, 92%). 
1H NMR (400.13 MHz, D2O): δ = 3.99 (dd, 3JHH = 9.0 Hz, 3JHH = 3.8 Hz, 1H, NCHCOOH), 
3.95-2.90 (br, 22H, NCH2), 2.68 (m, 2H, CH2CH2COOH), 2.01 (m, 2H, CH2CH2COOH). 
13C{1H} NMR (100.61 MHz, D2O): δ = 177.4 (CH2CH2COOH), 175.2, 174.0, 170.4 (br, 
NCH2COOH), 59.6 (br, CHCOOH), 55.9, 53.8, 51.0, 48.5, 45.6, 44.3 (br, NCH2), 31.4 
(CH2CH2COOH), 21.7 (CH2CH2COOH). HRMS (FTICR): [M+H]+ calc.: 477.21912, found: 
477.21900. 
5.2.8.11 Synthesis of Gadoxane G (GG) 
60 (49 mg, 8.74×10-5 mol) was dissolved in an aqueous solution of n-Bu4NOH (20 %, 
548 µL, 4.18×10-4 mol), followed by the addition of 1.1 equivalents of a stock solution of 
LnCl3. The pH was verified to be between 6 and 7. The solution was heated to 70°C for about 
3 h. The solvent was removed under reduced pressure and the remaining solid residue was 
dried for 4 to 6 days in vacuo. Under argon atmosphere the residue was taken up in dry 
DMSO (1 mL) and stirred for 1 day. To the resulting solution 29 dissolved in dry DMSO 
(10 mg, 8.51×10-6 mol in 0.5 mL dry DMSO) was added, followed by DIPEA (0.1 mL, 
5.84×10-4 mol) and TBTU (33 mg, 1.02×10-4 mol). After 30 min of stirring at room 
temperature the reaction mixture was added drop-wise to an acetic acid/sodium acetate buffer 
(buffer capacity of 12 mmol/L, pH 5.5, 50 mL). This solution was poured into 50 mL of 
distilled water in the reservoir of a Pall Minimate™ Tangential Flow Filtration System. 
Diafiltration was carried out using a membrane with a molecular weight cutoff of 3K. The 
permeated volume was continuously replaced by an aqueous solution of NaCl (1 %, 400 mL), 
followed by pure water (400 mL). After the volume replacement was stopped, the diafiltration 
was continued until the volume had reduced to about 10 mL. The remaining solution was 
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collected in a schlenk flask (rinsed with 10 mL H2O). The solvent was removed in vacuo at 
25°C to afford GG as a white solid. Absence of non-coordinated lanthanide ions was 
confirmed by the xylenol test.136 The yield calculated from the gadolinium(III) concentration 
obtained by the BMS method (see chapter 5.2.7.2) was about 37 %. 
Characterisation data of the yttrium complex: 
1H NMR (500.13 MHz, D2O,): δ = 3.63 (br d, 16H, CHHCOO-), 3.25 (br d, 16H, CHHCOO-), 
3.63 (br d, 8H, CHHCOO-), 3.22 (br d, 8H, CHHCOO-), 3.48, 2.47 (br, 32H, Cyclen CH2), 
3.45, 2.44 (br, 16H, Cyclen CH2), 3.36 (br, 8H, NCHCOO-), 3.25, 3.14 (br, 16H, NCH2CH2), 
3.07, 2.81 (br, 16H, Cyclen CH2), 2.84, 2.73 (br, 16H, Cyclen CH2), 2.77 (br, 32H, Cyclen 
CH2), 2.67 (br, 16H, Cyclen), 2.63, 2.35 (br, 16H, CH2CON), 2.04, 1.88 (br, 16H, CHCH2), 
1.64 (br, 16H, CH2CH2Si), 0.75 (br, 16H, CH2Si). 13C{1H} NMR (125.76 MHz, D2O): δ = 
180.7, 180.5, 180.3 (COO-), 175.4 (CON), 68.4 (NCHCOO-), 65.9, 65.8 (br, CH2COO-) 56.1, 
55.9, 55.6, 55.4, 55.1, 54.7, 54.4, 45.8 (br, Cyclen CH2), 41.6 (NCH2CH2), 34.8 (CH2CON), 
22.0 (CH2CH2Si), 20.4 (CHCH2), 8.4 (CH2Si). 29Si{1H} NMR (99.36 MHz, D2O): δ = -65.3. 
HRMS (FTICR): [M]8- calc.: 653.48706, found: 653.48702 
5.2.8.12 Synthesis of DOTAMA (64) 
Synthesis of dimethyl 2-bromomalonate (67) 
To a solution of dimethyl malonate (66) (13.21 g, 100 mmol) in freshly distilled carbon 
tetrachloride (15 mL) dry bromine (16.2 g, 101 mmol) was added gradually under stirring. 
After the first few milliliters of bromine had been added to the solution, an electric bulb was 
held under the flask until the reaction started. Then the rest of the bromine was added at such 
a rate as to keep the solution boiling gently. After the last addition the solution was refluxed 
for 45 min. The mixture was cooled, washed with aqueous K2CO3 (5%) and dried over 
magnesium sulfate. Repeated distillation under reduced pressure afforded the product in 98 % 
purity (2 % dimethyl malonate) as a colorless liquid (9.60 g, 45 %). 
1H NMR (500.13 MHz, CDCl3): δ = 4.85 (s, 1H, CHBr), 3.83 (s, 6H, COOCH3). 13C{1H} 
NMR (125.76 MHz, CDCl3): δ = 165.1 (COOCH3), 54.1 (COOCH3), 41.7 (CHBr). 
Synthesis of DOTAMA(tBu)3(Me)2 (72) 
Under argon atmosphere DO3A(tBu)3 (34) (600 mg, 1.166 mmol) was added to a solution of 
67 (271 mg, 1.282 mmol) in dry acetonitrile (25 mL), followed by K2CO3 (242 mg, 
1.749 mmol). The mixture was stirred for 16 h at 70°C. After cooling to room temperature the 
solid was filtered off and the solvent removed under reduced pressure. The crude product was 
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purified on a silica gel column (pure CHCl3, gradually increasing the ratio of MeOH to 15%) 
resulting in a yellow solid (631 mg, 84 %). 
1H NMR (400.13 MHz, CDCl3): δ = 4.22 (s, 1H, CH(COOCH3)2), 3.73 (s, 6H, COOCH3), 
3.43, 2.78 (m, 2H, NCH2COOtBu), 3.38, 2.53 (m, 2H, Cyclen CH2), 3.36, 2.10 (m, 2H, 
Cyclen CH2) 3.34, 2.81 (m, 4H, NCH2COOtBu), 3.30, 2.11 (m, 4H, Cyclen CH2), 2.87, 2.30 
(m, 2H, Cyclen CH2), 2.47, 2.31 (m, 2H, Cyclen CH2), 2.45, 2.35 (m, 4H, Cyclen CH2), 1.41, 
1.40 (s, 27H, C(CH3)3). 13C{1H} NMR (100.61 MHz, CDCl3): δ = 173.1, 172.9 
(NCH2COOtBu), 171.0, 167.1 (COOCH3), 82.4, 82.0 (C(CH3)3), 64.6 (CH(COOCH3)2), 55.9, 
55.6 (NCH2COOtBu), 52.8, 52.3, 48.8, 48.3, 48.2, 46.0, (Cyclen CH2), 52.7, 52.4 (COOCH3), 
27.9, (C(CH3)3). HRMS (FTICR): [M+Na]+ calc.: 667.38887, found: 667.38902. 
Synthesis of DOTAMA(Me)2 (75) 
72 (265 mg, 0.411 mmol) was dissolved in dichloromethane (5 mL) and trifluoroacetic acid 
(5 mL) was added carefully. After stirring for 20 h at room temperature the volatile matter 
was removed under reduced pressure. To remove the excess of trifluoroacetic acid methanol 
(5 mL) was twice added and evaporated off. The viscous residue was taken up in a minimum 
amount of methanol and added drop-wise to cold diethyl ether. The precipitate was filtered off 
and dried under reduced pressure to yield 171 mg (87%) of an off-white powder. 
1H NMR (500.13 MHz, D2O): δ = 5.24 (s, 1H, CH(COOCH3)2), 4.00 (br, 4H, NCH2COOH), 
3.83 (s, 6H, COOCH3), 3.69 (br, 2H, NCH2COOH), 3.60, 3.50 (m, 4H, Cyclen CH2), 3.57, 
3.47 (m, 4H, Cyclen CH2), 3.28, 3.19 (m, 4H, Cyclen CH2), 3.13, 3.02 (m, 4H, Cyclen CH2). 
13C{1H} NMR (125.76 MHz, D2O): δ = 174.3 (COOH), 169.7 (COOH), 168.8 (COOCH3), 
63.3 (CH(COOCH3)2), 56.0 (CH2COOH), 53.3 (COOCH3), 52.8 (CH2COOH), 51.6, 71,0, 
47.9, 45.5 (Cyclen CH2). HRMS (FTICR): [M+Na]+ calc.: 499.20106, found: 499.20143. 
Synthesis of DOTAMA (64*) 
Method 1: 75 (49 mg, 1.02x10-4 mol) was dissolved in an aqueous solution of n-Bu4NOH 
(20 %, 682 µL, 5.20×10-4 mol) and H2O (500 µL) was added. The solution was stirred for 
21 h, after which the solvent was removed under reduced pressure. 
Method 2: 75 (26 mg, 5.46x10-5 mol) was dissolved in an aqueous solution (1 mL) of sodium 
hydroxide (11.6 mg, 2.89x10-4 mol) and the solution was stirred for 26 h, after which the 
solvent was removed under reduced pressure. 
Characterisation data of the sodium salt: 
1H NMR (400.13 MHz, D2O): δ = 3.98 (s, 1H, CH(COO-)2), 3.12 (br, 4H, NCH2COO-), 3.07 
(s, 2H, NCH2COO-) 2.72, 2.71, 2.58, 2.42 (br, 16H, Cyclen CH2). 13C{1H} NMR 
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(100.61 MHz, D2O): δ = 180.6, 180.0 (NCH2COO-), 177.1 (CH(COO-)2), 70.7 (CH(COO-)2), 
58.2, 57.9 (NCH2COO-), 51.3, 50.5, 50.1, 48.2 (Cyclen CH2). HRMS (FTICR) of the 
gadolinium(III) complex of 64: [M]- calc.: 602.074376, found: 602.074098. 
5.2.8.13 Attempted synthesis of compound 77 
DOTAMA(nBu4N)5 (64*) (1.02×10-4 mol) was dissolved in distilled water (0.8 mL) and 1.4 
equivalents of a stock solution of YCl3 were added. A light precipitate could be observed. The 
pH was verified to be 7.2±0.1 The suspenion was stirred at room temperature for 17 h, after 
which a clear solution (pH 7.0) was obtained. The solvent was removed under reduced 
pressure and the remaining solid residue was dried for 2 days in vacuo. Under argon 
atmosphere the residue was taken up in dry DMSO (1 mL) and stirred for 2 days. To the 
resulting almost clear solution TBTU (33 mg, 1.02×10-4 mol) and a solution of octa(3-
chloroammoniumpropyl)silsesquioxane in dry DMSO (10 mg, 8.51×10-6 mol, 0.5 mL dry 
DMSO) were added, followed by DIPEA (0.1 mL, 5.84×10-4 mol). After 30 min of stirring at 
room temperature the reaction mixture was added drop-wise to an acetic acid/sodium acetate 
buffer (buffer capacity of 12 mmol/L, pH 5.5, 50 mL). The solution was poured into 50 mL of 
distilled water in the reservoir of a Pall Minimate™ Tangential Flow Filtration System. 
Diafiltration was carried out using a membrane with a molecular weight cutoff of 3K. The 
permeated volume was continuously replaced by an aqueous solution of NaCl (1 %, 400 mL), 
followed by pure water (400 mL). After the volume replacement was stopped, the diafiltration 
was continued until the volume had reduced to about 10 mL. The remaining solution was 
collected in a schlenk flask (rinsed with 10 mL H2O). The solvent was removed under 
reduced pressure at 25°C. No product could be obtained. 
5.2.8.14 Synthesis of DOTABA (65) 
Synthesis of 4-(carboxymethyl)benzoic acid (69) 
69 was prepared from methyl 4-(cyanomethyl)-benzoate (68) according to the literature138 in 
84 % yield. 
Synthesis of methyl 4-((methoxycarbonyl)methyl)benzoate (70) 
Under argon atmosphere 69 (1.00 g, 5.55 mmol) was dissolved in dry methanol (20 mL) and 
cooled to 0°C. A solution of thionyl chloride (1 mL, 13.78 mmol) in dry methanol (20 mL) 
was added drop-wise over 15 min. The solution was allowed to reach room temperature and 
stirred for 22 h. Removal of the volatile matters under reduced pressure resulted in a yellow 
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1H NMR (400.13 MHz, CDCl3): δ = 8.00 (m, A-portion of an [AB]2-system, 2H, Ar-2-H, Ar-
6-H), 7.37 (m, B-portion of an [AB]2-system, 2H, Ar-3-H, Ar-5-H) 3.67 (s, 2H, CH2), 3.90 (s, 
3H, ArCOOCH3), 3.69 (s, 3H, CH2COOCH3). 13C{1H} NMR (100.61 MHz, CDCl3): δ = 
171.1 (CH2COOCH3), 166.7 (ArCOOCH3), 138.8 (Ar-4-C), 129.8 (Ar-2-C, Ar-6-C), 129.3 
(Ar-3-C, Ar-5-C), 128.9 (Ar-1-C), 52.5 (CH2COOCH3), 52.4 ArCOOCH3), 41.2 (CH2). 
Synthesis of methyl 4-((methoxycarbonyl)bromomethyl)benzoate (71) 
Under argon atmosphere N-bromosuccinimide (NBS) (0.970 g, 5.450 mmol) and AIBN 
(50 mg, 0.304 mmol) were added to a solution of 70 (1.075 g, 5.163 mmol) in freshly distilled 
carbon tetrachloride (20 mL). The mixture was heated to reflux for 5 h, after which 1H-NMR 
indicated only 49 % conversion. Therefore new AIBN (50 mg, 0.304 mmol) was added and 
the mixture was refluxed for additional 17 h. The white solid was filtered off and the solvent 
removed under reduced pressure. The crude product (73 % due to 1H NMR) was purified on a 
silica gel column (n-hexane:ethyl acetate 3:1) resulting in a colorless oil (711 mg, 48 %). 
1H NMR (250.13 MHz, CDCl3): δ = 8.04 (m, A-portion of an [AB]2-system, 2H, Ar-2-H, Ar-
6-H), 7.63 (m, B-portion of an [AB]2-system, 2H, Ar-3-H, Ar-5-H) 5.39 (s, 1H, CHBr), 3.93 
(s, 3H, ArCOOCH3), 3.81 (s, 3H, CHBrCOOCH3). 13C{1H} NMR (62.90 MHz, CDCl3): δ = 
168.4 (CHBrCOOCH3), 166.3 (ArCOOCH3), 140.5 (Ar-4-C), 130.9 (Ar-1-C), 130.0 (Ar-2-C, 
Ar-6-C), 128.7 (Ar-3-C, Ar-5-C), 53.6 (CHBrCOOCH3), 52.3 ArCOOCH3), 45.4 (CHBr). 
Anal. calc. for C11H11BrO4 : C, 46.02, H, 3.84, found: C, 46.22, H, 3.54. 
Synthesis of DOTABA(tBu)3(Me)2 (73) 
Under argon atmosphere DO3A(tBu)3 (34) (600 mg, 1.166 mmol) was dissolved in dry 
acetonitrile (25 mL) and 71 (368 mg, 1.282 mmol) was added followed by K2CO3 (242 mg, 
1.749 mmol). The mixture was stirred for 17 h at 70°C. After cooling to room temperature the 
solid was filtered off and the solvent removed under reduced pressure. The crude product was 
purified on a silica gel column (pure CHCl3, gradually increasing the ratio of MeOH to 10%) 
resulting in an off-white powder (719 mg, 86 %). 
1H NMR (500.13 MHz, CDCl3): δ = 8.00 (m, A-portion of an [AB]2-system, 2H, Ar-2-H, Ar-
6-H), 7.11 (m, B-portion of an [AB]2-system, 2H, Ar-3-H, Ar-5-H), 4.72 (s, 1H, 
CHCOOCH3), 3.89 (s, 3H, ArCOOCH3), 3.67 (s, 3H, CHCOOCH3), 3.56 (d, 2JHH = 17.4 Hz, 
1H, NCHHCOOtBu), 2.87 (d, 2JHH = 17.4 Hz, 1H, NCHHCOOtBu), 3.41 (d, 2JHH = 17.5 Hz, 
1H, NCHHCOOtBu), 2.94 (d, 2JHH = 17.5 Hz, 1H, NCHHCOOtBu), 3.37 (d, 2JHH = 17.3 Hz, 
1H, NCHHCOOtBu), 2.83 (d, 2JHH = 17.3 Hz, 1H, NCHHCOOtBu), 3.34, 2.22 (m, 2H, 
Cyclen CH2), 3.27, 2.12 (m, 2H, Cyclen CH2), 3.24, 2.09 (m, 2H, Cyclen CH2), 3.17, 2.25 (m, 
EXPERIMENTAL PART  133 
2H, Cyclen CH2), 2.86, 1.71 (m, 2H, Cyclen CH2), 2.71, 2.52 (m, 2H, Cyclen CH2), 2.51, 
2.35 (m, 2H, Cyclen CH2), 2.50, 2.36 (m, 2H, Cyclen CH2), 1.46, 1.43 (overl. s, 27H, 
C(CH3)3). 13C{1H} NMR (125.76 MHz, CDCl3): δ = 174.7 (CHCOOCH3), 173.9, 173.3, 
173.1 (COOtBu), 166.5 (ArCOOCH3), 136.9 (Ar-4-C), 130.3 (Ar-1-C), 130.1 (Ar-3-C, Ar-5-
C), 129.7 (Ar-2-C, Ar-6-C), 82.5, 82.2, 82.1 (C(CH3)3), 65.0 (CHCOOCH3), 56.1, 55.9, 55.6 
(CH2COOtBu) 52.9, 52.6, 52.5, 49.0, 48.5, 48.3, 48.1, 45.1 (Cyclen CH2), 52.6 
(CHCOOCH3), 52.3 (ArCOOCH3), 28.1, 28.0, 27.9 (C(CH3)3). HRMS (FTICR): [M+Na]+ 
calc.: 743.42017, found: 743.42024. 
Synthesis of DOTABA (65) 
73 was dissolved in aqueous 6 N hydrochloric acid (20 mL) and refluxed for 16 h. The 
solution was allowed to reach room temperature and washed with diethyl ether. Removal of 
the solvent under reduced pressure afforded the ammonium chloride salt of DOTABA 
(containing 85 % pure DOTABA) as an off-white powder (291 mg, 90%). 
1H NMR (500.13 MHz, D2O): δ = 8.01(m, A-portion of an [AB]2-system, 2H, Ar-2-H, Ar-6-
H), 7.55 (br m, B-portion of an [AB]2-system, 2H, Ar-3-H, Ar-5-H), 5.45 (br s, 1H, 
CHCOOH), 4.63-2.38 (br, 22H, CH2). 13C{1H} NMR (125.76 MHz, D2O): δ = 174.9, 173.5, 
168.9, 167.8 (extr. br) (COOH), 169.6 (ArCOOH), 138.4 (Ar-4-C), not observed (Ar-1-C), 
130.5 (Ar-2-C, Ar-6-C), 130.4 (Ar-3-C, Ar-5-C), 63.3 (CHCOOH), 54.9, 53.2, 52.0(br), 
51.2(br), 50.0-46.1(extr. br), 45.6, 43.3 (CH2). HRMS (FTICR): [M+H]+ calc.: 525.21912, 
found: 525.21938. 
5.2.8.15 Synthesis of Gadoxane B (GB) 
65 (65 mg, 1.02×10-4 mol) was dissolved in distilled water (1 mL) and an aqueous solution of 
n-Bu4NOH (20 %, 802 µL, 6.12×10-4 mol) was added, followed by 1.1 equivalents of a stock 
solution of LnCl3. The pH was verified to be between 6 and 7. The suspension was heated to 
70°C for about 3 h. The solvent was removed under reduced pressure and the remaining solid 
residue was dried for 4 to 6 days in vacuo. Under argon atmosphere the residue was taken up 
in dry DMSO (5 mL) and stirred for 2 days. To the resulting suspension octa(3-
chloroammoniumpropyl)silsesquioxane (10 mg, 8.51×10-6 mol) was added, followed by 
DIPEA (0.1 mL, 5.84×10-4 mol) and TBTU (33 mg, 1.02×10-4 mol). After 3 h of stirring at 
room temperature the reaction mixture was added drop-wise to an acetic acid/sodium acetate 
buffer (buffer capacity of 12 mmol/L, pH 5.5, 50 mL), resulting in a clear solution. This 
solution was poured into 50 mL of distilled water in the reservoir of a Pall Minimate™ 
Tangential Flow Filtration System. Diafiltration was carried out using a membrane with a 
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molecular weight cutoff of 3 K. The permeated volume was continuously replaced by an 
aqueous solution of NaCl (1 %, 400 mL), followed by pure water (400 mL). After the volume 
replacement was stopped, the diafiltration was continued until the volume had reduced to 
about 10 mL. The remaining solution was collected in a schlenk flask (rinsed with 10 mL 
H2O). The solvent was removed in vacuo at 25°C to afford GB as a white solid. Absence of 
non-coordinated lanthanide ions was confirmed by the xylenol test. The yield calculated from 
the gadolinium(III) concentration obtained by the BMS method (see chapter 5.2.7.2) was 
about 30 %. 
NMR characterisation data of the yttrium complex: 
1H NMR (500.13 MHz, D2O): δ = 7.77 (m, A-portion of an [AB]2-system, 16H, Ar-2-H, Ar-
6-H), 7.37 (br m, B-portion of an [AB]2-system, 16H, Ar-3-H, Ar-5-H), 4.70 (br s, 8H, 
CHCOO-), 3.79 (br, 8H, CHHCOO-), 3.31 (br, 8H, CHHCOO-), 3.69 (br, 8H, CHHCOO-), 
3.31 (br, 8H, CHHCOO-), 3.66 (br, 8H, CHHCOO-), 3.28 (br, 8H, CHHCOO-), 3.29, 2.63 (br, 
16H, Cyclen CH2), 3.29, 2.35 (br, 16H, Cyclen CH2), 3.29, 2.06 (br, 16H, Cyclen CH2), 3.22 
(br, 16H, NCH2CH2), 2.94, 2.75 (br, 16H, Cyclen CH2), 2.94, 2.37 (br, 16H, Cyclen CH2), 
2.83, 2.21 (br, 16H, Cyclen CH2), 2.81, 2.47 (br, 16H, Cyclen CH2), 2.79 (br, 16H, Cyclen 
CH2), 1.71 (br, 16H, CH2CH2Si), 0.76 (br, 16H, CH2Si). 13C{1H} NMR (125.76 MHz, D2O): 
δ = 180.8 (br, CH2COO-), 178.3 (br, CHCOO-), 168.8 (br, ArCON), 135.3 (br, Ar-4-C), 133.9 
(br, Ar-1-C), 132.7 (br, Ar-3-C, Ar-5-C), 126.8 (br, Ar-2-C, Ar-6-C), 74.1 (br, CHCOO-), 
66.0 (br, CH2COO-), 56.0, 55.9, 55.4, 55.2, 55.0, 54.7, 45.7 (br, Cyclen CH2) 41.7 
(NCH2CH2), 22.2 (CH2CH2Si), 8.4 (CH2Si). 29Si{1H} NMR (99.36 MHz, D2O): δ = -65.4. 
HRMS data of the gadolinium complex: 
HRMS (FTICR): [M]8- calc.: 769.880308, found: 769.881065. 
5.2.8.16 General procedure for the synthesis of complexes 63 and 78 
Ligand 60 or 65 was dissolved in distilled water (0.5 mL) and a stock solution of LnCl3 (1.1 
equivalents for YCl3 and 0.9 equivalents for GdCl3) was added. The pH was adjusted to 6-7 
using a 1 M solution of NaOH. The mixture was heated to 70°C for 1 h. After cooling to room 
temperature, the pH was adjusted to 7.0 using a 1 M solution of NaOH, followed by the 
evaporation of the solvent. The absence of non-coordinated Gd3+ ions in the gadolinium(III) 
complexes was confirmed by the xylenol test. 
NMR data of Y-DOTAGA (63): 
1H NMR (500.13 MHz, D2O, pD 7.0): δ = 3.63 (br d, 2H, CHHCOO-), 3.25 (br d, 2H, 
CHHCOO-), 3.63 (br d, 1H, CHHCOO-), 3.22 (br d, 1H, CHHCOO-), 3.48, 2.47 (br, 4H, 
Cyclen CH2), 3.45, 2.44 (br, 2H, Cyclen CH2), 3.38 (br, 1H, NCHCOO-), 3.07, 2.81 (br, 2H, 
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Cyclen CH2), 2.84, 2.73 (br, 2H, Cyclen CH2), 2.77 (br, 4H, Cyclen CH2), 2.67 (br, 2H, 
Cyclen), 2.58, 2.29 (br, 2H, CH2CH2COO-), 1.99, 1.86 (br, 2H, CHCH2). 13C{1H} NMR 
(125.76 MHz, D2O, pD 7.0): δ = 181.0 (CH2CH2COO-), 180.7 (br, COO-), 68.6 (NCHCOO-), 
66.0, 65.7 (br, CH2COO-), 56.1, 55.9, 55.6, 55.4, 55.1, 54.7, 54.3, 45.7 (br, Cyclen CH2), 36.2 
(CH2CH2COO-), 20.4 (CHCH2). 
NMR data of Y-DOTABA (78): 
1H NMR (400.13 MHz, D2O, pD 7.0): δ = 7.93 (m, A-portion of an [AB]2-system, 2H, Ar-2-
H, Ar-6-H), 7.37 (br m, B-portion of an [AB]2-system, 2H, Ar-3-H, Ar-5-H), 4.76 (br s, 1H, 
CHCOO-), 3.79 (br d, 1H, CHHCOO-), 3.31 (br d, 1H, CHHCOO-), 3.69 (br d, 1H, 
CHHCOO-), 3.31 (br d, 1H, CHHCOO-), 3.66 (br d, 1H, CHHCOO-), 3.28 (br d, 1H, 
CHHCOO-), 3.47, 2.47 (br, 2H, Cyclen CH2), 3.46, 2.80 (br, 2H, Cyclen CH2), 3.43, 2.43 (br, 
2H, Cyclen CH2), 3.02, 2.76 (br, 2H, Cyclen CH2), 2.99, 2.37 (br, 2H, Cyclen CH2), 2.96, 
2.39 (br, 2H, Cyclen CH2), 2.81, 2.48 (br, 2H, Cyclen CH2), 2.79 (br, 2H, Cyclen CH2). 
13C{1H} NMR (100.61 MHz, D2O, pD 7.0): δ = 180.7 (CH2COO-), 179.4 (CHCOO-), 175.3 
(ArCOOH), 136.2 (Ar-4-C), 133.9 (Ar-1-C), 132.0 (Ar-3-C, Ar-5-C), 128.6 (Ar-2-C, Ar-6-
C), 74.5 (CHCOO-), 65.9 (br, CH2COO-), 56.0, 55.9 (2), 55.3, 55.1, 55.0, 54.7, 45.6 (br, 
Cyclen CH2). 
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Summary 
The evolvement of magnetic resonance imaging (MRI) to one of the most powerful tools in 
medical diagnosis is strongly related to the development of paramagnetic contrast agents 
(CAs). Today, more than 30% of all MRI investigations use a CA. These are mainly 
gadolinium based extracellular perfusion agents which distribute non-specifically throughout 
plasma and interstitial spaces. The next generation of CAs is aimed at a more efficient and 
more specific imaging.  
Since calcium(II) plays an important role in regulating a great variety of neuronal processes, 
there is a strong interest to generate gadolinium(III) complexes which can act as calcium(II)-
sensors in functional magnetic resonance imaging (fMRI). In this work the mechanistic 
aspects of the calcium(II) sensitivity of a series of DO3A-based lanthanide(III) chelates, 
bearing an alkyl aminobisphosphonate group (alkyl = propyl–hexyl, L1–L4) as the additional 
coordination site, were investigated. 
 
Instead of increasing, as observed for other calcium(II) sensitive CAs, the longitudinal 
relaxivity r1 (the paramagnetic longitudinal proton relaxation rate enhancement referred to 
one millimolar concentration of Gd3+) of the respective gadolinium(III) complexes of L2–L4 
decreased after the addition of calcium(II) at low concentrations of the CA (2.5 mM), whereas 
r1 of GdL1 showed no calcium(II) dependence at this complex concentration. 
Concentration-dependent relaxivity and pulsed gradient spin echo (PGSE) diffusion 1H NMR 
measurements revealed that calcium(II)-induced aggregation is responsible for the observed 
changes in relaxivity. GdL1 has a lower tendency to form aggregates in the presence of 
calcium than GdL2-GdL4, resulting in a calcium(II) dependent relaxivity change only at high 
complex concentrations. This can be attributed to a different coordination behavior of the 
phosphonate groups in GdL1 as compared to GdL2-GdL4. 31P NMR and luminescence 
measurements on the europium(III) analogues indicated the coordination of one phosphonate 
group to the lanthanide(III) ion for GdL1 in the absence and presence of calcium(II), but not 
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for GdL2-GdL4. In the case of GdL1, only one phosphonate group per lanthanide(III) 
complex is involved in the calcium(II)-induced aggregation, explaining the lower tendency to 
form aggregates. In contrast, for GdL2-GdL4, where no coordination of a phosphonate group 
to the lanthanide(III) ion is observed, both phosphonate groups can be involved in the 
calcium(II)-induced aggregate formation, resulting in larger and more stable aggregates. In all 
cases, the water access to the inner and/or the second sphere of the lanthanide(III) complexes 
is significantly hindered after aggregation, shown by a reduction in the apparent hydration 
number q. The hindered access of water molecules to the paramagnetic centre is therewith the 
explanation for the observed decrease in relaxivity. Furthermore, variable temperature 17O 
NMR measurements revealed an extremely high water exchange rate kex298 for these 
complexes, being in the same order of magnitude as that of the [Gd(H2O)8]3+ aqua ion.  
The second part of the dissertation focuses on macromolecular silsesquioxane based CAs. 
Macromolecules are considerably useful for constructing highly-sensitive CAs as their high 
molecular weight increases the rotational correlation time of the molecule and therefore 
enhances their relaxivity especially at higher field strength as used in today’s clinical MR 
scanners. Furthermore, the grafting of several gadolinium(III) complexes to a macromolecule 
leads to a higher local concentration of paramagnetic centres. Both factors allow the use of 
significantly lower CA concentrations, while achieving the same or even better contrast 
qualities. A high local concentration of gadolinium(III) complexes with high relaxivities is 
particularly needed for the development of targeted CAs. The main drawback of most of the 
so far developed large macromolecular CAs is their slow excretion rate from the body, which 
increases the risk of releasing toxic gadolinium(III) from the chelates. Furthermore, such large 
macromolecules often have poorly defined structures and therefore random morphologies, 
which can lead to inconsistent pharmacokinetics. 
Functionalised T8-silsesquioxanes could be ideal building blocks for the development of 
macromolecular CAs, which overcome these problems. As the dendrimeric core, 
functionalised T8-silsesquioxanes could allow the binding of eight gadolinium(III) complexes 
already in the first generation. This would result in macromolecular CAs which possess a high 
local gadolinium(III) concentration, while still having a defined globular structure and a 
molecular size small enough to be excreted from the body within reasonable time.  
Hence, several synthetic strategies to functionalise T8-silsesquioxanes each with eight 
appropriate gadolinium(III) complexes were investigated in the course of this work. It turned 
out to be more convenient to directly graft the gadolinium(III) complexes to the 
silsesquioxane than to introduce a protected ligand, which needs subsequent deprotection and 
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complexation. These reaction steps increase the risk of destroying the silsesquioxane cage. 
Furthermore, it could be shown that the introduction of a charge is necessary to achieve 
sufficient solubility of these highly symmetric systems in aqueous media. Therefore 
macrocyclic ligands were synthesised which form charged lanthanide(III) complexes and 
possess an additional functional group for binding to a silsesquioxane. Two of these systems 
could be successfully attached to a T8-silsesquioxane to yield Gadoxane G (GG) and 
Gadoxane B (GB).  
 
Both Gadoxanes possess eight monohydrated lanthanide(III) (Ln3+ = Gd3+, Y3+) complexes, 
spherically arranged around the silsesquioxane core, but differ in the rigidity of the linking 
group. The structure and size of the novel CAs was fully characterised by multinuclear (1H, 
13C, 29Si) NMR spectroscopy, high resolution mass spectrometry and PGSE diffusion 1H 
NMR spectroscopy. Relaxivity measurements revealed fairly high longitudinal relaxivities r1 
per gadolinium(III) as compared to commercial CAs like Dotarem™. At a proton resonance 
frequency of 40 MHz and a temperature of 37°C, r1 of GG is about three-times and r1 of GB 
is more than four-times higher than r1 of Dotarem™. Per CA the relaxivity of GB is even 35-
times higher than that of Dotarem™. The discrepancy in the relaxivities of the Gadoxanes 
arises from a different local rotational correlation time of the Gd-Hwater vector of GG and GB, 
due to the higher rigidity of the phenyl ring of GB as compared to the ethylene spacer of GG. 
Apart from their distinct increase in relaxivity, the most important feature of these CAs is the 
lability of the silsesquioxane core in aqueous media. The hydrolysis of the Si-O-Si bonds was 
investigated by 29Si NMR and PGSE diffusion 1H NMR spectroscopy, ESI-MS as well as by 
relaxivity measurements. No decomposition was observed when the solutions were stored at -
28°C for at least 10 months. At 25°C and pH 7.0, hydrolysis takes place within days to weeks, 
whereas at 37°C and pH 7.4 the compounds decompose within several hours. Since the 
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cleavage of the first Si-O-Si moieties has negligible influence on the structure of the CA, the 
relaxivity and most likely the pharmacokinetics remain unchanged within the first three to 
four hours, after which a decrease in relaxivity can be observed due to the shortened rotational 
correlation times of the arising fragments.  
Even though both Gadoxanes are small enough to be excreted sufficiently fast via the kidneys, 
the lability of the silsesquioxane core may allow the development of even larger and still well 
defined macromolecular CAs for MRI, whose fragments are then readily excreted. In 
addition, the strong effect of the replacement of an ethylene spacer in GG by a phenyl ring in 
GB on the relaxivity points out the high potential of silsesquioxane-based CAs to become 
extremely efficient, once the rigidity is further improved and the water exchange rate is 
optimised. Moreover, the introduction of additional functional groups into these systems, e.g. 
via functionalisation of the remaining methylene groups of the complexes, could allow their 
use in the targeting of biomolecules within the body. 
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